

F2

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number
WO 01/24781 A2(51) International Patent Classification⁷: A61K 31/00

(74) Agent: HELLER, David, J.; Ridout & Maybee, One Queen Street East, Suite 2400, Toronto, Ontario M5C 3B1 (CA).

(21) International Application Number: PCT/CA00/01188

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 6 October 2000 (06.10.2000)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

— Without international search report and to be republished upon receipt of that report.

(26) Publication Language: English

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(30) Priority Data:

2,285,690	7 October 1999 (07.10.1999)	CA
60/158,043	7 October 1999 (07.10.1999)	US
60/217,765	12 July 2000 (12.07.2000)	US

(71) Applicant (for all designated States except US): NOVA-NEURON INC. [CA/CA]; 5859 University Avenue, Sir Charles Tupper Medical Bldg., Room 15D7, Halifax, Nova Scotia B3H 4H7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROBERTSON, Harold, A. [CA/CA]; 2384 Clifton Street, Halifax, Nova Scotia B3K 4V1 (CA). DENOVAN-WRIGHT, Eileen, M. [CA/CA]; 22 Fleming Drive, Halifax, Nova Scotia B3P 1A9 (CA).



WO 01/24781 A2

(54) Title: GENE NECESSARY FOR STRIATAL FUNCTION, USES THEREOF, AND COMPOUNDS FOR MODULATING SAME

(57) Abstract: PDE10A, a gene that is normally highly expressed in mammalian striatum and elsewhere, has been found to decrease in expression during the development of CAG repeat disorders such as Huntington's disease. The invention teaches a method for detecting the presence of or the predisposition for a CAG repeat disorder. Compounds which modulate CAG repeat disorders and their uses are taught. Methods for screening for further compounds to modulate CAG repeat disorders are also taught.

BEST AVAILABLE COPY

Gene Necessary for Striatal Function, Uses Thereof, and
Compounds for Modulating Same

CROSS-REFERENCE

This patent claims priority from Canadian Patent application no. 2,285,690 filed October 7, 1999, US provisional application no. 60/158,043 filed October 7, 1999, and US provisional application no. 60/217,765 filed July 12, 2000, entitled **Gene Necessary for Striatal Function, Uses Thereof, and Compounds for Modulating Same**.

FIELD OF THE INVENTION

The present invention relates to a polynucleotide, PDE10A, which is down-regulated during the development of CAG repeat disorders, such as Huntington's disease. The present invention also describes compounds that modulate CAG repeat disorders, processes for expressing PDE10A, and its agonists and antagonists, and uses of PDE10A, and its variants, derivatives, agonists and antagonists.

BACKGROUND OF THE INVENTION

Very few if any effective treatments exist for neurological disorders characterized by progressive cell loss, known as neurodegenerative diseases, as well as those involving acute cell loss, such as stroke and trauma.

Huntington's disease (HD) is an inherited neurological disorder that is transmitted in

autosomal dominant fashion. HD results from genetically programmed degeneration of neurons in certain areas of the brain. Huntington's disease is caused by a mutation of the gene *IT-15* that codes for the protein huntingtin. The huntingtin gene contains a polymorphic stretch of repeated CAG trinucleotides that encode a polyglutamine tract within huntingtin. If this tract exceeds 35 in number, Huntington's disease results. Huntington's disease is only one of a number of neurological diseases which are characterised by these polyglutamine repeats (Ross, 1997). Schizophrenia, Alzheimer's disease, stroke, trauma, and Parkinson's disease also affect the basal ganglia.

Huntingtin has no sequence similarity to known proteins (Group THDCR, 1993; Sisodia, 1998). The function of the normal or mutated HD form of huntingtin has not been defined by the prior art. It is evident, however, that the expression of the HD form of huntingtin leads to progressive and selective neuronal loss. It has been demonstrated that the GABA- and enkephalin-containing medium spiny projection neurons of the caudate-putamen eventually die as a result of HD (Richfield et al., 1994). Patients with minimal cell loss, however, still present with motor and cognitive symptoms suggesting that neuronal dysfunction, and not simply cell loss, contribute to the symptoms of HD. The motor symptoms of HD include the development of chorea, dystonia, bradykinesia and tremors (Young et al., 1986). Voluntary movements may also be affected such that there may be disturbances in speech (Ludlow et al., 1987) and degradation of fine motor co-ordination (Young et al., 1986). In addition to motor decline, emotional disturbances and cognitive loss are also evident during the progression of HD (Caine et al., 1978).

Despite the fact that huntingtin is ubiquitously expressed, HD specifically affects cells of the

basal ganglia, structures deep within the brain that have a number of important functions, including co-ordinating movement. The basal ganglia includes the caudate nucleus, the putamen, the nucleus accumbens and the olfactory tubercle. HD also affects the brain's outer surface, or cortex, which controls thought, perception, and memory. The mechanism by which only a small group of neurons in the striatum and cortex are rendered vulnerable to this ubiquitously expressed mutant protein is not known. There are no effective treatments for Huntington's disease.

Huntington's disease is widely believed to be a gain-of function disorder but neither the normal function nor the gained function of huntingtin is known. Because the function for huntingtin is not known, there is little insight into the disease process. It was believed that huntingtin was related to neuronal intranuclear inclusions (NII). However, recent results have cast doubt on our understanding of the role of the NII in Huntington's disease (Saudou et al., 1998) or in other CAG repeat disorders (Klement et al., 1998; see also commentary by Sisodia, 1998).

The development of a mouse carrying the 5' end of the human Huntington's disease gene (the promoter and first exon; Mangiarini et al., 1996) was an important step in the development of the tools that will allow us to understand the function (and gain-of-function) associated with huntingtin. R6/2 mice exhibit a rapidly progressing neurological phenotype with onset at about 8 weeks. This phenotype includes a movement disorder characterised by shuddering, resting tremor, epileptic seizures and stereotyped behaviour. These symptoms suggest that the function of the basal ganglia is affected by the expression of the human exon 1 transgene prior to neuronal cell death. By 12 weeks the affected mice have significantly reduced brain

weights and they die by about 13 weeks of age. Neuronal intranuclear inclusions (NII) develop at about 4 weeks (Davies et al., 1997). As is observed in human Huntington's disease patient, the R6/2 mice show changes in neuronal receptors (Cha et al., 1998). The present inventors have also demonstrated that changes in the expression of DARPP-32 and cannabinoid receptors change over time in HD mice; such changes have also been observed in human Huntington's disease patients (unpublished results). The loss of the cannabinoid receptor is one of the earliest documented changes that occur prior to neuronal degeneration in human HD patients. The R6/2 model, therefore, mimics the early phases of HD; a point in disease development where intervention would be most appropriate.

Human PDE10 was recently identified by identification of cDNA fragments published on the National Center for Biotechnology Information (NCBI) Expressed Sequence Tags (EST) database (Loughney et al., WO99/42596). While PDE10 was found to share homology with known PDEs, no function could be identified for PDE10.

SUMMARY OF THE INVENTION

The present invention provides the function and uses of a nucleotide segment, PDE10A, and compounds which inhibit or promote the development of CAG repeat disorders such as Huntington's Disease.

The invention teaches a method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of: (a) selecting a control animal having PDE10A and a test animal having PDE10A; (b) treating said test animal using a compound; and (c)

determining the relative quantity of RNA corresponding to PDE10A, as between said animals. In an embodiment, the animal is a mammal, preferably a mouse, and preferably a transgenic mouse. In an embodiment, the CAG repeat disorder is Huntington's disease.

The invention also teaches a method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of: (a) selecting a host cell containing PDE10A; (b) cloning said host cell and separating said clones into a test group and a control group; (c) treating said test group using a compound; and (c) determining the relative quantity of RNA corresponding to PDE10A, as between said test group and said control group. In an embodiment, the CAG repeat disorder is Huntington's disease.

The invention further teaches a method for detecting the presence of or the predisposition for a CAG repeat disorder, said method comprising determining the level of expression of RNA corresponding to PDE10A in an individual relative to a predetermined control level of expression, wherein a decreased expression of said RNA as compared to said control is indicative of a CAG repeat disorder. Preferably, the expression is measured by in situ hybridization, fluorescent in situ hybridization, polymerase chain reaction, or DNA fingerprinting technique. In an embodiment, the CAG repeat disorder is Huntington's disease.

The invention further teaches compositions for treating a CAG repeat disorder comprising a compound which modulates PDE10 expression and a pharmaceutically acceptable carrier. The compound can be selected from the group consisting of: quinpirole, alloxan, miconazole nitrate, MDL-12330A and tetracycline derivatives such as demeclocycline. The compound

may be selected from the group consisting of: (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2', 1':6,1]pyrido[3,4-b]indole-1,4-dione, (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-3-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, and (3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2,3-dimethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, or from the group consisting of: KS-505, IC224, SCH 51866, IBMX and Dipyridamole. The disorder can be HD.

The invention also teaches the use of a composition which modulates PDE10 for treating a CAG repeat disorder comprising administering the composition to a subject in need of such treatment, and such use of the composition which modulates PDE10 for treating HD.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a portion of an autoradiogram of the differential display reaction identifying PDE10A in mouse brain mRNA.

FIG. 2 is a northern blot confirming that PDE10A has a lower steady-state level of expression in the striatum of transgenic HD mice.

FIG. 3 is a nucleotide sequence of the differential display cDNA fragment of pPDE10A.

FIG. 4 shows the *in situ* hybridization of probe 1 to coronal and saggital brain sections of 10 week-old wild-type and HD mice.

FIG. 5 shows the *in situ* hybridization corresponding to spatial and temporal expression of PDE10A in brain sections of wild-type and HD mice over the period of time that the HD mice develop abnormal movements and postures.

FIG. 6 shows the *in situ* hybridization corresponding to expression of PDE10A in brain sections of one day old wild-type and HD mice.

FIG. 7 shows the *in situ* hybridization corresponding to distribution of the mRNA of PDE10A in mouse striatal neurons.

FIG. 8 is the *in situ* hybridization corresponding to mRNA distribution of the rat homologue of PDE10A in rat brain tissue.

FIG. 9 shows a Southern blot analysis of DNA from wild-type and transgenic HD mice hybridized to the pPDE10A cDNA probe.

FIG. 10 is a nucleotide sequence of cPDE10-1, and corresponds to SEQ ID NO. 1.

FIG. 11 is a restriction map of cPDE10-1.

FIG. 12 is a nucleotide sequence of cPDE10-2, and corresponds to SEQ ID NO. 2.

FIG. 13 is a restriction map of cPDE10-2.

FIG. 14 is a schematic diagram showing the alignment of cPDE10-1 and -2 and the regions that are identical and unique between the two clones.

FIG. 15 is a nucleotide sequence of cPDE10A and RACEs, corresponding to SEQ ID NO. 11.

FIG. 16 is a map of PDE10A coding sequence and restriction sites.

FIG. 17 is a map of PDE10A coding sequence and features.

FIG. 18 is a restriction map of PDE10A.

FIG. 19 is a nucleotide sequence of cPDE10A and corresponds to SEQ ID NO. 12.

DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION

The following illustrative explanations are provided to facilitate understanding of certain terms used frequently herein. The explanations are provided as a convenience and are not limitative of the invention.

“Host cell” is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.

“Identity”, “similarity” or “homologous”, as used in the art, are relationships between two or

more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. Both identity and similarity can be readily calculated (Lesk, A. M., 1988; Smith, D. W., 1993; Griffin, A. M., and Griffin, H. G., 1994; von Heinje, G., 1987; and Gribskov, M. and Devereux, J., 1991). While there exist a number of methods to measure identity and similarity between two polynucleotide sequences, both terms are well known to skilled artisans (von Heinje, G., 1987; Gribskov, M. and Devereux, 1991; and Carillo, H., and Lipman, D., 1988). Methods commonly employed to determine identity or similarity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D. (1988). Methods to determine identity and similarity are codified in computer programs. Computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., 1984), BLASTP, BLASTN, and FASTA (Atschul, S. F. et al., 1990).

"Isolated" means altered "by the hand of man" from its natural state; i.e., that, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a naturally occurring polynucleotide naturally present in a living organism in its natural state is not "isolated," but the same polynucleotide separated from coexisting materials of its natural state is "isolated", as the term is employed herein. As part of or following isolation, such polynucleotides can be joined to other polynucleotides, such as DNA, for mutagenesis, to form fusion proteins, and for propagation or expression in a host, for instance. The isolated polynucleotides, alone or joined to other polynucleotides such as vectors, can be introduced into host cells, in culture or in whole organisms. Introduced into host cells in

culture or in whole organisms, such DNA still would be isolated, as the term is used herein, because they would not be in their naturally occurring form or environment. Similarly, the polynucleotides may occur in a composition, such as a media formulations, solutions for introduction of polynucleotides, for example, into cells, compositions or solutions for chemical or enzymatic reactions, for instance, which are not naturally occurring compositions, and, therein remain isolated polynucleotides within the meaning of that term as it is employed herein.

“Plasmids”. Starting plasmids disclosed herein are either commercially available, publicly available, or can be constructed from available plasmids by routine application of well known, published procedures. Many plasmids and other cloning and expression vectors that can be used in accordance with the present invention are well known and readily available to those of skill in the art. Moreover, those of skill readily may construct any number of other plasmids suitable for use in the invention.

“Polynucleotides(s)” of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The DNA may be double-stranded or single-stranded. Single-stranded polynucleotides may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand. Polynucleotides generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as used herein refers to, among others, single-and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-,

double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded, or a mixture of single- and double-stranded regions. In addition, polynucleotide as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term polynucleotide also includes DNA or RNA that contain one or more modified bases. Thus, DNA or RNA with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNA or RNA comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term polynucleotide as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, *inter alia*. Polynucleotides embraces short polynucleotides often referred to as oligonucleotide(s). It will also be appreciated that RNA made by transcription of this doubled stranded nucleotide sequence, and an antisense strand of a nucleic acid molecule of the invention or an oligonucleotide fragment of the nucleic acid molecule, are contemplated within the scope of the invention. An antisense sequence is constructed by inverting the sequence of a nucleic acid molecule of the invention, relative to its normal presentation for transcription. Preferably, an antisense sequence is

constructed by inverting a region preceding the initiation codon or an unconserved region. The antisense sequences may be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.

"Stringent hybridization conditions" are those which are stringent enough to provide specificity, reduce the number of mismatches and yet are sufficiently flexible to allow formation of stable hybrids at an acceptable rate. Such conditions are known to those skilled in the art and are described, for example, in Sambrook, et al, (1989). By way of example only, stringent hybridization with short nucleotides may be carried out at 5-10° below the T_m using high concentrations of probe such as 0.01-1.0 pmole/ml. Preferably, the term "stringent conditions" means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.

"Variant(s)" of polynucleotides are polynucleotides that differ in nucleotide sequence from another, reference polynucleotide. Generally, differences are limited so that the nucleotide sequences of the reference and the variant are closely similar overall and, in many regions, identical. Changes in the nucleotide sequence of the variant may be silent. That is, they may not alter the amino acids encoded by the polynucleotide. Where alterations are limited to silent changes of this type a variant will encode a polypeptide or polynucleotide with the same amino acid sequence as the reference. Changes in the nucleotide sequence of the variant may alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Such nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide or polynucleotide encoded by the reference sequence.

As hereinbefore mentioned, the present inventors have identified and sequenced a DNA sequence encoding PDE10A. The DNA sequence is shown in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11.

It will be appreciated that the invention includes nucleotide or amino acid sequences which have substantial sequence homology with the nucleotide sequences shown in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11. The term "sequences having substantial sequence homology" means those nucleotide and amino acid sequences which have slight or inconsequential sequence variations from the sequences disclosed in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11; i.e. the homologous sequences function in substantially the same manner to produce substantially the same polypeptides as the actual sequences. The variations may be attributable to local mutations or structural modifications. It is expected that a sequence having 85-90% sequence homology with the DNA sequence of the invention will provide a functional PDE10 polypeptide.

As used herein, "PDE10A" comprises a polynucleotide sequence which is down regulated in the course of CAG repeat disorders selected from the group consisting of: (a) a sequence comprising SEQ ID NO:1; (b) a sequence comprising SEQ ID NO:2; (c) a sequence comprising SEQ ID NO:11; (d) a sequence comprising nucleotides 257 to 2596 of SEQ ID NO:11; (e) a sequence which is at least 90% homologous with a sequence of (a), (b), (c) or (d), and; (f) a sequence which hybridizes to (a), (b), (c) or (d) under stringent conditions. In an embodiment, the isolated polynucleotide segment is cDNA. The invention also teaches an isolated polynucleotide segment, which retains substantially the same biological function or

activity as the polynucleotide encoded by the polynucleotide sequence.

Further embodiments of the invention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding PDE10 polypeptide or polynucleotide, and polynucleotides which are complementary to such polynucleotides. Other embodiments are polynucleotides that comprise a region that is at least 80% identical over their entire length to a polynucleotide encoding PDE10 of SEQ ID NO.11 and polynucleotides complementary thereto. This includes polynucleotides at least 90% identical over their entire length to the same, and among these embodiments are polynucleotides with at least 95%. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

The polynucleotides of the present invention may be employed as research reagents and materials for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein.

Analysis of the complete nucleotide and amino acid sequences of the protein of the invention using the procedures of Sambrook et al., *supra*, have been used to determine the expressed region, initiation codon and untranslated sequences of the PDE10A gene. The transcription regulatory sequences of the gene are determined by analyzing fragments of the DNA for their ability to express a reporter gene such as the bacterial gene lacZ.

The nucleic acid molecules of the invention allow those skilled in the art to construct

nucleotide probes for use in the detection of nucleotide sequences in biological materials. As shown in FIG. 11, 13, 15 and 16, a number of unique restriction sequences for restriction enzymes are incorporated in the nucleic acid molecule identified in the Sequence Listing as SEQ ID NO:1, NO:2 and NO:11, and these provide access to nucleotide sequences which code for polypeptides unique to the PDE10A polypeptide of the invention. Nucleotide sequences unique to PDE10A or isoforms thereof, can also be constructed by chemical synthesis and enzymatic ligation reactions carried out by procedures known in the art.

A nucleotide probe may be labeled with a detectable marker such as a radioactive label which provides for an adequate signal and has sufficient half-life such as ^{32}p , $^{3\text{H}}$, ^{14}C or the like. Other detectable markers which may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a labeled antigen, and chemiluminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. The nucleotide probes may be used to detect genes related to or analogous to PDE10A of the invention.

Accordingly, the present invention also provides a method of detecting the presence of nucleic acid molecules encoding a polypeptide related to or analogous to PDE10A in a sample comprising contacting the sample under hybridization conditions with one or more of the nucleotide probes of the invention labeled with a detectable marker, and determining the degree of hybridization between the nucleic acid molecule in the sample and the nucleotide probes.

Hybridization conditions which may be used in the method of the invention are known in the art and are described for example in Sambrook J, et al., *supra*. The hybridization product may be assayed using techniques known in the art. The nucleotide probe may be labeled with a detectable marker as described herein and the hybridization product may be assayed by detecting the detectable marker or the detectable change produced by the detectable marker.

The nucleic acid molecule of the invention also permits the identification and isolation, or synthesis of nucleotide sequences which may be used as primers to amplify a polynucleotide molecule of the invention, for example in polymerase chain reaction (PCR). The length and bases of the primers for use in the PCR are selected so that they will hybridize to different strands of the desired sequence and at relative positions along the sequence such that an extension product synthesized from one primer when it is separated from its template can serve as a template for extension of the other primer into a nucleic acid of defined length.

Primers which may be used in the invention are oligonucleotides i.e. molecules containing two or more deoxyribonucleotides of the nucleic acid molecule of the invention which occur naturally as in a purified restriction endonuclease digest or are produced synthetically using techniques known in the art such as, for example, phosphotriester and phosphodiester methods (See Good et al, 1977) or automated techniques (see, for example, Conolly, B. A., 1987). The primers are capable of acting as a point of initiation of synthesis when placed under conditions which permit the synthesis of a primer extension product which is complementary to the DNA sequence of the invention e.g. in the presence of nucleotide substrates, an agent for polymerization such as DNA polymerase and at suitable temperature and pH. Preferably, the primers are sequences that do not form secondary structures by base

pairing with other copies of the primer or sequences that form a hair pin configuration. The primer may be single or double-stranded. When the primer is double-stranded it may be treated to separate its strands before using it to prepare amplification products. The primer preferably contains between about 7 and 25 nucleotides.

The primers may be labeled with detectable markers which allow for detection of the amplified products. Suitable detectable markers are radioactive markers such as P-32, S-35, I-125, and H-3, luminescent markers such as chemiluminescent markers, preferably luminol, and fluorescent markers, preferably dansyl chloride, fluorescein-5-isothiocyanate, and 4-fluor-7-nitrobenz-2-oxa-1,3 diazole, enzyme markers such as horseradish peroxidase, alkaline phosphatase, β -galactosidase, acetylcholinesterase, or biotin.

It will be appreciated that the primers may contain non-complementary sequences provided that a sufficient amount of the primer contains a sequence which is complementary to a nucleic acid molecule of the invention or oligonucleotide sequence thereof, which is to be amplified. Restriction site linkers may also be incorporated into the primers allowing for digestion of the amplified products with the appropriate restriction enzymes facilitating cloning and sequencing of the amplified product.

Thus, a method of determining the presence of a nucleic acid molecule having a sequence encoding PDE10A or a predetermined oligonucleotide fragment thereof in a sample, is provided comprising treating the sample with primers which are capable of amplifying the nucleic acid molecule or the predetermined oligonucleotide fragment thereof in a polymerase chain reaction to form amplified sequences, under conditions which permit the formation of

amplified sequences and, assaying for amplified sequences.

The polymerase chain reaction refers to a process for amplifying a target nucleic acid sequence as generally described in Innis et al, Academic Press, 1989, in Mullis et al., U.S. Pat. No. 4,863,195 and Mullis, U.S. Pat. No. 4,683,202 which are incorporated herein by reference. Conditions for amplifying a nucleic acid template are described in M. A. Innis and D. H. Gelfand, 1989, which is also incorporated herein by reference.

The amplified products can be isolated and distinguished based on their respective sizes using techniques known in the art. For example, after amplification, the DNA sample can be separated on an agarose gel and visualized, after staining with ethidium bromide, under ultra violet (UV) light. DNA may be amplified to a desired level and a further extension reaction may be performed to incorporate nucleotide derivatives having detectable markers such as radioactive labeled or biotin labeled nucleoside triphosphates. The primers may also be labeled with detectable markers. The detectable markers may be analyzed by restriction and electrophoretic separation or other techniques known in the art.

The conditions which may be employed in the methods of the invention using PCR are those which permit hybridization and amplification reactions to proceed in the presence of DNA in a sample and appropriate complementary hybridization primers. Conditions suitable for the polymerase chain reaction are generally known in the art. For example, see M. A. Innis and D. H. Gelfand, 1989, which is incorporated herein by reference. Preferably, the PCR utilizes polymerase obtained from the thermophilic bacterium *Thermus aquatics* (Taq polymerase, GeneAmp Kit, Perkin Elmer Cetus) or other thermostable polymerase may be used to amplify

DNA template strands.

It will be appreciated that other techniques such as the Ligase Chain Reaction (LCR) and Nucleic-Acid Sequence Based Amplification (NASBA) may be used to amplify a nucleic acid molecule of the invention. In LCR, two primers which hybridize adjacent to each other on the target strand are ligated in the presence of the target strand to produce a complementary strand (Barney, 1991 and European Published Application No. 0320308, published Jun. 14, 1989). NASBA is a continuous amplification method using two primers, one incorporating a promoter sequence recognized by an RNA polymerase and the second derived from the complementary sequence of the target sequence to the first primer (U.S. Ser. No. 5,130,238 to Malek).

The present invention also teaches vectors which comprise a polynucleotide or polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polynucleotides of the invention by recombinant techniques.

In accordance with this aspect of the invention the vector may be, for example, a plasmid vector, a single or double-stranded phage vector, a single or double-stranded RNA or DNA viral vector. In certain embodiments in this regard, the vectors provide for specific expression. Such specific expression may be inducible expression or expression only in certain types of cells or both inducible and cell-specific. Particular among inducible vectors are vectors that can be induced for expression by environmental factors that are easy to manipulate, such as temperature and nutrient additives. A variety of vectors suitable to this

aspect of the invention, including constitutive and inducible expression vectors for use in prokaryotic and eukaryotic hosts, are well known and employed routinely by those of skill in the art. Such vectors include, among others, chromosomal, episomal and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids, all may be used for expression in accordance with this aspect of the present invention.

The following vectors, which are commercially available, are provided by way of example. Among vectors for use in bacteria are pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia, and pBR322 (ATCC 37017). Among eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. These vectors are listed solely by way of illustration of the many commercially available and well known vectors that are available to those of skill in the art for use in accordance with this aspect of the present invention. It will be appreciated that any other plasmid or vector suitable for, for example, introduction, maintenance, propagation or expression of a polynucleotide or polypeptide of the invention in a host may be used in this aspect of the invention. Generally, any vector suitable to maintain, propagate or express polynucleotides to express a polypeptide or polynucleotide in a host may be used

for expression in this regard.

The appropriate DNA sequence may be inserted into the vector by any of a variety of well-known and routine techniques. In general, expression constructs will contain sites for transcription initiation and termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will include a translation initiating AUG at the beginning and a termination codon appropriately positioned at the end of the polynucleotide to be translated.

The DNA sequence in the expression vector is operatively linked to appropriate expression control sequence(s), including, for instance, a promoter to direct mRNA transcription. Promoter regions can be selected from any desired gene using vectors that contain a reporter transcription unit lacking a promoter region, such as a chloramphenicol acetyl transferase ("CAT") transcription unit, downstream of restriction site or sites for introducing a candidate promoter fragment; i.e., a fragment that may contain a promoter. As is well known, introduction into the vector of a promoter-containing fragment at the restriction site upstream of the cat gene engenders production of CAT activity, which can be detected by standard CAT assays. Vectors suitable to this end are well known and readily available, such as pKK232-8 and pCM7. Promoters for expression of polynucleotides of the present invention include not only well known and readily available promoters, but also promoters that readily may be obtained by the foregoing technique, using a reporter gene. Among known prokaryotic promoters suitable for expression of polynucleotides and polypeptides in accordance with the present invention are the *E. coli* lacI and lacZ and promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR, PL promoters and the trp promoter. Among

known eukaryotic promoters suitable in this regard are the CMV immediate early promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus ("RSV"), and metallothionein promoters, such as the mouse metallothionein-I promoter.

Vectors for propagation and expression generally will include selectable markers and amplification regions, such as, for example, those set forth in Sambrook et al., *supra*.

As hereinbefore mentioned, the present invention also teaches host cells which are genetically engineered with vectors of the invention.

Polynucleotide constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. The PDE10A polynucleotide or polypeptide products or isoforms or parts thereof, may be obtained by expression in a suitable host cell using techniques known in the art. Suitable host cells include prokaryotic or eukaryotic organisms or cell lines, for example bacterial, mammalian, yeast, or other fungi, viral, plant or insect cells. Methods for transforming or transfecting cells to express foreign DNA are well known in the art (See for example, Itakura et al., U.S. Pat. No. 4,704,362; Hinnen et al., 1978; Murray et al., U.S. Pat. No. 4,801,542; Upshall et al., U.S. Pat. No. 4,935,349; Hagen et al., U.S. Pat. No. 4,784,950; Axel et al., U.S. Pat. No. 4,399,216; Goeddel et al., U.S. Pat. No. 4,766,075; and Sambrook et al, 1989, all of which are incorporated herein by reference). Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, *E. coli*, *streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila S2*

and *Spodoptera Sf9* cells; animal cells such as *CHO*, *COS*, *HeLa*, *C127*, *3T3*, *BHK*, *293* and *Bowes melanoma* cells; and plant cells.

Host cells can be genetically engineered to incorporate polynucleotides and express polynucleotides of the present invention. Introduction of polynucleotides into the host cell can be affected by calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al. (1986) and Sambrook et al. (1989).

As hereinbefore mentioned, the present invention also teaches the production of polynucleotides of the invention by recombinant techniques.

The PDE10 polynucleotides encode a polypeptide which is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in vivo*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed

such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In sum, a polynucleotide of the present invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences which are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

The polypeptides of the invention may be prepared by culturing the host/vector systems described above, in order to express the recombinant polypeptides. Recombinantly produced PDE10A based protein or parts thereof, may be further purified using techniques known in the art such as commercially available protein concentration systems, by salting out the protein followed by dialysis, by affinity chromatography, or using anion or cation exchange resins.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using DNA derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook et al., *supra*.

Polynucleotides of the invention, encoding the heterologous structural sequence of a

polynucleotide or polypeptide of the invention generally will be inserted into a vector using standard techniques so that it is operably linked to the promoter for expression. The polynucleotide will be positioned so that the transcription start site is located appropriately 5' to a ribosome binding site. The ribosome binding site will be 5' to the AUG that initiates translation of the polynucleotide or polypeptide to be expressed. Generally, there will be no other open reading frames that begin with an initiation codon, usually AUG, and lie between the ribosome binding site and the initiation codon. Also, generally, there will be a translation stop codon at the end of the expressed polynucleotide and there will be a polyadenylation signal in constructs for use in eukaryotic hosts. Transcription termination signal appropriately disposed at the 3' end of the transcribed region may also be included in the polynucleotide construct.

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polynucleotide or polypeptide. These signals may be endogenous to the polynucleotide or they may be heterologous signals. Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art. PDE10A polynucleotide or polypeptide can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for

purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polynucleotide is denatured during isolation and or purification.

In an embodiment, a nucleic acid molecule of the invention may be cloned into a glutathione S-transferase (GST) gene fusion system for example the pGEX-1 T, pGEX-2T and pGEX-3X of Pharmacia. The fused gene may contain a strong lac promoter, inducible to a high level of expression by IPTG, as a regulatory element. Thrombin or factor Xa cleavage sites may be present which allow proteolytic cleavage of the desired polypeptide from the fusion product. The glutathione S-transferase-PDE10A fusion protein may be easily purified using a glutathione sepharose 4B column, for example from Pharmacia. The 26 kd glutathione S-transferase polypeptide can be cleaved by thrombin (pGEX-1 or pGEX-2T) or factor Xa (pGEX-3X) and resolved from the using the polypeptide using the same affinity column. Additional chromatographic steps can be included if necessary, for example Sephadex or DEAE cellulose. The two enzymes may be monitored by protein and enzymatic assays and purity may be confirmed using SDS-PAGE.

The PDE10A protein or parts thereof may also be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964) or synthesis in homogenous solution (Houbenweyl, 1987).

Within the context of the present invention, PDE10A polypeptide includes various structural forms of the primary protein which retain biological activity. For example, PDE10A polypeptide may be in the form of acidic or basic salts or in neutral form. In addition,

individual amino acid residues may be modified by oxidation or reduction. Furthermore, various substitutions, deletions or additions may be made to the amino acid or nucleic acid sequences, the net effect being that biological activity of PDE10A is retained. Due to code degeneracy, for example, there may be considerable variation in nucleotide sequences encoding the same amino acid.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals but also additional heterologous functional regions. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the C- or N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage. Also, fusion proteins may be added to the polynucleotide or polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polynucleotide or polypeptide. The addition of peptide moieties to polynucleotide or polypeptides to engender secretion or excretion, to improve stability or to facilitate purification, among others, are familiar and routine techniques in the art. In drug discovery, for example, proteins have been fused with antibody Fc portions for the purpose of high-throughput screening assays to identify antagonists (see Bennett et al., 1995, and Johanson et al., 1995).

Detecting Presence of or Predisposition for CAG Repeat Disorders

This invention is also related to the use of the PDE10A polynucleotides to detect complementary polynucleotides as a diagnostic reagent. Detection of the level of expression of PDE10A in a eukaryote, particularly a mammal, and especially a human, will provide a

method for diagnosis of a disease. Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, exhibiting decreased levels of PDE10A may be detected by a variety of techniques. Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as the striatum, nucleus accumbens and olfactory tubercle. RNA may be used directly for detection or may be amplified enzymatically by using PCR (Saiki et al., 1986) prior to analysis. As an example, PCR primers complementary to the nucleic acid encoding PDE10A can be used to identify and analyze PDE10A presence and/or expression. Using PCR, characterization of the level of PDE10A present in the individual may be made by comparative analysis.

The invention thus provides a process for detecting disease by using methods known in the art and methods described herein to detect decreased expression of PDE10 polynucleotide. For example, decreased expression of PDE10 polynucleotide can be measured using any one of the methods well known in the art for the quantification of polynucleotides, such as, for example, PCR, RT-PCR, DNase protection, northern blotting and other hybridization methods. Thus, the present invention provides a method for detecting triplet-repeat disorders, and a method for detecting a genetic pre-disposition for triplet-repeat disorders and other disorders of the basal ganglia including schizophrenia, stroke, trauma, Parkinson's disease and Alzheimer's disease (AD). More generally, the present invention provides a method for detecting a genetic pre-disposition for neurological disorders characterized by progressive cell loss.

Drug Screening Assays

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of PDE10 polypeptides or polynucleotides, such as its interaction with PDE10-binding molecules. The identification of mutations in specific genes in inherited neurodegenerative disorders, combined with advances in the field of transgenic methods, provides those of skill in the art with the information necessary to further study human diseases. This is extraordinarily useful in modeling familial forms of triplet-repeat disorders and other disorders of the basal ganglia including schizophrenia, stroke, trauma, Parkinson's disease and Alzheimer's disease (AD). More generally, the present invention is useful for modeling neurological disorders characterized by progressive cell loss, as well as those involving acute cell loss, such as stroke and trauma.

For example, to screen for agonists or antagonists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, may be prepared from a cell that expresses a molecule that binds PDE10. The preparation is incubated with labeled PDE10 in the absence or the presence of a candidate molecule which may be a PDE10 agonist or antagonist. The ability of the candidate molecule to bind the binding molecule is reflected in decreased binding of the labeled ligand.

PDE10-like effects of potential agonists and antagonists may be measured, for instance, by determining activity of a reporter system following interaction of the candidate molecule with a cell or appropriate cell preparation, and comparing the effect with that of PDE10 or molecules that elicit the same effects as PDE10. Reporter systems that may be useful in this

regard include, but are not limited to, colorimetric labeled substrate converted into product, a reporter gene that is responsive to changes in PDE10 activity, and binding assays known in the art.

Another example of an assay for PDE10 antagonists is a competitive assay that combines PDE10 and a potential antagonist with membrane-bound PDE10-binding molecules, recombinant PDE10 binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. PDE10 can be labeled, such as by radioactivity or a colorimetric compound, such that the number of PDE10 molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing PDE10-induced activities, thereby preventing the action of PDE10 by excluding PDE10 from binding.

Potential antagonists include a small molecule which binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, 1988, for a description of these molecules).

Potential antagonists include compounds related to and derivatives of PDE10.

Developing modulators of the biological activities of specific PDEs requires differentiating PDE isozymes present in a particular assay preparation. The classical enzymological approach of isolating PDEs from natural tissue sources and studying each new isozyme may be used. Another approach has been to identify assay conditions which might favor the contribution of one isozyme and minimize the contribution of others in a preparation. Still another approach has been the separation of PDEs by immunological means. Each of the foregoing approaches for differentiating PDE isozymes is time consuming. As a result many attempts to develop selective PDE modulators have been performed with preparations containing more than one isozyme. Moreover, PDE preparations from natural tissue sources are susceptible to limited proteolysis and may contain mixtures of active proteolytic products that have different kinetic, regulatory and physiological properties than the full length PDEs.

Recombinant PDE10 polypeptide products of the invention greatly facilitate the development of new and specific PDE10 modulators. The need for purification of an isozyme can be avoided by expressing it recombinantly in a host cell that lacks endogenous phosphodiesterase activity (e.g., yeast strain YKS45 deposited as ATCC 74225). Once a compound that modulates the activity of the PDE10 is discovered, its selectivity can be evaluated by comparing its activity on the PDE10 to its activity on other PDE isozymes. Thus, the combination of the recombinant PDE10 products of the invention with other recombinant PDE products in a series of independent assays provides a system for developing selective modulators of PDE10. Selective modulators may include, for example, antibodies and other proteins or peptides which specifically bind to the PDE10 or PDE10 nucleic acid,

oligonucleotides which specifically bind to the PDE10 (see Patent Cooperation Treaty International Publication No. WO93/05182 published Mar. 18, 1993 which describes methods for selecting oligonucleotides which selectively bind to target biomolecules) or PDE10 nucleic acid (e.g., antisense oligonucleotides) and other non-peptide natural or synthetic compounds which specifically bind to the PDE10 or PDE10 nucleic acid. Mutant forms of the PDE10 which alter the enzymatic activity of the PDE10 or its localization in a cell are also contemplated. Crystallization of recombinant PDE10 alone and bound to a modulator, analysis of atomic structure by X-ray crystallography, and computer modelling of those structures are methods useful for designing and optimizing non-peptide selective modulators. See, for example, Erickson et al., *Ann. Rep. Med. Chem.*, 27: 271-289 (1992) for a general review of structure-based drug design.

Targets for the development of selective modulators include, for example: (1) the regions of the PDE10 which contact other proteins and/or localize the PDE10 within a cell, (2) the regions of the PDE10 which bind substrate, (3) the allosteric cGMP-binding site(s) of PDE10, (4) the metal-binding regions of the PDE10, (5) the phosphorylation site(s) of PDE10 and (6) the regions of the PDE10 which are involved in dimerization of PDE10 subunits.

Thus, the present invention provides a method for screening and selecting compounds which promote triplet-repeat disorders, and a method for screening and selecting compounds which treat or inhibit triplet-repeat disorders, as well as schizophrenia, stroke, trauma, Parkinson's disease and Alzheimer's disease. More generally, the present invention provides a method for screening and selecting compounds which promote or inhibit neurological disorders characterized by progressive cell loss, as well as those involving acute cell loss, such as

stroke and trauma.

The selected antagonists and agonists may be administered, for instance, to inhibit progressive and acute neurological disorders, such as Huntington's disease, Parkinson's disease, schizophrenia, Alzheimer's disease (AD), stroke or trauma.

Antagonists and agonists and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds. The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by direct microinjection into the affected area, or by intravenous or other routes. These compositions of the present invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of antagonists or agonists of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation is prepared to suit the mode of administration.

Inhibition of PDE10A will be highly detrimental to striatal brain function. The progressive decline in PDE10A mRNA levels in HD may lead to dysregulation of cAMP levels and neuronal dysfunction. Up-regulation of PDE10A will be effective in combating such neuronal dysfunction.

Gene Therapy

A variety of gene therapy approaches may be used in accordance with the invention to modulate expression of the PDE10A gene in vivo. For example, antisense DNA molecules may be engineered and used to block translation of PDE10A mRNA in vivo. Alternatively, ribozyme molecules may be designed to cleave and destroy the PDE10A mRNAs in vivo. In another alternative, oligonucleotides designed to hybridize to the 5' region of the PDE10A gene (including the region upstream of the coding sequence) and form triple helix structures may be used to block or reduce transcription of the PDE10A gene. In yet another alternative, nucleic acid encoding the full length wild-type PDE10A message may be introduced in vivo into cells which otherwise would be unable to produce the wild-type PDE10A gene product in sufficient quantities or at all.

In a preferred embodiment, the antisense, ribozyme and triple helix nucleotides are designed to inhibit the translation or transcription of PDE10A. To accomplish this, the oligonucleotides used should be designed on the basis of relevant sequences unique to PDE10A.

For example, and not by way of limitation, the oligonucleotides should not fall within those region where the nucleotide sequence of PDE10A is most homologous to that of other PDEs, such as PDE2 PDE5 and PDE6, herein referred to as "unique regions".

In the case of antisense molecules, it is preferred that the sequence be chosen from the unique regions. It is also preferred that the sequence be at least 18 nucleotides in length in order to

achieve sufficiently strong annealing to the target mRNA sequence to prevent translation of the sequence. Izant and Weintraub, 1984, Cell, 36:1007-1015; Rosenberg et al., 1985, Nature, 313:703-706.

In the case of the "hammerhead" type of ribozymes, it is also preferred that the target sequences of the ribozymes be chosen from the unique regions. Ribozymes are RNA molecules which possess highly specific endoribonuclease activity. Hammerhead ribozymes comprise a hybridizing region which is complementary in nucleotide sequence to at least part of the target RNA, and a catalytic region which is adapted to cleave the target RNA. The hybridizing region contains nine (9) or more nucleotides. Therefore, the hammerhead ribozymes of the present invention have a hybridizing region which is complementary to the sequences listed above and is at least nine nucleotides in length. The construction and production of such ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, 1988, Nature, 334:585-591.

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one which occurs naturally in *Tetrahymena Thermophila* (known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug, et al., 1984, Science, 224:574-578; Zaug and Cech, 1986, Science, 231:470-475; Zaug, et al., 1986, Nature, 324:429-433; published International patent application No. WO 88/04300 by University Patents Inc.; Been and Cech, 1986, Cell, 47:207-216). The Cech endoribonucleases have an eight base pair active site which hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes which target eight base-pair active site sequences

that are present in PDE10A but not other PDEs.

The foregoing compounds can be administered by a variety of methods which are known in the art including, but not limited to the use of liposomes as a delivery vehicle. Naked DNA or RNA molecules may also be used where they are in a form which is resistant to degradation such as by modification of the ends, by the formation of circular molecules, or by the use of alternate bonds including phosphothionate and thiophosphoryl modified bonds. In addition, the delivery of nucleic acid may be by facilitated transport where the nucleic acid molecules are conjugated to poly-lysine or transferrin. Nucleic acid may also be transported into cells by any of the various viral carriers, including but not limited to, retrovirus, vaccinia, AAV, and adenovirus.

Alternatively, a recombinant nucleic acid molecule which encodes, or is, such antisense, ribozyme, triple helix, or PDE10A molecule can be constructed. This nucleic acid molecule may be either RNA or DNA. If the nucleic acid encodes an RNA, it is preferred that the sequence be operatively attached to a regulatory element so that sufficient copies of the desired RNA product are produced. The regulatory element may permit either constitutive or regulated transcription of the sequence. *In vivo*, that is, within the cells or cells of an organism, a transfer vector such as a bacterial plasmid or viral RNA or DNA, encoding one or more of the RNAs, may be transfected into cells e.g. (Llewellyn et al., 1987, *J. Mol. Biol.*, 195:115-123; Hanahan et al. 1983, *J. Mol. Biol.*, 166:557-580). Once inside the cell, the transfer vector may replicate, and be transcribed by cellular polymerases to produce the RNA or it may be integrated into the genome of the host cell. Alternatively, a transfer vector containing sequences encoding one or more of the RNAs may be transfected into cells or

introduced into cells by way of micromanipulation techniques such as microinjection, such that the transfer vector or a part thereof becomes integrated into the genome of the host cell.

Composition, Formulation, and Administration of Pharmaceutical Compositions

The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules,

liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In

addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds

may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer,

and an aqueous phase. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied.

Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various of sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

Many of the compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding

free base forms.

Suitable routes of administration may, for example, include oral, rectal, transmucosal, transdermal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.

Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into an affected area, often in a depot or sustained release formulation.

Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with an antibody specific for affected cells. The liposomes will be targeted to and taken up selectively by the cells.

The pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific indication or indications. It is appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like. In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic. A therapeutically effective dose further refers to that amount of the compound sufficient to result in amelioration of symptoms associated with such disorders. Techniques for formulation and administration of the compounds of the instant

application may be found in "*Remington's Pharmaceutical Sciences*," Mack Publishing Co., Easton, Pa., latest edition. For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.001 mg/kg to 10 mg/kg, typically around 0.01 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

The invention further provides diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration.

EXAMPLES

The present invention is further described by the following examples. These examples, while illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

EXAMPLE 1 - Isolation of PDE10A

Wild-type (B6CBAF1) and HD transgenic [B6CBA-TgN(Hdexon1)62Gpb] mice (Jackson Laboratories) and adult Sprague-Dawley rats (250-300 g; Charles River Laboratories) and were used in this study. The genotype of the mice was determined by PCR amplification of a 100 bp region of the integrated human HD exon 1 transgene using primers corresponding to nts 3340-3459 (5'-AGG GCT GTC AAT CAT GCT GG-3') and nts 3836-3855 (5'-AAA CTC ACG GTC GGT GCA GC-3') of clone E4.1 of the human HD gene (Accession number L34020). PCR conditions used are described in Mangiarini et al.(1996). DNA was extracted from a tail clip and an ear punch from each mouse used in this study. Both samples were subjected to PCR genotype analysis. For *in situ* hybridization analysis, the animals were anesthetized with >100 mg/kg sodium pentobarbital, decapitated, the brains removed and stored at -70°C prior to sectioning. For RNA isolation, animals were anesthetized, decapitated and the striatum and cortex were excised and stored in liquid nitrogen prior to RNA extraction. Animal care was given according to protocols approved by Dalhousie University and the Canadian Council of Animal Care.

Differential display was used to identify novel mDNA or previously described mDNA whose relative expression levels are altered as a result of the presence of the transgene. Using differential display, the mRNA populations derived from the striatum of 10 week old wild type were compared with age-matched R6/2 transgenic mice. Differential display has been used extensively (> 750 references) since its development (Liang and Pardee, 1992) to identify changes in gene expression in cells and in tissues including brain (Douglass et al., 1995; Babity et al., 1997a; Livesey et al., 1997; Berke et al., 1998). Perhaps the most

important finding was the demonstration by Qu et al., (1996) that differential display can be used to isolate genes differentially expressed in inbred strains of mice. The power of differential display is that the sequence information obtained can be directly related to the experimental paradigm. Moreover, such sequence information includes sufficient information to identify transcripts and can then lead to experiments that reveal function of the cognate protein in the experimental model.

DNA sequence information of potentially differentially expressed cDNA can be used to generate oligonucleotide probes for *in situ* hybridization to define the anatomical and temporal patterns of expression of specific transcripts (see Babity et al., 1997a). This technique is especially useful to study changes in steady-state levels of mRNA in heterogeneous tissue such as brain. Brain tissue can be micro-dissected (Babity et al., 1997b). This enabled the present inventors to reduce the requirement for tissue, and hence compare the mRNA populations derived from individual animals for each experimental group.

Thus RT-PCR (Denovan-Wright et al., 1999) was used to identify differences in the patterns of gene expression between the striatum of wild-type and transgenic mice that were hemizygous for the 5' UTR, exon 1 and part of intron 1 of the human Huntington's Disease gene. Total cellular RNA was isolated from the striatum and cortex of three 10 week-old wild-type and three 10 week-old R6/2 HD mice (Mangiarini et al., 1996) and used as the template to generate single-stranded cDNA. Total cellular RNA from each animal and tissue was purified using Trizol™ reagent (Gibco BRL) and the manufacturer's protocol. 10 µg aliquots of total RNA were treated with RQ1 DNase-free DNase (Promega) in the presence

of DNAsin™ (Promega) DNase inhibitor to remove trace genomic DNA and then converted to single-stranded cDNA. The primers and conditions for PCR amplification follow those of the Delta™ RNA fingerprinting manual (Clontech).

The cDNA was then used as the substrate for PCR reactions using 57 differential display primer combinations. The radio-labelled PCR products were fractionated on a denaturing acrylamide sequencing gels using a Genomyx LR™ sequencing apparatus, transferred to 3MM filter paper and dried. The dried acrylamide gels were exposed to autoradiography film (BioMax MR™) overnight. After fractionating the radio-labelled PCR products on denaturing acrylamide gels, it was found that the overwhelming majority of the approximately 18,000 PCR products screened were common to both the wild-type and HD mice (data not shown). One PCR product, amplified using the primers P7 (5'-ATT AAC CCT CAC TAA ATG CTG TAT G- 3') and T6 (5'- CAT TAT GCT GAG TGA TAT CTT TTT TTT TCG- 3') of approximately 500 bp, was observed in each of three samples derived from the striatum of wild-type mice (FIG. 1). This 500 bp band was absent from the samples derived from the striatum of the HD mice (FIG. 1) and was absent from each of the samples derived from the cortical tissue (data not shown).

FIG. 1 shows the Down-regulated in Huntington's Disease (PDE10A) transcript, identified by differential display RT PCR. A band of approximately 500 bp (arrow) was amplified from cDNA made from 10 week-old wild-type but not 10 week-old HD striatal tissue. Total RNA from individual animals (numbered 1-6) was used as the substrate for the generation of single-stranded cDNA. Animals 1, 2 and 3 were transgenic HD mice. Animals 4, 5 and 6 were wild-type mice.

EXAMPLE 2 - Cloning of PDE10A

The 500 bp band, designate PDE10Apcr, was excised from the dried gel and rehydrated in 40 μ l of H₂O for 10 min at room temperature. The eluted DNA was subjected to PCR re-amplification using the P7 and T6 primers, rTaq polymerase (Pharmacia) and the following conditions: 60" @ 94°C, 19 x (30" @ 94°C, 30" @ 58°C, 120" @ 68°C + 4" per cycle), 7' @ 68°C. The PCR reaction was subjected to agarose gel electrophoresis and the 500 bp band was removed from the gel, extracted from the agarose using the Qiagen gel extraction protocol and cloned into the vector, pGem-T using standard methods. Plasmid DNA was isolated from selected transformants using Qiagen spin columns. The resultant clone was named pPDE10A.

EXAMPLE 3 - Identification of PDE10A

The cloned insert of pPDE10A was radio-labelled and used as a hybridization probe in northern blot analysis (FIG. 2). Northern blots of total RNA were prepared using the method described in Denovan-Wright et al. (1998). The 500 bp cloned insert of PDE10A was radio-labelled with [α -32P]dCTP (3000 Ci/mmol) using the Ready-to-Go dCTP beads (Pharmacia). Northern blot hybridization, brain tissue preparation and *in situ* hybridization are described in Denovan-Wright et al. (1998). The 500 bp cloned insert of pPDE10A annealed to a transcript of approximately 9.5 kb in total RNA isolated from the striatum of ten week-old wild-type mice.

FIG. 2 demonstrates that PDE10A is expressed in the striatum but not the cortex of wild-type mice and the steady-state levels of PDE10A are reduced in 10 week old transgenic HD mice. The differential expression of PDE10A in HD mice was confirmed by northern blot analysis. The cloned insert of pPDE10A was radio-labelled and used as a hybridization probe in northern blot analysis. The northern blot was prepared by size-fractionating total RNA from the striatum and cortex of three individual 10 week-old HD (1, 2 and 3) and wild-type (4, 5 and 6) mice. Following the hybridization of pPDE10A, the radio-label was removed and the blot was subsequently allowed to hybridize with a probe that detects constitutively expressed cyclophilin. The hybridization pattern of the cyclophilin probe is aligned below the northern blot demonstrating that equivalent amount of RNA were present in each lane. The relative mobility of RNA molecular weight standards (RNA ladder, Gibco BRL) are shown on the left of the northern blot.

The hybridization signal of pPDE10A was significantly lower in the RNA samples derived from the striatum of 10 week-old HD mice. No expression of the PDE10A mRNA was detected in the cortical RNA samples derived from either the wild-type or HD mice.

EXAMPLE 4 - Sequencing PDE10A

The sequence of the cloned differential display band, pPDE10A, was determined using M13 universal forward and reverse sequencing primers and the T7 sequencing kit (Pharmacia). The 484 bp cDNA fragment did not have sequence similarity to any Genbank entries.

FIG. 3 shows the nucleotide sequence of the cloned PDE10A differential display product,

pPDE10A. The position of the primers used to amplify the fragment are underlined and labelled. The nucleotide sequence and position of oligonucleotide probes 1 and 2 within the pPDE10A sequence are shown.

EXAMPLE 5 - Isolation and Characterization of cDNA PDE10A

In order to isolate PDE10A cDNA clones, oligonucleotide probes 1 and 2 were used in 5' and 3' Rapid Amplification of cDNA Ends (RACE) reactions using commercially prepared RACE-ready mouse striatal cDNA (Clontech). Several independent clones were isolated and those that contained the sequence of pPDE10A were selected for further analysis. Each of the 5' RACE clones was identical in sequence over the length that the clones could be aligned. The difference in length between these clones is a result of termination of the original reverse-transcriptase reaction at different positions along the mRNA. No difference in size or sequence was detected between several 3' RACE clones. The longest 5' RACE clone and one 3' RACE clone were completely sequenced using internal primers. The present inventors were able to isolate a very short clone that extended the 5' RACE clone using an internal primer (probe 3, 5'- CTA TTT CAC AAG AGA CTG ACC AGC CAA TAA ATC TC- 3'). The compiled sequence of the first PDE10A cDNA clone, named cPDE10A-1 is presented in FIG. 10. cPDE10A-1 is 3235 bp in length. The restriction map of cPDE10A-1 is shown in FIG. 11.

The mRNA that hybridized with pPDE10A was approximately 9.5 kilobases in length. In order to obtain PDE10A cDNA clone that was larger than cPDE10-1, the present inventors screened a mouse brain cDNA library. Several clones were identified that hybridized with

the pPDE10 probe. The sequence of the largest of these cDNA clones, cPDE10-2, was determined. The sequence (FIG. 12) was 5753 base pairs in length. The restriction map of cPDE10-2 is shown in FIG. 13.

cPDE10-1 and cPDE10-2 share sequence identity over 2095 bp. However, the 5' 1142 bp of cPDE10-1 and the 5' 1689 bp of cPDE10-2 are unique to each clone. Clone cPDE10-2 extends 1969 bp in the 3' direction compared to cPDE10-1. A schematic showing the regions of sequence identity and the unique sequences of cPDE10-1 and -2 are shown in FIG. 14.

The compiled sequence of the mouse PDE10 cDNA clone, named cPDE10A, is presented in FIG. 15 with RACEs. A further sequence, without RACEs, is shown in FIG. 19. The coding sequence and restriction map of cPDE10A is shown in FIG. 16, and updated at FIG. 17. FIG. 18 is a restriction map of PDE10A. The coding region has a met initiator commencing at nucleotide 257, with a stop codon ending at nucleotide 2596.

PDE10A was found to have extremely high homology with human PDE10s identified by Loughney et al., WO99/42596, the contents of which are incorporated herein by reference.

EXAMPLE 6 - Localization of PDE10A in the Brain

In order to identify the coding strand and to localize the transcript in the wild-type mouse brain, two oligonucleotide probes were designed (probe 1, 5'- GAA CAT GTA GCA TAT ACT CCA GAC AAC AGA TCA TAT GG - 3'; probe 2, 5' - CAG CTT CTC CAC AGG AAC ACA GTA ACA AAG AG -3') that were complementary to different regions and

strands of the 484 bp pPDE10A clone. These oligonucleotides were used for *in situ* hybridization analysis. Using high stringency post *in situ* hybridization washes (2 x 30' in 1X SSC @ 58°C, 4 x 15' in 1X SSC @ 58°C, 4 x 15' in 0.5X SSC @ 58°C, 4 x 15' in 0.25X SSC @ 58°C), it was found that oligonucleotide probe 1 annealed with mRNA in the striatum, nucleus accumbens and olfactory tubercle of ten week-old wild-type mice (FIG. 4). The hybridization signal was significantly reduced in the striatum, nucleus accumbens and olfactory tubercle of the 10 week-old HD mice (FIG. 4).

FIG. 5 shows *in situ* hybridization of probe 1 to coronal (top three sections) and saggital (bottom section) 10 week-old wild-type (WT) and HD mouse brain sections. Specific hybridization of the probe was observed in the striatum, nucleus accumbens and olfactory tubercle of wild-type mice. The top three sections represent the distribution of PDE10A throughout the rostral-caudal axis of the striatum.

The *in situ* hybridization results confirmed the northern blot analysis demonstrating, 1) that the expression of PDE10A mRNA was restricted to the striatum, nucleus accumbens and olfactory tubercle and 2) that the levels of PDE10A mRNA were decreased in HD mice compared to the wild-type. The probe did not anneal with mRNA in any other brain nuclei. No hybridization of oligonucleotide probe 2 was observed in any region of the brain in wild-type or HD mice (Fig. 3). Based on this hybridization, the coding strand, complementary to probe 1, of pPDE10A was defined.

EXAMPLE 7 - Characterization of PDE10

The *in situ* hybridization using oligonucleotide probe 1 demonstrated that PDE10A mRNA levels in the striatum, nucleus accumbens and olfactory tubercle were decreased in ten week-old HD mice. By ten weeks of age, the HD mice all showed motor symptoms including resting tremor and stereotypic involuntary movements. Moreover, these mice immediately clasped their feet together and curled into a tight ball when picked up by their tails.

As the phenotypic signs are progressive over a number of weeks, the present inventors examined whether the PDE10A transcript was ever expressed in the striatum of the HD mice or whether the steady-state levels of the transcript diminished in the striatum in a course that paralleled the development of the motor disorders. Wild-type and HD mice were sacrificed at 5, 7 and 8 weeks of age and their brains were prepared for *in situ* hybridization analysis using probe 1 (FIG. 5).

FIG. 5 shows the levels of PDE10A mRNA decrease in HD mice over the period of time that the HD mice develop abnormal movements and postures. *In situ* hybridization analysis of coronal and saggital sections of wild-type and HD mouse brain using oligonucleotide probe 1 which is complementary to the coding strand of PDE10A. At 5 weeks of age, before the development of motor symptoms, the HD mice express the PDE10A transcript in the same brain nuclei and at the same relative levels as wild-type mice. The steady-state level PDE10A decreases in the striatum, nucleus accumbens and olfactory tubercle from 5 to 10 weeks in the HD but not wild-type mice. By 9 weeks of age, the HD mice have abnormal

movement and posture. The numbers refer to the age in weeks of the wild-type (WT) and Huntington's (HD) transgenic mice.

None of the mice at these ages had overt motor symptoms. Sections taken throughout the rostral-caudal axis of the striatum showed that PDE10A was expressed in the 5 week-old wild-type and HD mice. The relative hybridization of probe 1 did not change in 5, 7, 8 and 10 week-old wild-type mice. The intensity of the hybridization signal appeared to decrease in the striatum, nucleus accumbens and olfactory tubercle of HD mice from 5 to 10 weeks compared to their wild-type litter mates (FIG. 5).

The levels of PDE10A were significantly reduced by 8 weeks of age in the HD mice, using two *in situ* oligonucleotide probes, one complementary to the 3' UTR, the second complementary to an internal portion of the coding region. The hybridization pattern observed in the wild-type and HD mice was the same for both the probes employed. This analysis demonstrated that there is a reduction in the complete PDE10A mRNA levels during the development of the HD phenotype and not that there was a differential reduction in the PDE10A coding region as compared to the extensive 3' UTR. Moreover, *in situ* hybridization using the PDE10A-specific probe against neurologically normal and HD human brain tissue demonstrated that there was a decrease in PDE10A levels in human HD patients.

One day old wild-type and HD mice were frozen, sectioned on a cryostat and whole mouse sections were prepared for *in situ* hybridization using probe 1. The same high stringency post-hybridization washing conditions were employed for the one day-old mouse body sections as were used for the adult mouse brain sections. Parallel *in situ* hybridization

experiments using the probe 2 were performed in order to determine the level of non-specific signal in the mouse sections. Probe 1 specifically annealed to the developing striatum (FIG. 6).

FIG. 6 demonstrates that PDE10A is expressed in the developing striatum of one day-old wild-type and HD mice. The sections on the left were subjected to *in situ* hybridization using probe 1. Following hybridization, the sections were counter-stained with cresyl violet to visualize the mouse organs. The signal outside the brain was non-specific as probe 2 and other unrelated control oligonucleotide probes all labelled these tissues.

There was no difference in the pattern of hybridization between the one day-old wild-type and HD mice demonstrating that PDE10A was expressed in the developing brain of both wild-type and HD mice.

Following *in situ* hybridization, the sections were covered in autoradiographic emulsion, left in the dark to expose for 4 weeks and then developed and viewed under dark-field microscopy or, after counter-staining the sections with cresyl violet to visualize neuronal cell bodies, under bright-field microscopy. Silver grains were observed to be concentrated in the striatum of the wild-type mice. FIG. 7 shows emulsion autoradiography of mouse brain sections following *in situ* hybridization of probe 1 demonstrated that the PDE10A transcript is expressed in neurons. PDE10A is not homogeneously distributed throughout the mouse striatum. Dark field illumination of the sections after emulsion autoradiography showed that the silver grains were clustered in specific regions of the 10 week old wild-type mouse striatum (A and C). Sections from 10 week old HD mice subjected to identical *in situ* and

emulsion autoradiographic conditions are shown in B and D. The photomicrographs shown in A and B were viewed using the 10X objective (bar represents 100 μ m). The micrographs shown in C and D, were viewed under the 20X objective (bar represents 25 μ m). The insert in panel C is a portion of the section in A and C counter-stained with cresyl violet to visualize the neurons, viewed using the 40X objective under bright filed illumination. Note the distribution of the silver grains over some, but not all, of the striatal neurons as well as being concentrated around clusters of neurons. It appeared that the silver grains were absent from fibre tracks within the striatum. It appeared that PDE10A mRNA was not confined to regions close to the nucleus but was dispersed in cellular processes.

Huntingtin with an expanded polyglutamine tract (htt-HD) is expressed in neurons of the brain and body throughout development and during the lifetime of HD patients (The Huntington's Disease Research Collaborative, 1993; Ross, 1995). Transgenic HD mice express a portion of htt-HD and develop a phenotype with many of the symptoms of HD after a period of normal development and growth (Carter et al., 1999; Cha et al., 1998; Mangiarini et al., 1996). Using differential display RT PCR, northern blot and *in situ* hybridization, we have demonstrated that PDE10A mRNA levels decline in the striatum of HD mice. This specific member of the PDE multigene family is highly expressed in the striatum and olfactory tubercle of mice (Soderling et al., 1999) and rats (Fujishige et al., 1999) and in the caudate and putamen of humans (Fujishige et al., 1999; Loughney et al., 1999). The levels of PDE10A were the same in 5 week old wild-type and HD mice. PDE10A mRNA levels then began to decline and were almost undetectable in the striatum and olfactory tubercle by the time the mice reached 8 weeks of age. This time coincides with the onset of overt motor symptoms in the HD mice indicating that the loss of PDE10A in striatal neurons leads to

dysfunction of the nuclei that control movement. The R6/2 mice develop the HD phenotype in the absence of cell death. The decrease in PDE10A mRNA, therefore, is not due to the loss of PDE10A-expressing cells but rather a change in steady-state RNA levels that occurs due to the expression of mutant huntingtin.

The particular isoform that decreases in HD is PDE10A. PDE10A has been cloned from human lung and fetal brain cDNA libraries (Fujishige et al., 1999; Loughney et al., 1999). It appears that the presence of the expanded polyglutamine tract in huntingtin alters gene expression in the striatum, and that this is the mechanism by which only a small group of neurons in the striatum and cortex are rendered vulnerable to this ubiquitously expressed mutant protein.

EXAMPLE 8 - PDE10A is Highly Conserved Among Mammalian Species

The oligonucleotide (probe 1) complementary to the coding strand of the PDE10A transcript, was also used as an *in situ* hybridization probe against coronal brain sections derived from adult rats. FIG. 8 shows *in situ* hybridization analysis of adult rat brain sections using oligonucleotide probe 1 complementary to the coding-strand of PDE10A revealed that the pattern of expression of PDE10A is the same in rats and mice. The hybridization conditions used to detect the rat homologue of PDE10A in rat brain tissue differed from those used to detect the transcript in mice only in that the stringency of the post-hybridization washes were reduced.

No hybridization was observed in the rat striatum using the post-hybridization washes

employed following the *in situ* hybridization of mouse brain sections. However, when the stringency of the post-hybridization washes was lowered (2 x 60' in 1X SSC @ 42°C, 2 x 60' in 0.5X SSC @ 42°C, 2 x 60' in 0.25X SSC @ room temperature), the PDE10A oligonucleotide probe specifically labelled the adult rat striatum, nucleus accumbens and olfactory tubercle in a pattern indistinguishable from that observed in mouse brain sections. It appears, therefore, that a transcript which shares nucleotide sequence and expression pattern is present in both mice and rats. The evolutionary conservation of PDE10A suggests that it is important for normal function of the basal ganglia.

By northern blot, Fujishige et al. (1999) demonstrated that PDE10A is expressed in human fetal brain. The homology between mouse and human PDE10A is extremely high (data not shown).

EXAMPLE 9 - Analysis of PDE10A in Genomic DNA

Because the transgenic mice employed in this study have a copy of the human HD 5' UTR, exon 1 with expanded CAG repeat and 262 bp of the intron 1 that has been integrated into an undefined locus of the mouse genome, it was possible that the integration event disrupted the PDE10A gene preventing its expression in the HD mouse striatum. Genomic DNA was isolated from wild-type and HD mice and subjected to Southern blot analysis.

Genomic DNA was isolated from wild-type and HD mice and subjected to Southern blot analysis using pPDE10A as a hybridization probe. The size of the *Bam*HI and *Eco*RI fragments that are present in the transgenic R6/2 line that correspond to the insertion of the

human exon 1 gene fragment are 1.9 and 0.8 (*Bam*HI) and 1.9 (*Eco*RI) kb. Analysis of the size of the fragments that hybridized with pPDE10A demonstrated that there was no difference in the size of the hybridizing fragments between the wild-type and HD mice. FIG. 9 shows the genomic DNA restriction fragments that hybridized with pPDE10A were the same in wild-type and HD mice. The size of the hybridizing *Bam*HI and *Eco*RI fragments in each genomic DNA sample is approximately 8 kb and 3 kb, respectively. If the 1.9 kb *Sac*I-*Eco*RI HD gene fragment integrated into the genome within the *Bam*HI and *Eco*RI fragments that hybridized with the DHDM cDNA cloned insert, the sizes of the HD hybridizing bands would have been distinct from those of the wild-type. This Southern blot analysis indicates that the gene encoding PDE10A is present as a single-copy in the mouse genome. The numbers at the left of the blot are the relative mobility of molecular weight markers (1 kb ladder, BioRad).

The PDE10A cDNA has since been cloned using a bioinformatics search strategy involving screening of the expressed sequence tag (EST) database for novel PDE cDNA clones. Independently, the mouse PDE10A cDNA was identified after an EST search for novel PDEs with conserved cGMP binding domains (Soderling et al., 1999). The rat isoforms of PDE10A and splice variants have also been described (Fujishige et al., 1999). Human, mouse and rat PDE10A splice variants differ in their 5' untranslated and part of the 5' coding region but are identical in the coding region when the various splice variants are compared within each species. The human, mouse and rat PDE10A coding regions contain 779, 779 and 794 amino acids, respectively, encoding a protein of approximately 88.5 kDa.

EXAMPLE 10 - Distribution of PDE10A

In mouse, PDE10A mRNA was detected in testis and to a much lesser extent in brain but not in heart, spleen, lung, liver, skeletal muscle, kidney, ovary, pancreas, smooth muscle, eye or in total RNA isolated from 7, 11, 15 or 17 day old embryo (Soderling et al., 1999). This data agrees with the PDE10A mRNA pattern of distribution that we observed in wild-type and pre-symptomatic HD mice. In mice, two different size transcripts are detected in northern blots using the coding region as a probe. In mouse testis, the most abundant transcript is approximately 4 kb. A 9.5 kb transcript was also detected in mouse testis. It appears that the most abundant transcript in mouse brain is 9.5 k. Similarly, two sized PDE10A transcripts were observed in rats, however, it appears that, in rat, the 4 kb mRNA is expressed exclusively in testis while the 9.5 kb mRNA is expressed exclusively in brain (Fujishige et al., 1999). Within the brain, the rat PDE10A mRNA was expressed in striatum and olfactory tubercle and not cortex, cerebellum, hippocampus, midbrain or brainstem. In humans, PDE10A is expressed in the caudate, putamen and testis. As was observed in rodents, mRNAs of approximately 4 and 10 kb hybridized with the PDE10A probe. Again, it appears that, although both sized transcripts are present in brain and testis, the larger mRNA is predominant in the caudate and putamen and the smaller sized transcript is present in the testis. Each of the mouse, rat and human PDE10A sequences are not longer than 4 kb and span the coding region and parts of the 3' UTR. The difference in abundance of the short and long transcript in the testis and brain, respectively, in all three species suggest that the 3' UTR functions to provide transcript stability in the brain. As such, we present the complete sequence of the brain-specific transcript of PDE10A derived from mouse.

EXAMPLE 11 - Modulating Activity of PDE10A Using cGMP-PDE Activity

Cyclic nucleotides are the predominant second messengers that activate cellular signaling pathways (Beavo, 1995; Conti and Jin, 1999). The concentration of intracellular cyclic nucleotides is dependent on their rate of synthesis by adenyl and guanyl synthase, the rate of efflux from the cell, and the rate of degradation. PDEs hydrolyze cAMP and cGMP limiting both the duration and amplitude of the cyclic nucleotide signal (Beavo, 1995; Conti and Jin, 1999). In mammals, PDEs are encoded by a large multigene family. The various PDE family members have tissue-specific patterns of expression (Conti and Jin, 1999). PDEs have also been described in *Caenorhabditis*, *Drosophila*, *Dictyostelium*, *Saccharomyces*, *Candida* and *Vibrio* species demonstrating that this enzyme has been conserved throughout evolution. In mammals, PDEs are encoded by at least 10 gene families, each composed of one or more genes. In addition, numerous splice variants of individual gene family members have been described. These splice variants alter the 5' domain of the protein but share identical nucleotide binding and catalytic domains. The catalytic domain, found in the carboxy-terminus of the enzyme, is ~ 275 amino acids and highly conserved in amino acid sequence in all PDEs. In total, it appears that there are ~50 PDEs expressed within the mammalian body. Some PDEs are expressed in multiple tissues while others have a very limited tissue-specific distribution (Conti and Jin, 1999).

PDE gene families differ with respect to their affinity for cAMP and cGMP and their dependence on calcium and calmodulin (Beavo, 1995). Moreover, some PDEs are inhibited or activated by binding cyclic nucleotides to a non-hydrolytic site. For example, PDE2A has a lower K_m for cGMP than cAMP although it hydrolysed both nucleotides. The binding of

cGMP to an allosteric activator site within PDE2 enhances the rate of catalysis of cAMP. PDE2 is, therefore, a cGMP-stimulated cGMP and cAMP phosphodiesterase (Beavo, 1995). Conversely, the affinity of PDE4 for cAMP is much greater than for cGMP and PDE4 activity is not affected by cGMP or calmodulin (Beavo, 1995). The differences in substrate preference, modulation of activity and tissue-specific patterns of expression suggest that subtle alterations in the relative levels of cAMP and cGMP mediated through the action of various PDEs lead to a wide range of responses to extracellular signals.

cGMP-PDE activity of compounds is measured using a one-step assay adapted from Wells et al. (Wells, J. N., Baird, C. E., Wu, Y. J. and Hardman, J. G., *Biochim. Biophys. Acta* 384:430 (1975)) and adopted by Beavo et al, U.S. Patent No. 6,037,119. The reaction medium contains 50 mM Tris-HCl, pH 7.5, 5 mM Mg-acetate, 250 ug/ml 5'-Nucleotidase, 1 mM EGTA and 0.15 uM 8-[H³] -cGMP. The enzyme used is a human recombinant PDE V (ICOS, Seattle U.S.A.).

Compounds of interest are dissolved in DMSO finally present at 2% in the assay. The incubation time was 30 minutes during which the total substrate conversion did not exceed 30%.

The IC₅₀ values for the compounds examined are determined from concentration-response curves using typically concentrations ranging from 10 nM to 10 uM. Tests against other PDE enzymes using standard methodology also show compounds highly selective for the cGMP specific PDE enzyme.

Rat aortic smooth muscle cells (RSMC) are prepared according to Chamley et al. in *Cell Tissue Res.* 177:503-522 (1977) and used between the 10th and 25th passage at confluence in 24-well culture dishes. Culture media is aspirated and replaced with PBS (0.5 ml) containing the compound tested at the appropriate concentration. After 30 minutes at 37° C, particulates guanylate cyclase are stimulated by addition of ANF (100 nM) for 10 minutes. At the end of incubation, the medium is withdrawn and two extractions were performed by addition of 65% ethanol (0.25 ml). The two ethanolic extracts are pooled and evaporated until dryness, using a Speed-vat system. c-GMP was measured after acetylation by scintillation proximity immunoassay (AMERSHAM). The EC₅₀ values are expressed as the dose giving half of the stimulation at saturating concentrations.

EXAMPLE 12 - Selected Modulators of PDE10A Activity

The catalytic domain of PDE10A is most similar in amino acid sequence to PDE5A, PDE2A, PDE6B and PDE6A. These members of the PDE family each contain a cGMP binding sequence that is not observed in other PDE family members. The non-catalytic cGMP binding sites (GAF) domains found in PDE2, 5 and 6 are also found in PDE10. At least for PDE2, this site acts as an allosteric activator for cAMP hydrolytic activity. The GAF domain of PDE10A binds other small molecules that act as allosteric activators. PDE10A is a cAMP and cAMP-inhibited cGMP PDE (Fujishige et al., 1999; Fujishige et al., 1999; Loughney et al., 1999; Soderling et al., 1999).

Attenuation of the production of cAMP, may ameliorate the symptoms of HD and positively affect gene expression. Pharmaceutically acceptable modulators of cAMP include quinpirole,

alloxan, miconazole nitrate, MDL-12330A, and tetracycline derivatives such as demeclocycline and minocycline.

Compounds which are potent and selective modulators of cGMP-specific PDE, and are useful in a variety of therapeutic areas are taught by Daugan et al, U.S. patent No. 5,981,527, PCT publication No. WO 00/15639 to Icos Corporation and PCT publication No. WO 00/15228 to Icos Corporation, which are incorporated herein by reference. Such compounds include, for example:

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2',

1':6,1]pyrido[3,4-b]indole-1,4-dione,

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2',1':6,1]pyrido[3,4-
]indole-1,4-dione,

(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[
2',1':6,1]pyrido[3,4-b]indole-1,4-dione,

(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-3-methyl-pyrazino[
2',1':6,1]pyrido[3,4-b]indole-1,4-dione, and

(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2,3-dimethyl-pyraz
ino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione.

PDE1B1 is expressed throughout the brain and is most abundant in the striatum, nucleus accumbens and olfactory tubercle (Polli and Kincaid, 1994; Yan et al., 1994). PDE1B is a cGMP, Ca/calmodulin-dependent PDE. Therefore, PDE1B and 10A are both expressed in the majority, but not all, striatal neurons and, it is likely that both genes are co-expressed in a subset of striatal projection neurons. Selective inhibitors for PDE1 include KS-505, IC224,

and SCH 51866. Of these inhibitors, it appears that SCH 51866 has a ten-fold higher Km for PDE1 than PDE10 (Soderling et al., 1999). The non-specific PDE inhibitor IBMX is a potent inhibitor of PDE10A. Dipyridamole and SCH51866 had the highest potency of inhibitors tested on PDE10A activity. Dipyridamole was considered to be a PDE5- and PDE6-specific inhibitor, however, the Km for dipyridamole is 10 times higher for PDE10A than the other PDEs (Soderling et al., 1999). Selective inhibitors of PDE5, 2, 3 and 4 had much greater IC50 for PDE10 (Soderling et al., 1999).

EXAMPLE 13 - Clinical use of PDE10A Modulator

A 38 year-old female was admitted to hospital from a long-term care facility due to progressive deterioration of her physical and mental symptoms caused by Huntington's disease. The patient had been diagnosed with Huntington's disease at age 26. Prior to admission to the hospital, she had become increasingly aggressive and uncooperative. Moreover, there appeared to be an increase in the number of psychotic episodes. SPECT showed no abnormality of brain blood flow but MRI showed bilateral caudate atrophy as well as global atrophy of the cerebrum and corpus callosum.

The patient had been stable for a number of years on the antipsychotic haloperidol (3 mg/day). For the last two years, the haloperidol had been replaced by olanzapine (2.5-7.5 mg/day).

Minocycline, a tetracycline derivative, was administered at 50 mg twice daily for 7 days, followed by 100 mg twice daily for 7 days and finally 200 mg twice daily for 5 weeks. After 5 weeks of 200 mg twice daily minocycline administration, there was a mild improvement

compared to the baseline clinical global assessment made at the time of admission. The minocycline treatment was suspended for 7 days. Due to a significant increase in the number of aggressive incidence and decrease in cooperativity, minocycline (200 mg twice daily) treatment was resumed. The patient responded within 3 days to the resumed minocycline-treatment with a return to mild-improvement compared to the baseline clinical global assessment made at the time of admission. Minocycline (200 mg twice daily) treatment will continue indefinitely. The improvement in behaviour and decrease in apparent psychosis has allowed for the transfer of the patient from the acute care facility back to long-term care.

While the present invention has been described in terms of specific embodiments, it is understood that variations and modifications will occur to those skilled in the art. Accordingly, only such limitations as appear in the appended claims should be placed on the invention.

Non-patent Literature Cited

Atschul, S. F. et al.(1990), *J. Molec. Biol.* 215: 403.

Babity, J.M., Armstrong, J.N., Plumier, J.-C., Currie, R.W., and Robertson, H.A. (1997a) A novel seizure-induced synaptotagmin gene identified by differential display. *Proc. Nat. Acad. Sci. U.S.A.* 94: 2638-2641.

Babity, J.M., Newton, R.N., Guido, M.E. and Robertson, H.A. (1997b) The Application Of Differential Display To The Brain: Adaptations For The Study Of Heterogeneous Tissue. *Methods Mol Biol.* 85 (1997) 285-95.

Barney (1991) in *PCR Methods and Applications*, Aug., Vol. 1(1), page 5.

Beavo, J. (1995). Cyclic nucleotide phosphodiesterase: functional implications of multiple isoforms. *Physiol. Rev.* 75, 725-748

Beretta, S., Robertson, H. and Graybiel, A. (1992) Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatum. *J. Neurophysiol.* 68, 767-777

Bennett, D. et al.,(1995) *Journal of Molecular Recognition*, Vol. 8 52-58.

Berke, J.D., Paletzki, R.F., Aronson, G.J., Hyman, S.E. and Gerfen, C.R. (1998) A Complex Program of Striatal Gene Expression Induced by Dopaminergic Stimulation. *J. Neurosci.* 18: 5301-5310.

Caine E.D., Hunt R.D., Weingartner H., Ebert M.H. (1978) Huntington's dementia. Clinical and neuropsychological features. *Arch-Gen-Psychiatry.* 35, 377-84.

Carillo, H., and Lipman, D.(1988), *SIAM J. Applied Math.*, 48: 1073.

Carter, R. J., Lione, L. A., Humby, T., Mangiarini, L., Mahal, A., Bates, G. P., Dunnet, S. B., and Morton, A. J. (Apr. 1999). Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. *J Neurosci* 19, 3248-57

Cha, J.-H. J., Kosinski, C.M., Kerner, J.A., Alsdorf, S.A., Mangiarini, L., Davies, S.W., Penny, John B., Bates, G.P., Young, A.B. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. *Proc. Natl. Acad. Sci. USA* 95: 6480-6485.

Conolly, B. A. (1987) *Nucleic Acids Res.* 15:15(7): 3131.

Conti, M., and Jin, S. L. (1999). The molecular biology of cyclic nucleotide phosphodiesterases. *Prog Nucleic Acid Res Mol Biol* 63, 1-38

Crino, P., Khodakhah, K., Becker, K., Ginsberg, S., Hemby, S. and Eberwine, J. (1998) Presence and phosphorylation of transcription factors in developing dendrites. *Proc. Natl. Acad. Sci. USA* 95: 2313-2318

Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L. and Bates, G.P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. *Cell* 90, 537-548.

Davis et al., (1986) *Basic Methods in Molecular Biology*.

Denovan-Wright, E.M., Newton, R.A., Armstrong, J.N., Babity, J.M., Robertson, H.A. (1998) Acute administration of cocaine, but not amphetamine, increases the level of synaptotagmin IV mRNA in the dorsal striatum of rat. *Mol. Brain Res.* 55, 350-354.

Denovan-Wright, E.M., Gilby, K.L., Howlett, S.E. and Robertson, H.A. (1999) Cloning of differentially expressed brain cDNA. In *Differential Display - A Practical Approach*, H.A. Robertson and R.A. Leslie, Eds. Oxford University Press (in press).

Devereux, J., et al.(1984), *Nucleic Acids Research* 12(1): 387.

Douglass, J., McKinzie, A.A. and Couceyro, P. (1995) PCR differential display identifies a rat brain mRNA that is transcriptionally regulated by cocaine and amphetamine. *J.*

Neurosci. 15, 2471-2481.

Douglas, J. and Daoud, S. (1996) Characterization of the human cDNA and genomic DNA encoding CART: a cocaine- and amphetamine-regulated transcript. *Gene* 169, 241-245

Eberwine, J. (1996) Amplification of mRNA populations using aRNA generated from immobilized oligo(dt)-T7 primed cDNA. *Biotechniques* 20: 584-589

Eberwine, J., Yeh, H., Miyashiro, K., Cao, Y., Nair, S., Finnell, R., Zettel, M., Coleman, P., (1992) Analysis of gene expression in single live neurons. *Proc. Natl. Acad. Sci. USA* 89: 3010-3014

Fujishige, K., Kotera, J., Michibata, H., Yuasa, K., Takebayashi, S., Okumura, K., and Omori, K. (June 25, 1999). Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). *J Biol Chem* 274, 18438-45

Glass, M., Faull, R.L.M. and Dragunow, M. (1993) Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. *Neuroscience* 56: 523-527

Good et al (1977), *Nucl. Acid Res* 4:2157.

Gribskov, M. and Devereux, J., eds., *Sequence Analysis Primer*, M Stockton Press, New York, 1991.

Griffin, A. M., and Griffin, H. G., eds., *Computer Analysis of Sequence Data, Part I*, Humana Press, New Jersey, 1994.

Group THDCR (1993) A novel gene containing a trinucleotide repeat that is extended and unstable on Huntington's disease chromosomes. *Cell* 72: 971-983.

Hardy, J. and Gwinn-Hardy, K. (1998) Genetic classification of primary neurodegenerative disease. *Science* 282: 1075-1079

Hinnen et al., (1978) *PNAS USA* 75:1929-1933.

Houbenweyl, (1987) *Methods of Organic Chemistry*, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart.

Innis, M. A. and D. H. Gelfand (1989), PCR Protocols, A guide to Methods and Applications, M. A. Innis, D. H. Gelfand, J. J. Shinsky and T. J. White eds, pp 3-12, Academic Press.

Johanson, K. et al.(1995), *The Journal of Biological Chemistry*, Vol. 270, No. 16, pp 9459-9471.

Klement, I.A., Skinner, P.J., Kaytor, M.D., Yi, H., Hersch, S.M., Clark, H.B., Zoghbi, H.Y. and Orr, H.T. (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in *SCA1* transgenic mice. *Cell* 95: 41-53.

Lesk, A. M., ed., *Computational Molecular Biology*, Oxford University Press, New York, 1988.

Liang, P. and Pardee, A.B. (1992) Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. *Science* 257: 967-971.

Livesey, F.J., O'Brien, J.A., Li, M., Smith, A.G., Murphy, L.J. and Hunt, S.P. (1997) A Schwann cell mitogen accompanying regeneration of motor neurons. *Nature* 390: 614-618.

Livesey, F.J. and Hunt, S.P. (1996) Identifying changes in gene expression in the nervous system: mRNA differential display. *Trends Neurosci.* 19: 84-88

Loughney, K., Snyder, P. B., Uher, L., Rosman, G. J., Ferguson, K., and Florio, V. A. (June 1999). Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase. *Gene* 234, 109-17

Ludlow, C.L., Connor, N.P., Bassich, C.J. (1987) Speech timing in Parkinson's and Huntington's disease. *Brain-Lang*, 32, 195-214.

Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C. Lawton,

M., Trottier, Y., Lehrach, H., Davies, S. W. and Bates, G. P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell* 87: 493-506.

Merrifield, (1964), *J. Am. Chem. Assoc.* 85:2149-2154.

Okano, J., (1988) *Neurochem.* 56: 560.

Pardee, A.B. (1997) Complete genome expression monitoring: the human race. *Nat. Biotechnol.* 15: 1343-1344

Polli, J.W., and Kincaid, R. L. (1994). Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. *J. Neurosci.* 14, 1251-1261

Qu,-D., Ludwig,-D.S., Gammeltoft, S., Piper, M., Pelleymounter, M.A., Cullen, M.J. Mathes, W.F., Przypek, R., Kanarek, R. and Maratos-Flier, E. (1996) A role for melanin-concentrating hormone in the central regulation of feeding behaviour. *Nature* 380: 243-247.

Richfield, E.K. and Herkenham, M. (1994) Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. *Ann. Neurol.* 36: 577-584.

Ross, C.A., (1997) Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? *Neuron* 19: 1147-1150.

Saiki et al., (1986) *Nature*, 324: 163-166.

Sambrook, et al, (1989), *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

Saudou, F., Finkbeiner, S., Devys, D. and Greenberg, M.E. (1998) Huntington acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear

inclusions. *Cell* 95: 55-66.

Sisodia, S.S., (1998) Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental or beneficial? *Cell* 95: 1-4.

Smith, D. W., ed., *Biocomputing: Informatics and Genome Projects*, Academic Press, New York, 1993.

Soderling, S. H., Bayuga, S. J., and Beavo. J. A. (June 1999). Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. *Proc Natl Acad Sci U S A* 96, 7071-6

von Heinje, G., *Sequence Analysis in Molecular Biology*, Academic Press, 1987.

Yan, C., Bentley, J. K. Sonnenburg, W. K., and Beavo, J. A. (1994). Differential expression of the 61 kDa a 63 kDa calmodulin-dependent phosphodiesterase in the mouse brain. *J. Neurosci.* 14, 973-984

Young, A.B., Penney, J.B., Starosta-Rubinstein, S., Markel, D.S., Berent, S., Giordani, B., Ehrenkaufer, R., Jewett, D., Hichwa, R. (1986) PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. *Ann-Neurol.* 20, 296-303.

We claim:

1. A composition for treating a CAG repeat disorder comprising a compound which modulates PDE10A expression and a pharmaceutically acceptable carrier.
2. A composition as claimed in claim 1, wherein said compound is selected from the group consisting of: quinpirole, alloxan, miconazole nitrate MDL-12330A, and tetracycline derivatives such as demeclocycline.
3. A composition as claimed in claim 1, wherein said compound is selected from the group consisting of:
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2-isopropyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,
(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-3-methyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione,
(3S,6R,12aR)-2,3,6,7,12,12a-Hexahydro-6-(5-benzofuranyl)-2,3-dimethyl-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione.
4. A composition as claimed in claim 1, wherein said compound is selected from the group consisting of: KS-505, IC224, SCH 51866, IBMX and Dipyridamole.

5. A composition as claimed in any one of claims 1 to 4, wherein said disorder is Huntington's disease.
6. The use of a composition as claimed in any one of claims 1 to 5 for treating a CAG repeat disorder comprising administering said composition to a subject in need of such treatment.
7. The use of a composition of claim 6 for treating Huntington's disease comprising administering said composition to a subject in need of such treatment.
8. A method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of:
 - (a) selecting a control animal having PDE10A and a test animal having PDE10A;
 - (b) treating said test animal using a compound; and,
 - (c) determining the relative quantity of RNA corresponding to PDE10A, as between said animals.
9. A method of claim 8, wherein said animal is a mammal.
10. A method of claim 9, wherein said mammal is a mouse.
11. A method of claim 10, wherein said mouse is R6/2 transgenic mouse.
12. A method of any one of claims 8 to 11, wherein said CAG repeat disorder is Huntington's disease.

13. A method for identifying a compound which inhibits or promotes a CAG repeat disorder, comprising the steps of:

- (a) selecting a host cell containing PDE10A;
- (b) cloning said host cell and separating said clones into a test group and a control group;
- (c) treating said test group using a compound; and
- (c) determining the relative quantity of RNA corresponding to PDE10A, as between said test group and said control group.

14. A method of claim 13, wherein said CAG repeat disorder is Huntington's disease.

15. A method for detecting the presence of or the predisposition for a CAG repeat disorder, said method comprising determining the level of expression of RNA corresponding to PDE10A in an individual relative to a predetermined control level of expression, wherein a decreased expression of said RNA as compared to said control is indicative of a CAG repeat disorder.

16. A method of claim 15, wherein said CAG repeat disorder is Huntington's disease.

17. A method of claim 15 or 16, wherein said expression is measured by *in situ* hybridization.

18. A method of claim 15 or 16, wherein said expression is measured using a polymerase chain reaction.

19. A method of claim 15 or 16, wherein said expression is measured using a DNA fingerprinting technique.

HD WT
— —
1 2 3 4 5 6




Figure 1




Figure 2

Figure 3

5' 11 21 31 41
 1 TGTATGGAA TAGTGTCCATATGATCTGTTGCTGGAGTATATGCTAC
 1 ACATACCCCTTATCACAAGGTATACTAGACAACAGACCTCATATACGATG
 5' 61 71 81 91
 1 ATGTTCAATTACTGTACAAAACCCAGTGCAGCTGATGATGCAAAGCAGT
 51 TACAAGTAAATGACATGTT TTGGGTACGTCGACTACTACGTTCGTCA
 5' 11 21 31 41
 101 CTCTCTGTGTACAGTGC~~CC~~CACCTATTAAAATCACG TACTTGCCCA
 GAGAGAGACA CATGTCACGGGGTGGATAAA TTTTTAGTGCATGAACGGGT
 5' 61 71 81 91
 151 GAACACTGTGAAACACTTAA CATAAGAACAAACGCAGCGT CTGGATTCTT
 CTTGTGACACTTGTGAATTGTATTCTTGT TTGCGTCGCAACCTAAGAA
 5' 11 probe 2 21 31 41
 201 TCCAAGGAGAGCAGCTTCTCCACAGGAACACAGTAACAAAAGAGGTCCG
 AGGTTCCCTCTCGTCAAAGAGGGTGTCCCTTG TGTCAATTGTT TTCTCCAGGC
 5' 61 71 81 91
 251 CCGCCATCCA CACCCAGCCAAGACACCTCAGAGGCCATAGGGACAACCTC
 GGCAGTAGGTGTGGTCGGTTCTGTGGAGT CTCCGGTATC CCTGTTGGAG
 5' 11 21 31 41
 301 CTTGCTGGCCAACACCTGCTGGAGCAGGGG CACAGGTCCCAGCAACTGAT
 GAACGACCGG TTGTGGACGA CCTCGTCCCCGTGTCCAGGGTCGTTGACTA
 5' 61 71 81 91
 351 CCTCAGTGGATGGGCTCTGCAGCCAAAGCCTTAATGGGCTCTCTTTGAAG
 GGAGTCACCTACCCAGACGT CGGTTTGGAAATTACCCGAGAGAAAACCTC
 5' 11 21 31 41
 401 GGGAAAGAAAAGAATTCAAG CTTATGATATCCAATATTAT TATAGTTGAT
 CCCTTCTTTCTTAAAGTTCGAATACTATAGTTATAATAATATCAACTA
 5' 61 71 81 91
 451 GAGTTAGTAAATTCCAAAAAA
 451 CTCAATCATTAAAGTTTTTTTTT



WT HD

Figure 4

5 7 8 10




Figure 5




Figure 6




Figure 7



Figure 8




Figure 9

Figure 10

5' 11 21 31 41
 1 CACTGAAGCTGGTCCACGTCTATAAACAGGTGACACTGGCTGCAGCAAAA
 1 GTGACTTCGACCAGGTGCAGATATTGTCCACTGTGACCGACGTCGTTT
 5' 61 71 81 91
 51 AGCCATTCGATCCACACAAA TTGATCTTCTATCATCTTGGAAATCTGAATT
 51 TCGGTAAGCTAGGTGTTTAACTAGAAGA TAGTAGAACCTTAGACTTAA
 5' 11 21 31 41
 101 GCAGGGAGGA GCAGTATGTAAGACGACCGTTAATTCAAGGCATTCCGAAG
 101 CGTCCCTCCTCGTCATACATTCTGCTGGCAAATTAGTCCGTAAGGCTTC
 5' 61 71 81 91
 151 GCATGAGCGCATGGATTCTGTCACCAAGCGTATAAAAGGA CCCTGGCATT
 151 CGTACTCGCGTACCTAACAGACAGTGGTCGATATTTCCTGGACCGTAA
 5' 11 21 31 41
 201 GGGAAACCTATGACGGACTGTTTTGCTGTTAGAAGTAGGGATTACAGA
 201 CCCTTGGAATACTGCCTGACAAAAACGACATCTTCATCCCCTAAATGTCT
 5' 61 71 81 91
 251 AGTCTCCTTGAATTGCCCCCTGCCTGGGGCAGTTTGCTGAGAGGAACCTGCC
 251 TCAGAGGAACCTAACGGACCGACGTCAAACGTCTCCTGGACGG
 5' 11 21 31 41
 301 AGAGATTATTGGCTGGTCAGTCTCTTGTGAAATAGTATCATGTGAGAAA
 301 TCTCTAAATAACCGACCAGTCAGAGAACACTTTATCATAGTACACTCTT
 5' 61 71 81 91
 351 CAGTTGTAGAAAAAAACTATACCTGGGAAGACCTTGCAACACATTGTTCC
 351 GTCAAACATCTTTTGATATGGACCCCTCTGGAAACGTGTAAACAAGG
 5' 11 21 31 41
 401 TTCCATGGGCCAAGACTCAGTTAGGAGGCAAAATCTGCCCGGAATAAAC
 401 AAGGTACCCGGTCTGAGTCAATCCTCCGTATTTAGACGGGCCTTATTG
 5' 61 71 81 91
 451 TAGGCCAGGA TACAGCCATGTTAGTTAATAAATTGGTTTTAGAATTCA
 451 ATCCGGTCCTATGTCGGTACAAATCAATTAA TAAACCAAAATCTTAAGTG
 5' 11 21 31 41
 501 ACAGGCAGGA TTGGTTTTTTGTGTCTTGGCAAGTGGAGCATATTAAACA
 501 TGTCGTCCTAACCAAAACACAGAACCGTTCACCTCGTATAAATTGT
 5' 61 71 81 91
 551 TACAGGCATGGGAATCCTGCCCTCTTAGCTTTCCCACCCCTTTGTCTCAC
 551 ATGTCCGTACCCCTAGGACGGAGAACGAACTGAAAAGGGTGGGAGAACAGAGTG
 5' 11 21 31 41
 601 CAAGTTTTCTCTCCAAAGGTTCCAGGAATTCTCATTAAATGGCTGAT
 601 GTTCAAAAAAGAGAGGTTCCAAAGGTCCCTAAAGAGTAAATTACCGACTA

Figure 10 continued

5' 61 71 81 91
 651 GCAAACCTTAGTGAATAATAATGAATATAAA CAATGCTCACCTCACCAAAA
 CGTTGAATCACTTATTATTACTTATTTGTTACGAGTGAGTGGTTTT
 5' 11 21 31 41
 701 TTATATTATTTCAGTCATTGATGATAACACAAATTTATCGCAATGGTT
 AATATAATAAACGTCAGTAAACACTATTGTGTTAAAATAGCGTTACCAA
 5' 61 71 81 91
 751 ATTATTTAATTGTGCCACACACTGTGGTTATCTTTGTGTTGGTTGTT
 TAATAAATTAAACACCGGTG TGTGACACCAATAGAAAACAACACCAACAA
 5' 11 21 31 41
 801 TCTGAGAAAAATGTTCTTGGATATGTAAGTGCACATACAGTGTGAAAGTAT
 AGACTCTTTACAAGAACCTATACATTACGGTTATGGTCACACTTCATA
 5' 61 71 81 91
 851 TGATCCCGGGCAGCAAAATA CAGCCTAAGGTTGTAAACATCAATTCTAT
 ACTAGGGCCCGTCGTTTATGTCGGATTCAAACATTGTAGTTAAGATA
 5' 11 21 31 41
 901 CTCAGTTCATCAGAGGGCCTGAGAAGCTGCAGGTAAAGTAAAGT
 GAGTCAAGTAGTCTCCGGACTCTTCGACGCCCGTCACATTTCATTCA
 5' 61 71 81 91
 951 ATGCTGGGCTGGTGGTGGTCAGCCTCCGCCTGAAGAGTGACCAAGTGCTG
 TACGACCCGACCAACCACCAAGTCGGAGGGCGGACTTCTCACTGGTCACGAC
 5' 11 21 31 41
 1001 GCCCGACGGATCGCTGAGATATTCTCCATAATGGCAAAAAAAATAGGCAG
 CGGGCTGCCTAGCGACTCTATAAGAGGGTATTACCGTTTTTATCCGTC
 5' 61 71 81 91
 1051 TTTGATGTGACCTGTTAGTGTGGCTCTCCTCTTTGAGCATGTGTTAGC
 AAACTACACTGGACAAATCAACCGAGAGGAGAAAACTCGTACACAATCG
 5' 11 21 31 41
 1101 ATTTTATTTATACTCATCAGTGAACCTTGCTCTTCCAAGTGTGTTCA
 TAAAAATAAAATATGAGTAGGTCACTTGAGACGAGAAGGTTCACACAAGT
 5' 61 71 81 91
 1151 TGTATGTGCTAGATATATTAGCACAGCCTGCCTCTGCTGCACAAACGCCT
 ACATACACGA TCTATATAATCGTGTGGACGGAAAGACGACGTGTTGCGGA
 5' 11 21 31 41
 1201 TAGAGACCCGGCCTTCAATGAGCTTAGCTTGTGCTCTGTTCTGCTCTC
 ATCTCTGGGCCGGAAAGTTACTCGAATCGAACACGGAGACAAAGACGAGAG
 5' 61 71 81 91
 1251 TTAGGTCTAAACTATGGTGTCAAGTTTAATAGAACAAAAGTATGCATCTT
 AATCCAGATTGATACCAACAGTCAAAATTATCTTGTGTTTCATACGTAGAA

Figure 10 continued

5' 11 21 31 41
 1301 GCCTTGGCTT GAGCCTTT CGTTT CAATG CTGACTT CTC CCCC TTCTCT
 CGGAACCGAAC TCGGAAAAG CAAAAGTTACGACTGAAGAGGGAGAGAGA

5' 61 71 81 91
 1351 CCTGTGCTCACCTTACCTTT CCAGAGTGTAAAGGGACAACTTTAAGGAGG
 GGACACGGAGTGGAAATGGAAAGGTCTCACATTCCCTGTTGAAAATTCCCTCC

5' 11 21 31 41
 1401 CGTGTCCCTGGTAGGGGCATCCCTGTTCACCAAGGTGCCTGTCATCACCCC
 GCACAGGGACCATCCCCTAGGGACAAGTGGTCCACGGACAGTAGTGGGG

5' 61 71 81 91
 1451 ACTTGACTGACATCTACCCCTGGTGA CTTGGTTCCCTCTTGTGTAGGG
 TGAAC TGACTGTAGATGGGACCACTGATA CCAAGGAGAACAAACATCCC

5' 11 21 31 41
 1501 AACGGTGGCTCCAGGTGGAGGCATCAATCTGTTGGGTTCTGGTCCCGGC
 TTGCCACCGAGGTCCACCTCCGTAGTTAGACAACCCAAGACCAAGGGCCG

5' 61 71 81 91
 1551 TGCCTTGGTTTGAAAGTCTCTCTGTATATTCCTACCTGCATTG
 ACGGAAACCAAAACTTCAGAGAAGAGACATATAAGGATGGACGTAAAC

5' 11 21 31 41
 1601 CTTTGTGTGGTGCTGATGCTGTGCGCAGTAGGATTCTGGATGACTCTCC
 GAAACACACCACGACTACCGAACCGCGTACCTAACGAAACCTACTGAGAGG

5' 61 71 81 91
 1651 ATCAGTCACAGACTCCCCCTGTTGCAAAGTGTCAAGGCTGA CTCGACAGTC
 TAGTCAGTGTCTGAGGGGGACAACGTTCAAGTCCGACTGAGCTGTCAG

5' 11 21 31 41
 1701 ACCGTAAAATCTGAGTCAGTCAACACACAGGCTGTCAGGCCACGGCTTCCAC
 TGGCATTTAGACTCAGTCAGTGTGTGTCCGACAGTCGGTGCCGAAGGTG

5' 61 71 81 91
 1751 TTGCATGGCTATTCTATTTCACACGTGAGTTCTGTTGCTGGCTGGCTG
 AACGTACCGATAAGATAAAAGTGTGCACTCAAAGACAAACGACCGACCGAC

5' 11 21 31 41
 1801 ACTGGCATTATCTATGCTAAAGTGAATCAGGAGTGC CAGCAGAGCCCA
 TGACCGTAATAGATACGATTCAACTTAGTCCTCACGGGT CGTCTCGGGT

5' 61 71 81 91
 1851 TCATTCTCACTGTCTTGAAACAAAGCTGTACGGTTGATCGATGAACGT
 AGTAAGAGTGA CAGAAACTTTGTTCGACATGCCAAACTAGCTACTTGCA

5' 11 21 31 41
 1901 ATTTAAAGCA TTTCATGCAA TGACAAAAGTGCTCAGTAGTGGAAAGGCAGGC
 TAAATTCTGTAAGTACGTTACTGTTCACGAGTCATCACCTCCGTCCG

Figure 10 continued

5' 61 71 81 91
 1951 TGTGACCAGT CTGCCTGCTC CTTACTATAA TTGTGAGGAT TTGTTACTGG
 ACACTGGTCAGACGGACGAGGAATGATATT AACACTCCTAAACAATGACC

5' 11 21 31 41
 2001 AACAGTACAT GGAGGCCTGACCTTGTGGGGC ACAGGGTG GAACCTTAGC
 TTGTCATGTA CCTCCGGACT GGAACACCCCC CGTGTCCCAC CTTGGAATCG

5' 61 71 81 91
 2051 TGAATATAGT GTGTGTCTCAAGAGGAAGTCAGGGTACTAG CTCAGTGCTC
 ACTTATATCACACACAGAGT TCTCCTCAG TCCCATGATCGAGTCACGAG

5' 11 21 31 41
 2101 AATCTCCAGG TACTATATACATTTGCCCGTTTATCTCTAAATGTGAAA
 TTAGAGGTCCATGATATATATGTAAACGGG CAAAATAGAGATTACACTTT

5' 61 71 81 91
 2151 TAAATCCCCAAACACTGTTTATCGTGTAG CGTACCTAAAAGACTATTCT
 ATTAGGGGTTTGTGAACAAATAGCACATCGCATGGATTTCTGATAAGA

5' 11 21 31 41
 2201 ATTATGGGTG TCCCCACTTT CTTGGTTGGTCACCCCGAT CCCCCGGTCT
 TAATACCCACAGGGGTGAAAGAACCAAACCAGTGGGGCTAGGGGGCAGA

5' 61 71 81 91
 2251 TCTGCTGTATCTAGAACAGT GACTATAAATGATGTATGGGAATAGTGT
 AGACGACATAGATCTGTCACTGATATTACTACATACCCCTATCACAAA

5' 11 21 31 41
 2301 CCATATGATCTGTTGTCTGGAGTATATGCTACATGTTCAAATTACTGTACA
 GGTATACTAGAACACAGACCTCATATACGA TGTACAAGTTAATGACATGT

5' 61 71 81 91
 2351 AAAACCCAGT GCAGCTGATGATGCAAAGCA GTCTCTCTGTGTACAGTG
 TTTGGGTCA CGTCGACTACTACGTTCGT CAGAGAGAGACACATGTCAC

5' 11 21 31 41
 2401 CCCCACCTATTAAAAATCA CGTACAASCC CAGAACACTG TGAAACACTT
 GGGGTGGATAAAATTAGTGCATGTTGGCTTGACACTTTGTGAA

5' 61 71 81 91
 2451 AACATAAGAA CAAACGCAGCGTCTGGATTCTTCCAAGGAGAGCAGCTT
 TTGTATTCTTGTGCGTCG CAGACCTAAGAAAGGTTCTCTCGTCAAA

5' 11 21 31 41
 2501 CTCCACAGGAACACAGTAAC AAAAGAGGTC CGCCGCCATC CACACCCAGC
 GAGGTGTCCATTGTGTCATTG TTTCTCCAG GCAGCGGTAGGTGTGGTCG

5' 61 71 81 91
 2551 CAAGACACCTCAGAGGCCATAGGGACAACCTCCTTGCTGG CCAACACCTG
 GTTCTGTGGAGTCTCCGGTA TCCCTGTTGGAGGAACGACC GGTTGTGGAC

Figure 10 continued

5' 11 21 31 41
 2601 CTGGAGCAGGGGCACAGGTC CCAGCAACTGATCCTCAGTGGATGGGTCCG
 GACCTCGTCCCCGTGTCAGGGTCACTAGGAGTCACCTACCCAGGC

5' 61 71 81 91
 2651 CAGTCAAAGCCTTAATGGGCTCTCTTTGAAGGGGAAAGAAAGAATTCA
 GTCAGTTCCGAAATTACCCGAGAGAAAACCTCCCCTTCTTCTTAAAGT

5' 11 21 31 41
 2701 AGCTTATGATATCCAACATTATTATAGTTGATGAGTTAGTAAATTCCAAA
 TCGAATACTATAGTTGTAATAATATCAACTACTCAATCATTAAAGGTTT

5' 61 71 81 91
 2751 AAAAAAAGATGATTTATATGTATGACATAAAAAAAATCTTGTAAGTG
 TTTTTTCTACTAAAATATACTACTGTATTTTTTAGAAACATTCAC

5' 11 21 31 41
 2801 CGCAAGTGCAATAATTAAAAGAGGTCTTATCTTGCAATTATAAAATTATA
 GCGTTCACGTTATTAAATTCTCCAGAATAGAAACGTAAATTTAAATAT

5' 61 71 81 91
 2851 AATATTGTACATGTGTGTAATTTCATGTATTCAATTGCAGTCAGTTGTA
 TTATAACATG TACACACATTAAAAGTACATAAGTAAACGTCAAGAACAT

5' 11 21 31 41
 2901 TTTAAAAAAACTTTACTGTTATGTTGTATAATAGAACATTAAATCATTAA
 AAATTTTTGAAATGACAATACAAACATATTATCTTGTAAATTAGTAAAT

5' 61 71 81 91
 2951 TTATAACTCAGACAAGGTGTAAATAAATTCAATTCAAA CAGCCAGTAT
 AATATTGAGTCTGTTCCACATTATTAAAGTATTAAGTTGTCGGTCATA

5' 11 21 31 41
 3001 ATATGCATATATGGGTGTTACATTGCAAAATCTCTATCTTGTCTATT
 TATACGTATAATACCCACAATGTAACGTTTAGAGATAGAAACAAGATAA

5' 61 71 81 91
 3051 CACATGCTTAAAGAAGTAAGAAATCTTTGTGGATATGTAATTACATA
 GTGTACGAATTCTTCATTCTTAGAAAACACCTACATTAATATGTAT

5' 11 21 31 41
 3101 TAAAGTATATATATATGTATGATACATGAAATATATTAGAAATGTTCAT
 ATTTCATATAATACATACTATGTACTTTATATAATCTTACAAGTA

5' 61 71 81 91
 3151 AATTTTAATGGATATTCTTGGTGTGAATAATTGAATACAAACATTAA
 TTAAAATTACCTATAAGAAACACACTTATTAACTTATGTTGTAAGAATT

5' 11 21 31 41
 3201 AATGAAAAAAAAAAAAAAAAAAAAAA
 TTACTTT




Figure 11
3236 bp

Figure 12

5' 11 21 31 41
 1 AAGTGTAAATAAAATAACATCTAATAAAAAAATTACATACCATAGAGG
 1 TTCACATTTATTTTATTGTAGATTATTTTTAATGTA TGGTATCTCC

 5' 61 71 81 91
 51 AACAAAGATAA TTTCTGCCAACTTCATACCCTCCAGCGTA TAGTGGAG
 51 TTGTTCTATTAAAGACGGGTTGAAGTATGGGAGGTCGCATATCACAACTC

 5' 11 21 31 41
 101 GTTTGGTCTGTTGCTGTGTATTGTAATGTAATGTTAAATTCTCTACCTGA
 101 CAAACCAGACAACGACACATAACATTACATTACAATTAA GAGATGGACT

 5' 61 71 81 91
 151 AGGTCTAGGCCTACAAGTGAATTCTCATGTTATAGAGTT TTGTTGTGCA
 151 TCCAGATCCGGATGTTCACTTAAGAGTACAAATATCTCAAAACAAACACGT

 5' 11 21 31 41
 201 AACCTTGTCTTAATTAAAATATGGTTAAAAAACAAAACAAAACGG
 201 TTGGAACAAGGAATTAAATTGATACCAA TTTTTGTTT TGTTTGACC

 5' 61 71 81 91
 251 CTACAGCCAA TAACTGAAGGGGGTACCTTGTGAAGGGGG TGGAAAAGAG
 251 GATGTCGGTTATTGACTTCCCCCAATGGAA CAACTTCCCCACCTTTCTC

 5' 11 21 31 41
 301 AGAGGAGGAAGAAGGGAGTT CAAGAGAAGGAGAAGAACAAAGGGAGAGGA
 301 TCTCCTCCTTCTTCCCTCAAGTTCTCTTCTCTTGTTCCTCTCCT

 5' 61 71 81 91
 351 GGAAGCTGCCACGAGGGGAGATGGGCCATGAGAACTTGGC CAGGAGAAAT
 351 CCTTCGACGGTGCTCCCTCTACCCGGTACTCTTGAAACCGGTCCTTTA

 5' 11 21 31 41
 401 AGCCAGTATCTGGAGTACAC CACTGAGGAGGTAGCCAGGC TAGCAGTTAG
 401 TCGGTCA TAGACCTCATGTGGTACTCCTCCATCGTCCGATCGTCAATC

 5' 61 71 81 91
 451 AAGAGTAGATTAGGGTTATTTCCCCCACTCCACATAGTTATCAAAGC
 451 TTCTCATCTAATCCCCAATAAAAGGGGGTGAGGTGTATCAATAGTTCG

 5' 11 21 31 41
 501 CAAATAAAATAACCATAGTCTGAGTCTCATCTATTGTAAGCTAGTTGGG
 501 GTTTATTTATTGGTATCAGACTCAGAGTAGATAAACATT CGATCAAACCC

 5' 61 71 81 91
 551 TATAAGATTAATTGGCTGTACTACAGTTAGATTCTAA CATAGGAAC
 551 ATATTCTAATTAACCGACATGATGTCAAATCTAAAGATTGTATCCTGA

 5' 11 21 31 41
 601 ATCAAAAACCTTGCTCAAACAAAGAACATGCTGACAATATTAAAATGATT
 601 TAGTTTTGAACGAGTTGTCTTGTACGACTGTTATAAAATTTACTAA

Figure 12 continued

5' 61 71 81 91
 651 ATTATATTGTTGCACCTTCTAAAGTTCTCTAAATGTTCCATGGTCA
 TAAATATAACAAACGTGAAAGATTCAAAGAAGATTACAAGGTACCAAGT

5' 11 21 31 41
 701 AATTAAAAAAATACATATTGGCTATTAAATCGTCTAAGTGGGGCTGGA
 TTAATTTTATATGTATAACCGATAATTAAAGCAGATTCAACCCGACCT

5' 61 71 81 91
 751 GAGATAGCTCAGAGGTTAACAGAGCACTGACTGCTCTCCAGAGGTCTGAG
 CTCTATCGAGTCTCCAATTCTCGTACTGACGAGAAGGTCTCCAGGACTC

5' 11 21 31 41
 801 TTCAATTCCCAGCGACCACATGGTGGCTCACAGCCATCTGTAATAGATAG
 AAGTTAAGGGTCGCTGGTGTACCAACCGAGTGTGGTAGACATTATCTATC

5' 61 71 81 91
 851 GATCTGACGCCCTCTGGAGTGTCTGAAGACAGCTACAAATGTACTCAT
 CTAGACTGCGGGAGAACACCTCACAGACTCTGTCGATGTTACATGAGTA

5' 11 21 31 41
 901 ATATATTAAATAAATAATATAGAAAATTCTCTAAAGTGTATCATTATA
 TATATAATTATTTATTATAATCTTTAAGAAGATTACACATAGTAAATAT

5' 61 71 81 91
 951 GAATATTTAATATATAAGTAAATGCCCTCAGGAAATATAAACTTGGAAATT
 CTTATAAATTATATATTCAATTACGGAGTCCTTATATTGAAACCTTAA

5' 11 21 31 41
 1001 AAATCAAAGAACTTCATGAGTAGTGGGCCACAAAAAAATGTGTACCAAGGGG
 TTTAGTTCTTGAAGTACTCATCACCCGGTGTACACATGGTCCCC

5' 61 71 81 91
 1051 AAGACCGGAGGGAGGGAGAAGGAAGGGATGGAGATAGAATTGGCCTCT
 TTCTGGCCTCCCTCCCTCTCCTCCCTACCTCTATCTAAACCGAGA

5' 11 21 31 41
 1101 GCATTCCTGGGCTGGCACAGGTATAATGCTGTGGGAATTGGGAAACTAC
 CGTAAGGAACCCGACCGTGTCCATATTACGACACCCCTAACCCCTTGATG

5' 61 71 81 91
 1151 AAGGAAGCTGCAAAGCTGGGCGGAACCTCGTTCCGCAAGCTGGGCTCATC
 TTCCTCGACGTTCGACCCGCCTGAGCAAAGCGTTCGACCCGAGTAG

5' 11 21 31 41
 1201 TAAGTGTCCATGCATGGCTGCCACACTGCAGTGAACCTTAAACATTGT
 ATTACAGGTACGTACCGACGGTGTGACGTCACTGAAATTGTAAACA

5' 61 71 81 91
 1251 GTTCCAGAGATGTAGAGATGCTCACAAATGACAAAGGCGGGAGGG
 CAAGGTCTACATCTACGAGTGTATCATGTTCCGCCCTCCCTCCA

Figure 12 continued

5' 11 21 31 41
 1301 ATTTCCAGACTAAGAGGAAGAAAAACCATTGCTGATTAAACATCTGCATA
 TAAAGGTCTGATTCTCCTCTTTGGTAA CGACTAATTGTAGACGTAT

5' 61 71 81 91
 1351 TGAGCGCCCCCACCTCCATACACACACACA CACACACACACACACACA
 ACTCGCGGGGGTGGAGGTATGTGTGTGTGTGTGTGTGTGTGTGTGT

5' 11 21 31 41
 1401 CAACCAAACAGAACAAATACACATGCATGTCTACAGCCTGCAGGAACAAA
 GTTGGTTTGTCTTGTATGTGTACGTACAGATGTCGGACGTCCTTGT

5' 61 71 81 91
 1451 ATGGTATGTC TGTGAGGAAC CAGGAGATGCACAGGTCTAACCTCTGTCT
 TACCATACAGACACTCCCTGGTCCCTCTACGTGTCCAGGATTGGAGACAGA

5' 11 21 31 41
 1501 CCTACAAGCCCTGAAGTCTGGTCAAGGGTCAAATGTACAAAAGCAGGCTAA
 GGATGTTGGACTTCAGAC CAGTCCCAGTTACATGTTTCGTCCGATT

5' 61 71 81 91
 1551 GGAAGCTGTTAGTCAAAGATTTCAGGAGATTCAGAACAAACCTAT
 CCTTCGACAAATCACTTCTAAAAAAAGAAGTTGAGATCCTTGTGGATA

5' 11 21 31 41
 1601 TTCCTAGGATTGGAGAGTGCTCAGGAGGAAACATTAGAACACTGATGC
 AAGGATCCTAAACCTCTCACGAGTCCTCTTGTAAAGTCTGTGACTACG

5' 61 71 81 91
 1651 TCTCTGTGTACCCAGATTCAAGGTATTGGGGTAGTTAGTTAGTGTGCTCATGT
 AGAGACACATGGGGTCTAAGTCCATAACCCATCAATCAA CACGAGTACA

5' 11 21 31 41
 1701 ATGTGCTAGATATATTAGCA CAGCCTGCCTTCTGCTGCACAACGCCCTAG
 TACACGATCTATATAATCGTGTGGACGGAAGACGACGTGTTGGAAATC

5' 61 71 81 91
 1751 AGACCCGGCTTCAATGAGCTTAGCTTGTGCTCTGTTCTGCTCTCTTA
 TCTGGGCCGGAAAGTTACTCGAATCGAACACGAGACAAAGACGAGAGAAT

5' 11 21 31 41
 1801 GGTCTAAACTATGGTGTCA GTTTAATAGAACAAAAGTATGCATCTGCC
 CCAGATTGA TACCACAGTCAGTCAAAATTATCTTGTCTCATACGTAGAACGG

5' 61 71 81 91
 1851 TTGGCTTGAGCCTTTCTGTTTCAATGCTGACTTCTCCCCCTTCTCTCCT
 AACCGAACTCGGAAAAGCAAAAGTTACGACTGAAGAGGGAAAGAGAGGA

5' 11 21 31 41
 1901 GTGCTCACCTTACCTTCCAGAGTGTAAAGGGACAACTTTAAGGAGGC
 CACGAGTGGAAATGGAAAGGTCTCACATTCCCTGTTGAAAATTCCTCCGCA

Figure 12 continued

5' 61 71 81 91
 1951 GTCCCTGGTAGGGGCATCCC TGTTCACCAAGGTGCCTGTCA TCACCCCCACT
 CAGGGACCATCCCCGTAGGGACAAGTGGTCACGGACAGTAGTGGGTGA

5' 11 21 31 41
 2001 TGACTGACATCTACCCTGGT GACTATGGTTCCCTCTTGTGTTGTAGGGAAC
 ACTGACTGTAGATGGGACCACTGATAACCAAGGAGAACAAACATCCCTG

5' 61 71 81 91
 2051 GGTGGCTCCAGGTGGAGGCATCAATCTGTTGGGTTCTGGTTCCCGGCTGC
 CCACCGAGGTCCACCTCCGTAGTTAGACAAACCAAGACCAAGGGCCGACG

5' 11 21 31 41
 2101 CTTTGGTTTGAAAGTCTCTCTCTGTATA TTCCTACCCCTGCATTGCTT
 GAAACCAAAACTTCAGAGAACAGACATATAAGGATGGGACGTAAACGAA

5' 61 71 81 91
 2151 TGTGTGGTGCTGATGCTGTGCGCAGCAGGA TTCTGGATGACTCTCCATC
 ACACACCACGACTACGACACGCCTCGTAAAGAACCTACTGAGAGGTAG

5' 11 21 31 41
 2201 AGTCACAGACTCCCCCTGTTGCAAAGTGTCAAGGCTGACTCGACAGTCACC
 TCAGTGTCTGAGGGGACAACTGTTCACAGTCCGACTGAGCTGTCAGTGG

5' 61 71 81 91
 2251 GTAAAATCTGAGTCAGTCACACACAGGCTGTCAGCCACGGCTTCCACTTG
 CATTAGACTCAGTCAGTG TGTGTCCGACAGTCGGTCCGAAGGTGAAC

5' 11 21 31 41
 2301 CATGGCTATTCTATTTCACACGTGAGTTCTGTTGCTGGCTGGCTGACT
 GTACCGATAAGATAAAAGTGTGCACTCAAAGACAACGACCGACCGACTGA

5' 61 71 81 91
 2351 GGCATTATCTATGCTAAGTTGAAATCAGGGGTGCCCAGCAGAGCCCCATCA
 CCGTAATAGATACGATTCAA CTTAGTCCCACGGGTCGTCTGGGTAGT

5' 11 21 31 41
 2401 TTCTCACTGTTGGAAACAAAGCTGTACGGTTGATCGATGAACAGTATT
 AAGAGTACGAGAAACTTGTTCGACATGCCAAACTAGCTACTTGCATAAA

5' 61 71 81 91
 2451 TAAAGCATTTCATGCAATGACAAAGTCTCAGTAGTGGAAAGGCAGGGCTGT
 ATTCGTAAGTACGTTACTGTTCACGAGTCATCACCTTCCGTCCGACA

5' 11 21 31 41
 2501 GACCAAGTCTGCTCCTTACTATAATTG TGAGGATTGTTACTGGAAC
 CTGGTCAGACGGACGAGGAATGATATTAAACACTCCTAAACAATGACCTG

5' 61 71 81 91
 2551 AGTACATGGAGGCCTGACCTTGTGGGGGCACAGGGTGGAACCTTAGCTGA
 TCATGTACCTCCGGACTGGAACACCCCCGTGTCCCACCTTGGAAATCGACT

Figure 12 continued

5' 11 21 31 41
 2601 ATATAGTGTG TGTCTCAAGAGGAAGTCAGGGTACTAGCTCAGTGCTCAAT
 TATATCACACACAGAGTTCTCCTTCAGTCCATGATCGAGTCACGAGTTA

5' 61 71 81 91
 2651 CTCCAGGTACTATATATACATTGCCGTTTATCTCTAAATGTGAAATAA
 GAGGTCCATGATATATGTAAACGGGCAAAATAGAGATTACACTTTATT

5' 11 21 31 41
 2701 ATCCCCAAACACTTGTATCGTGTAGCGTACCTAAAAGACTATTCTATT
 TAGGGGTTGTGAACAAATAGCACATCGATGGATTCTGATAAGATAA

5' 61 71 81 91
 2751 ATGGGTGTCCCCACTTCTGGTTGGTCACCCCGATCCCCGGTCTTCT
 TACCCACAGGGGTGAAAGAACAAACCAAGTGGGCTAGGGGCCAGAAGA

5' 11 21 31 41
 2801 GCTGTATCTAGAACAGTGAATATAATGATGTATGGAAATAGTGTTC
 CGACATAGATCTTGTCACTGATATTACTACATACCCTATCACAAAGGT

5' 61 71 81 91
 2851 TATGATCTGTGTCTGGAGTATATGCTACATGTTCACTGTACAAAAA
 ATACTAGACAACAGACCTCATATACGATGTACAAGTAAATGACATGTTT

5' 11 21 31 41
 2901 ACCCAGTGCAGCTGATGATGCAAAGCAGTCCTCTCTGTGTACAGTGCCC
 TGGTCACGTGACTACTACGTTCTCAGAGAGAGACATGTCACGGG

5' 61 71 81 91
 2951 CACCTATTTAAAAATCACGTACTTGCCCCAGAACACTGTAACACTTAAC
 GTGGATAAAATTTTAGTCATGAACGGGTCTTGTGACACTTTGTGAATTG

5' 11 21 31 41
 3001 ATAAGAACAAACGCAGCGTCTGGATTCTTCTCAAGGGAGAGCAGCTTCTC
 TATTCTGTTTGCCTCGCAGACCTAACGAAAGGTTCTCGTCGAAAGAG

5' 61 71 81 91
 3051 CACAGGAACACAGTAACAAAGAGGGTCCGCCATCCACACCCAGCCAA
 GTGTCCTTGTGTCATTGTTCTCCAGGCGGGTAGGTGTGGTCGGTT

5' 11 21 31 41
 3101 GACACCTCAGAGGCCATAGGGACAACCTCCTGCTGGCCAACACCTGCTG
 CTGTGGAGTCCTCGGTATCCCTGTTGGAGGAACGACGGTTGTGGACGAC

5' 61 71 81 91
 3151 GAGCAGGGGCACAGGTCCCAGCAACTGATCCTCAGTGGATGGGTCTGCAG
 CTCGTCGGGTGTCAGGGTCTGACTAGGAGTCACCTACCCAGACGTC

5' 11 21 31 41
 3201 CCAAAGCCTTAATGGGCTCTCTTTGAAGGGGAAAGAAAGAATTCAAGC
 GGTTTCGGAAATTACCCGAGAGAAAACCTCCCTTCTTCTTAAAGTCG

Figure 12 continued

5' 61 71 81 91
 TTATGATATCCAATATTATTATAGTGATGAGTTAGTAAATTCCAAAAAA
 3251 AATACTATAGTTATAATAATATCAACTACTCAATCATTTAAGGTTTTT
 5' 11 21 31 41
 AAAAGATGATTTATATGTATGACATAAAAAAAATCTTGTAAGTGCAC
 3301 TTTCTACTAAAATACATACACTGTATTTTTAGAACATTACGCG
 5' 61 71 81 91
 AAGTGCATAATTAAAGAGGGTCTTATCTT TGCATTATAAATTATAAAT
 3351 TTCACGTTATTAAATTCTCCAGAATAGAACGTAATATTAAATATTAA
 5' 11 21 31 41
 ATTGTACATGTGTAAATTTTGTATT CATTGCAGTCTTGATTT
 3401 TAACATGTACACACATTAAAAGTACATAAGTAAACGTCAGAACATAAA
 5' 61 71 81 91
 AAAAAAACTTACTGTTATGTTGTATAATAGAACATTAAATCATTATAA
 3451 TTTTTTGAAATGACAATACAAACATATTATCTTGTAAATTAGTAAATAAT
 5' 11 21 31 41
 TAACTCAGACAAGGTGAAATAAATTCTAAATTCAAACAGCCAGTATATA
 3501 ATTGAGTCTGTTCCACATTAAAGTATTAAAGTTGTCGGTCATATAT
 5' 61 71 81 91
 TGCATATATGGGTGTACATTGCAAAATCTCTATCTTGTTCTATTAC
 3551 ACGTATATAACCCACAATGTAACGTTTAGAGATAGAACAGATAAGTG
 5' 11 21 31 41
 ATGCTAAAGAAGTAAGAAAATCTTTGTGGATATGTAATTATACATATAA
 3601 TACGAATTCTTCATTCTTAGAAAACACCCTATACATTAAATATGTATATT
 5' 61 71 81 91
 AGTATATATATATGTATGATACATGAAATAATTAGAAAATGTTCTATAAAT
 3651 TCATATATATACACTATGTACTTATATAAATCTTACAAGTATTAA
 5' 11 21 31 41
 TTTAATGGATATTCTTGGTGTGAATAATTGAATACAACATTTTTAAAT
 3701 AAATTACCTATAAGAACCAACTTATTAACTTATGTTGAAAAATTAA
 5' 61 71 81 91
 AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA
 3751 TTT
 5' 11 21 31 41
 TTATTCCAGAGATTAAAGACACTAGATCTTAAACCTGTGAAGGGCAGGCAA
 3801 AATAAGGTCTTAATTCTGTGATCTAGAAATTGAAACTTCCGTCCGTT
 5' 61 71 81 91
 GAGGTGGCAATGCTGTCAAATAGAAGTCAGGGACCATTTCCTTCTTGA
 3851 CTCCAGCCGTTACGACAGTTGTATCTCAGTCCCTGGTAAAAGAAGAACT

Figure 12 continued

5' 11 21 31 41
 3901 ACATGCAGTCACTTCTGATTGCTCTCACATCCTCAAGGCTCCGGAAT
 TGTACGTCAGTGAAAGGACTAACGAGAAGTGTAGGAGTTCAGAGCCTTA

5' 61 71 81 91
 3951 TCCGGGGGTG TGGTGGGCTT TGATCTCAGGACTCTGGAGG CAGAAGCAGG
 AGGCCCCCACACCACCCGAAACTAGAGTCCTGAGACCTCCGTCTCGTCC

5' 11 21 31 41
 4001 CAGATCTCTGTGAATATGAGGCCAGCCTGCACTACACAGAGCTCCAGACC
 GTCTAGAGACACTTAACTCCGGTCCGACGTGATGTGTCTCGAGGTCTGG

5' 61 71 81 91
 4051 AGTCATGGCTACATCATGAAACCCCTGTCTCAAAAAGAAAAATAAAAACGT
 TCAGTACCGATGTAGTACTTGGGACAGAGTTTTCTTTATTTTGACA

5' 11 21 31 41
 4101 TGTGTTCTACCATAGTGTAAACTCAGAGTCTGAGTAATGTCGGGCTGA
 ACACAAAGATGGTATCACAAATTGAGTCTCAGACTCATTACAGCCCCACT

5' 61 71 81 91
 4151 CATGCTCGGGTGTTAACATACCTTCAGCTTGACGAGGCCTGAAACAGT
 GTACGAGCCCACAAATTGTA TGGAAAGTCGAAACTGCTCCGCGACTTGTCA

5' 11 21 31 41
 4201 CAAAGTCTGGCCTGGGAG CGGTGGCTGTGTTGTGCTCAAGTCCACCG
 GTTTCAGACCGGAACCCCTCGCCACCGACA CAAACACGAGTTCAAGGTGGC

5' 61 71 81 91
 4251 TGAAATCCTGATTGTGAATTGAGCAACCGTGTCCCTCTTCTTGGCCTTC
 ACTTTAGGACTAACACTTAAACCTGTTGGCACAGGAAGAACCGGAAAG

5' 11 21 31 41
 4301 CATGCAACCTCCAACCTCATGTTGGTCATTGTCAAAACACTGTGTGAT
 GTACGTTGGAGGTTGAAGTACAACCGATAAACAGTTGTGACACACTA

5' 61 71 81 91
 4351 GTTTTATCAATATACTGCCATTCCACATA TGTAGAGATGTAGTCTGCCT
 CAAAAATAGTTATATGACGGTAAGGTGTATACTCTACATCAGACGGA

5' 11 21 31 41
 4401 GGCTTCCTTCTCTTAGCCAATCGAATGCTCTGATCATGCCCTCAATC
 CCGAAAGGAAAGAAATCGGTTAGCTACGAGAACTAGTACGGGAGTTAG

5' 61 71 81 91
 4451 TCATCTCTAGCTTTATCACGTCTCTGCTAATTGAAACTTGAATCGA
 AGTAGAGATCGAAAATAGTGAGAGACGATTAGGACTTGAACCTAGCT

5' 11 21 31 41
 4501 AGTTTCTTCTGGTCATCTCAATGGTGTGTTAGCTTCTGAATCT
 TCAAAAGAAGACCAAGTAGAGTACCACTACAAGTCAAGGAAGACTTAGA

Figure 12 continued

5' 61 71 81 91
 4551 CATTCAAGTTTCTCGTACTCCCTCCATGTCAAAGTCAGTGACACACTCATCG
 GTAAGTCAAAGAGCATGAGGAGGTACAGTTCACTGTGACTGTGTGAGTAGC

5' 11 21 31 41
 4601 TCATTGGTGTAGGAAAGCTGCTCTTGGTAATCAGTTCCCTTAGCCAGGA
 AGTAACCACATCCTTCGACGAGAAACCATTAGTCAAGGAAATCGGTCC

5' 61 71 81 91
 4651 GATTGTTTGTTCACACTGTCTACCCCTGAACCACATACCTGGAAAAGCTG
 CTAACAAAACAAGTGTGACAGATGGGACTTGGGTATGGACCTTGAC

5' 11 21 31 41
 4701 TGTGCTCTATTTCCTTTCCAAAACCAGGGTGTCTTTGGGGAAAGCT
 ACACGAGATAAAAGAAAAGGTTTGGTCCCACAAGAAAAACCCCCTCGA

5' 61 71 81 91
 4751 TGCTGGGAAAGCCAAGAAAGGCTAAAGAGAAAATGGAAATTAATGTTTC
 ACGAACCCCTTCGGTTCTTCCGATTCTCTTTACCTTAATTACAAAG

5' 11 21 31 41
 4801 TTTTACTCCCTTCACATCAAGGTTAGGAAATATGTATTCATAAAAGCTA
 AAAATGAGGGAAAGTTGTAGTTCCAATCCTTATACATAAGTATTTCGAT

5' 61 71 81 91
 4851 ACAACTCACAGGAATCTTAGACATCACTGACTGCTTGGCAGGCGACTGC
 TGTTGAGTGTCCGTTAGAATCTGTAGTGACTGACGAACCGTCCGCTGACG

5' 11 21 31 41
 4901 TTGGGGGGAGCTGGAGAGCTTCTCTTTCTTCATGTTGTGCTAAAGAAAA
 AACCCCCCTCGACCTCTCGGAAGAGAAAGTACAACAGCATTTCGATTTTT

5' 61 71 81 91
 4951 TTGCAGAATA TGGGGCTGGAAGATAACAACTTAACTCTTACAGCCT
 AACGTCTTATACCCGACCTCTATTGTTGAAATTGAGAGAAGTGTGCGGA

5' 11 21 31 41
 5001 GCACTGATTTTTCTGGACAAATTCTCAA TGGCATCTATTATCGCTTT
 CGTGACTAAAAAAGACCTGTTAAGAAGTTACCGTAGATAATAGCGAAA

5' 61 71 81 91
 5051 GCTACTACGT TTGGGTCTGTGAGCATTT CCTTCAAAAAAACAAAAAAAGC
 CGATGATGCAAACCCAGGACAACACTCGTAAAGGAAGTTTTGTTTCGACGTT

5' 11 21 31 41
 5101 ACATTTTAAAAAGTCAGGTTAAGATCCA CCTGCAAAAAAAAGCTGCAA
 TGTAAAAAATTTTCACTGTTCAATTCTAGGTGGACGTTTTTCGACGTT

5' 61 71 81 91
 5151 TATAAGCGAGGAATTCTAGTTGTCACAGGAAATAAAAATGTCGTCTCCA
 ATATTGCTCCTTAAGATCAACAGTGTCCCTTATTTTACAGACAAAGGGT

Figure 12 continued

5' 11 21 31 41
 5201 CTATAATCAA TGTAGACTGATAATATTATGCCAGCAAATAGTTTGAAGT
 GATATTAGTTACATCTGACTATTATAATACGGTCGTTATCAAAACTTCA

5' 61 71 81 91
 5251 CCTAGGCACAGTGGGAGGGAGGTTTGTTCACGCTGTTCA TAAGCCAATA
 GGATCCGTGT CACCCTCCTCCAAAACAAGGTGCGACAAGTATTGGTTAT

5' 11 21 31 41
 5301 CCCCAGCAAAAGACCTTAAAGGACAAC TTGTAATTGGGA CATTCACATC
 GGGGTCGTTTCTGGAATT CCTGTTGAACATTAAACCTGTAAGTGTAG

5' 61 71 81 91
 5351 TGTCCCTTTCATCTGATCTGGCTCCAGTGTCACTCTCTAACACGGTCCT
 ACAGGAGAAGTAGACTAGACCGAGGGTCACAGTGAGAGATTGTGCCAGGA

5' 11 21 31 41
 5401 TAGAGGGACAATT TATCCCTGCCTCTGCTT GATCTTATGCATGTATCTGT
 ATCTCCCTGTTAAATAGGGACGGAGACGAACTAGAATACGTACATAGACA

5' 61 71 81 91
 5451 ATTCTTCCAGCCATCCCTGGCGACCTGATT TTTCTAAGGCACCCAAA ACT
 TAAGAAGGTGGTAGGGACCGCTGGACTAAAAAGATTCCGTGGGTTTGA

5' 11 21 31 41
 5501 GTAAGCTACTTCTTATAATCTATAATTCTGAGCATATTAGTTAGCCTGAG
 CATTGATGAAGAATATTAGATATTAAAGACTCGTATAATCAATCGGACTC

5' 61 71 81 91
 5551 CCTCCAGGATATCTTCTTCCCTATACTCAGTCCAGTTTAGCTGCCAG
 GGAGGTCCCTATAGAAAGAAGGGATATGAGTCAGGTAAAAATCGACGGGTC

5' 11 21 31 41
 5601 AAGGATTCAAAGCTGATCTACGAGTAGATCACTCCTGTCACAGCTTGT
 TTCTTAAGTTTCGACTAGATGCTCATCTAGTGAGGACAGATGTGAAACAA

5' 61 71 81 91
 5651 CCAGATCTGTTCTCAAGC CCTGGAAGCCATCAGCCAGGTAAGATTGTA
 GGTCTAGAACAAAGAGTTCGGGACCTTCGGTAGTCGGTCCATTCTAACAT

5' 11 21 31 41
 5701 AAACAATCCCCTTCTAATCA TGGGTGTGGCCCAAAGTGAA TGGCCGGAAT
 TTTGTTAGGGAAAGATTAGTACCCACACCGGGTTCACTTACCGGCCTTA

5' 61 71 81 91
 5751 TC
 AG




Figure 13
5752 bp




Figure 14

Figure 15

PDE10a and RACEs compiled

1 CGCCCGGGCA GGTCTGTTGG AGGGCAGTTG GTCAACCTGA CCAGAGAGAG CTGAGCTGGA
 GCGGGCCCGT CCAGACAACC TCCCGTCAAC CAGTTGGACT GGTCTCTCTC GACTCGACCT
 61 AGACCCCAC TATGGTGTGC TGCCTTCAG TCCAGGAAGA AAGAAAGGAA GGATTCTGAG
 TCTGGGGTGA CTACCAACACG ACGGAAAGTC AGGTCCCTCT TTCTTCCCTT CCTAAGACTC
 121 GATTGGGGA AAGCCACATT CCTGGAGAAG TCTGTATACT GATGCCAAC CCAAGAGCTG
 CTAAACCCGT TCCGGTGTAA GGACCTCTTC AGACATATGA CTACGGTTG GGTTCTCGAC
 181 AGCTGCTGAT GAGGCCAGG GAGTAGCCCA CGCGCCCTGA GCTGTTGGCT AGCAAGGCCT
 TCGACGACTA CTCCGGGTCC CTCATCGGGT GCGGGGACT CGACAAACCGA TCGTCCGGA
 241 TCCTGCTCCA TGTGGCATGG AAAAATTATA TGGTTTGACG GATGAAAAGG TGAAGGCCTA
 AGGACGAGGT ACACCGTACC TTTTAATAT ACCAAACTGC CTACTTTCC ACTTCCGGAT
 301 TCTTCTCTC CATCCCCAGG TATTAGATGA ATTTGTTTCT GAAAGTGTAA GTGCAGAGAC
 AGAAAGAGAG GTAGGGGTCC ATAATCTACT TAAACAAAGA CTTTCACAAT CACGTCTCTG
 361 TGTGGAAAAG TGGCTGAAGA GGAAAACCAA CAAAGCAAAA GATGAACCAT CTCCCAAGGA
 ACACCTTTTC ACCGACTTCT CCTTTGGTT GTTTCGTTT CTACTTGGTA GAGGGTCCCT
 421 AGTCAGCAGG TACCAAGGATA CGAATATGCA GGGAGTCGTG TACGAGCTGA ACAGCTACAT
 TCAGTCGTCC ATGGTCCTAT GCTTATACGT CCCTCAGCAC ATGCTCGACT TGTGATGTA
 481 AGAGCAGCGC CTGGACACGG GCGGGGACAA CCACCTGCTC CTCTATGAGC TCAGCAGCCT
 TCTCGTCGCG GACCTGTGCC CGCCCTGTT GGTGGACGAG GAGATACTCG AGTCGTCGTA
 541 CATCAGGATA GCCACAAAAG CCGACGGATT TGCACGTAC TTCTTGGAG AGTCAATAA
 GTAGTCCTAT CGGTGTTTC GGCTGCCTAA ACGTGACATG AAGGAACCTC TCACGTTATT
 601 TAGCCTGTGT GTGTTCATAC CACCCGGGAT GAAGGAAGGC CAACCCCGGC TCATCCCTGC
 ATCGGACACA CACAAGTATG GTGGGCGCTA CTTCCTTCG GTTGGGGCCG AGTAGGGACG
 661 AGGGCCCATC ACCCAGGGTA CCACCATCTC TGCCTACGTG GCCAAGTCTA GGAAGACGTT
 TCCC GGTTAGACGGTGGTAGAG ACGGATGCA CGGTTCAAGAT CCTTCTGCAA

EcoRV

721 GTTGGTAGAG GATATCCTTG GGGATGAGCG ATTTCCTCGA GGTACTGGCC TGGAAATCAGG
 CAACCATCTC CTATAGGAAC CCCTACTCGC TAAAGGAGCT CCATGACCGG ACCTTAGTCC
 781 AACCCGCATC CAGTCTGTT TTTGCTTGC CATTGTCACT GCCATTGGAG ACTTGATTGG
 TTGGCGTAG GTCAAGACAAG AAACGAACGG GTAACAGTGA CGGTAACCTC TGAACTAACC
 841 CATCCTGAA CTGTACAGGC ACTGGGGCA AGAGGCCCTC TGCCTCAGCC ATCAGGGAGGT
 GTAGGAACCTT GACATGTCGG TGACCCCGTT TCTCCGGAAG ACGGAGTCGG TAGTCCCTCA
 901 TGCACAGCC AATCTTGCCTT GGGCTCCGT AGCARACAC CAGGTGCAGG TGTGAGAGG
 ACGTTGTCGG TTAGAACGAA CCCGAAGGCA TCGTTATGTG GTCCACGTCC ACACATCTCC
 961 TCTCGCCAAA CAGACCGAAC TGAATGACTT CCTACTCGAC GTATCAAAGA CATACTTGA
 AGAGCGGTTT GTCTGGCTTG ACTTACTGAA GGATGAGCTG CATAGTTCT GTATGAAACT
 1021 TAACATAGTT GCCATAGACT CTCTACTTGA ACACATCATG ATATATGCAA AAAATCTAGT
 ATGTATCAA CGGTATCTGA GAGATGAAC TGTGAGTAC TATATACGTT TTTAGATCA
 1081 GAACGCCGAC CGCTGCCGCG TCTTCCAGGT GGACCCACAAG ACAAGGAGC TGTACTCGGA
 CTTGGGGCTG GCGACGCCGCG AGAAGGTCCA CCTGGGTTC TTGTTCCCTCG ACATGAGCCT
 1141 CCTGTTGAC ATTGGGGAGG AGAAGGAGGG GAAGCCCATC TCAAGAAGA CCAAGGAGAT
 GGACAAACTG TAACCCCTCC TCTTCCCTCC CTTGGGTAG AAGTCTCTT GTTCCCTCTA
 1201 CAGATTTCC ATTGAGAAAG GGATTGCTGG TCAAGGGCA AGAACAGGGG AAGTCTTGAA
 GTCTAAAAGG TAACCTTTT CCTAACGACC AGTTCAACCGT TCTTGTCCGC TTCAGAACTT
 1261 CATTCCCGAT GCCTACGGG ACCCTCGCTT TAACAGGGAG GTGGACCTGT ACACAGGCTA
 GTAAGGGCTA CGGATGCCGCG TGGGAGCGAA ATTGTCCTC CACCTGGACA TGTGTCGCGAT
 1321 CACCACGAGG AACATTCTGT GTATGCCCAT AGTGAACCGA GGCAGCGTGA TTGGCGTGGT
 GTGGTGCTCC TTGTAAGACA CATACGGGTA TCACTCGGCT CCGTCGCACT AACCGCACCA

Figure 15 (con't)

PDE10a and RACEs compiled

1381 GCAGATGGTG AACAGATCA GCGGTAGCGC CTTCTCCAAG ACAGACGAGA ACAACTTCAA
 CGTCTACCAAC TTGTTCTAGT CGCCATCGG GAAGAGGTT TGTCCTGCTCT TGTTGAAGTT
 BsmH

1441 GATGTTGCT GTCTCTGCG CACTGGCCTT GCACTGTGCT AACATGTACC ACAGGATCCG
 CTACAAACGA CAGAAGACGC GTGACCGGAA CGTACACGAA TTGTACATGG TGTCCTAGGC
 KpnI

1501 CCACTCAGAA TGCATCTACA GGGTTACCAT GGAGAAGCTT TCCTACCACA GCATCTGCAC
 GGTGAGTCTT ACGTAGATGT CCCAATGGTA CCTCTTCGAA AGGATGGTGT CGTAGACGTG

1561 CTCCGAGGAG TGGCAAGGCC TCATGCGCTT CAACCTACCA GCAOGCATCT GCGGGACAT
 GAGGCTCCTC ACCGTTCOGG AGTACCGGAA GTTGGATGGT CGTGCCTAGA CGGCGCTGTA

1621 CGAGCTATTC CACTTGACA TTGGTCTTT CGAGAACATG TGGGCTGGGA TCTTGTCTA
 GCTCGATAAG GTGAAACTGT AACCAGGAAA GCTCTGTAC ACCGGACCT AGAACACGAT

1681 CATGATCCAT CGGTCTGTG GGACATCCG TTTGAACCTT GAAAAAATTTGT GCGGTTTAT
 GTACTAGGTA GCCAGAACAC CCTGTAGGAC AAAACTTGAA CTTTTAACCA CGGCAAAATA

1741 CATGTCGTG AAGAAGAACT ATCGGCGGGT TCCTTACCAAC AACTGGAAAC ATGCAGTCAC
 GTACAGACAC TTCTCTGAA TAGCGCGCCA AGGAATGGTG TTGACCTTGTG TACGTCTGTG
 KpnI

1801 GGTGGCACAC TGCATGTATG CCATACTTCA AAACAACAAAT GGCTCTTCA CAGACCTCGA
 CCACCGTGTG ACGTACATAC GGTATGAAGT TTTGGTGTG CCGGAGAAGT GTCTGGAGCT
 KpnI

1861 GOGCAAAGGC CTGCTAATTG CGTGTCTGTG CCATGACCTG GACCACAGGG GCTTCAGTAA
 CGCGTTTCCG GACGATTAAC GCACAGACAC GGTACTGGAC CTGGTGTCCC CGAAGTCATT

1921 CAGCTACCTG CAGAAGTTTG ACCACCCCTT GGCGCGCTG TACTCCACCT CCACCATGGA
 GTCGATGGAC GTCTCTGAGC TGGTGGGGGA CGCGCGCGAC ATGAGGTGGA GGTGGTACCT

1981 GCAACACCCAC TTCTCCAGA CGGTGTOCAT CCITCAGCTG GAAGGGCACA ATATCTTCTC
 CGTTGTGGTG AAGAGGGTCT GGCACAGGTAA GGAAGTCGAC CTTCCCGTGT TATAGAAGAG

2041 CACCCCTGAGC TCCAGCGAGT ACGAGCAGGT GCTGGAGATC ATCCGAAAG CCATCATCGC
 GTGGGACTCG AGGTGCTCA TGCTCGTOCA CGACCTCTAG TAGGCGTTTC GGTAGTAGCG

2101 CACCGACCTC GCGCTATACT TTGGGAACAG GAGGAGTTG GAGGAGATGT ACCAGACAGG
 GTGGCTGGAG CGGGATATGA AACCCCTGTC CTTCCGTCAC CTCCTCTACA TGGTCTGTCC

2161 GTCGCTGAAC CTCCACAACC AGTCCCATCG AGACCGTGTG ATCGGCTTGA TGATGACTGC
 CGCGACTTG GAGGTGTTGG TCAGGGTAGC TCTGGCACAG TACCGAACACT ACTACTGACG

2221 CTGTGATCT TGCTCTGTGAA CCAAACATATG GCGAGTTACA AAATGACAG CGAATGATAT
 GACACTAGAA ACGAGACACT GGTTGATAC CGGTCAATGT TTTAACTGTC GCTTACTATA
 EcoR

2281 ATATGCAGAA TTCTGGGCTG AGGGTGATGAA GATGAAGAAG CTGGGCATAC AGCCCATTC
 TATACGTCTT AAGACCGAC TCCCACTACT CTACTTCTTC GACCCGTATG TCGGGTAAGG

2341 TATGATGGAC AGAGACAAGC GAGATGAAGT CCCTCAAGGG CAGCTGGAT TCTACAATGC
 ATACTACCTG TCTCTGTTCG CTCTACTTCA GGGAGTTCCC GTGAGCGTA AGATGTTACG

2401 TGTTGGCATT CCCCTGCTATA CCACCTTGAC GCAGATCCTC CCACCCACAG AGCCTCTGCT
 ACACCGGTAA GGGACGATAT GGTGGAACCTG CGTCTAGGAG GGTGGGTGTC TCGGAGACGA

2461 GAAGGCCTGC AGGGATAACC TCAATCAGTG GGAGAAGGTA ATTTCGCGGGG AAGAGACAGC
 CTTCCGGACG TCCCTATTGG AGTTAGTCAC CCTCTTCCAT TAAGCGCCCC TTCTCTGTG

2521 AATGTGGATT TCAGGCCAG GCGCGCGGCC TAGCAAGAGC ACACCTGAGA AGCTGAACGT
 TTACACCTAA AGTCCGGTC CGGGCGCGGG ATCGTCTCG TGTTGGACTCT TCGACTTGCA

2581 GAAGGGTGGAA GACTGATCTT GAGTGACGT CCTGATGTCT GCGCAGCAAC CGACTCAACC
 CTTCACATT CTGACTAGGA CTTCACTGCA GGACTACAGA CGGGTGTG GCTGAGTTGG

2641 TGCTCTGTG ACTTCGTTCT TTGTTTTTC AAGGGGTGAA AACCCCTGT CAGARGGTAC
 AGGAAGACAC TGAAGCAAGA AAAACAAAAG TTCCOCACCTT TTGGGGGACA GTCTCCATG

Figure 15 (con't)

PDE10a and RACEs compiled

2701 CGTCGCATAT CCATGTGAAG CAGACGACTC CCTGCTTGC GCACACACCT CGGACAGTGA
 GCAGCGTATA GGTACACTTC GTCTGCTGAG GGACGAACGG CGTGTGTGGA GCCTGTCACT
 2761 GCAACCCAGG CTCTGCCGTG TTCAGACGTC GGCTACTCCG TGGCTCCACC TGACCTCCGA
 CGTTGGGTCC GAGACGGCAC AAGTCTGAG CCGATGAGGC ACCGAGGTGG ACTGGAGGCT
 2821 ATGCTATTTG CTCCCAGGCC AGCACTGCAAC TGTCTGGAGG GGGCAGAGAC CACAGGAGAG
 TACGATAAAC GAGGGTCCGG TCGTACGTG ACAGACCTCC CCCGCTCTG GTGTCTCTC
 2881 GTCTTGCCT GCATCCTCCC ATGAGGGTGT GGCCAGTTCC CTAGTCTGT GCCATGCTGC
 CAAGAACGGA CGTAGGAGGG TACTCCCACA CCGGTCAAGG GATCAAGACA CGGTACGACG
 2941 TGCTTGGTGG CATTGGTTAG GAATGGGACA CACGGCCCTT GTTGTGAAGT TTACATGTGA
 ACGAACCACC GTAACCAATC CTTACCCCTGT GTGCCGGGAA CAACACTTCA AATGTACACT
 3001 CCTTCTTATA GGTTAATGTA GTTGTGGGC TGGACACATG TAATGAAGGT CACAGTCCAC
 GGAAGAATAT CCAATTGACT CAAACACCGG ACCTGTGTAC ATTACTTCA GTGTCAAGGTG
 3061 AGGTGACAGA GAAATCCAAA CTGTTGATTA CAGGTGCACT ACAGGTATGC TCTTCAGTC
 TCCACTGTCT CTTAGGTT GACAACATAAT GTCCACGTGA TGTCCATACG AGAAAGTCAG
 3121 TATCTGGGG CACATAGGTG AGTCTGCTCC ACTCAGAANN AAGCATAACCT CTGCCCTCAT
 ATAGACCCCC GTGTATCCAC TCAGACGAGG TGAGTCTTNN TTGCTATGGA GACGGGAGTA
 3181 CCAGGGGACA CAGGGTACAT CCCAGGCATC GGGGAACTGA AGCTCTCACT TCAAACCATG
 GGTCCCTGT GTCCCATGTA GGGTCCGTAG CCCCTTGACT TOGAGAGTGA AGTTGGTAC
 3241 TCAAAGAATT AAAACACCTC CCCTCCCCCT CACTGTAGCC TTCGACAACG GCGCCAATCC
 AGTTTCTTAA TTTTGTGGAG GGGAGGGGGA GTGACATCGG AAGCTGTGTA CGGGGTAGG
 3301 CTTTATACAA AGAAAATAAA AGTAAGGCAT ATAAATTTC TCCAGCAAGC AAATCTTGTG
 GAAAATATGTT TCTTTATTT TCATTCCGTA TATTAAAGG AGGTCGTTCG TTTAGAACAC
 3361 GGTAaaaaaaa AAGCATGTGA ATNNTAACAA CNTCTANANT NTCNCNGNAT GTTATGGCAG
 CCATTTTTT TTCGTACACT TANNATTGTT GNAGATNTNA NAGNGNCNTA CAATACCGTC
 3421 AATTTTAGTC ACGTCCAAA CAAAAAGATT ATTCCAGAAG ATACCTCATC CTATGCCTGA
 TTTAAATCAG TGCAGGTTT GTTTTCTAA TAAGGTCTTC TATGGAGTAG GATAACGGACT
 3481 AAGGCTCCAC AGCATGGGT CGGTCTCCCA GGGTCTGAT CCGTCTCCTC ACGGTGCAAT
 TTCCGAGGTG TCGTACCGCA GGCAGAGGGT CCCAAGACTA GGCAGAGGAG TGCCACGTTA
 3541 CAGGCAGGAC AGAGAGGGAGG GCTGCAGGGC TACCACATTG ACCCAGAAGG TATCTCCTCT
 GTCCGTCTG TCTCTCTCC CGACGTCCCG ATGGTGTAAAC TGGGTCTTCC ATAGAGGAGA
 3601 CACCAATTCA ACATCCATAA GGAATGCCAA ATGCTGTATT GAATAGTCT CTGTGTGACT
 GTGGTAAGTC TGTAGGTATT CCTTACGGTT TACGACATAA CTTATCAAGA GACACACTGA
 3661 TTCTAGAGAA GCCAGGACAC CCTGAGCCCT TCCNGGGAA CTCTAAGGAG TCACAGGTT
 AAGATCTCTT CGGTCTGTG GGACTCGGAA AGNNCCCTT GAGATTCTC AGTGTCCAAG
 3721 ACACCGTGG GATTTTCAGG ATAGCATGGA GACAGAGATC CGGTCTGTG TCTCACTCGT
 TGTCGACCC CTTAAAGTCC TATCGTACCT CTGCTCTAG GCCAGCAACA AGAGTGAGCA
 3781 GAGCCTTGAG AAGGAGAGAC TGACCAAGAAA CACTCACTCA GCACTCTGCA GGAGCAGGAG
 CTCGGAACTC TTCTCTCTG ACTGGTCTT GTGAGTGAGT CGTGAGACGT CCTCGTCTC
 3841 AAGATACTT AAGATGAATC TTGGATAGAT TTTGATACAC CCAATACCAT ACACACAGGA
 TTCTATGAAA TTCTACTTAG AACCTATCTA AAACATATGTG GGTTATGGTA TGTGTGTCT
 3901 GCTTGGCATT TGCAAAGTCT ATTCAAGTTTC CTTCCGGCT CTGACCCACG GTTGTAGCGG
 CGAACCGTAA ACGTTTCAGA TAAGTCAAAG GAAGGGCGGA GACTGGGTGC CAACATCGCC
 3961 AGTGGGCTGA ACACTGTAAAC ACTGTACATG CGATTTCCCC ATGGGCTCT AAAATGTCA
 TCACCCGACT TGTGACATTG TGACATGTAC GCTAAAGGGG TACCCGAAGA TTTTACAGTG
 4021 CATCTCCTCC CCTGCTGTGT CCTACTCCAT TTACTGGTTA CAAGGTGATG TCAACAAAGAG
 GTAGAGGAGG GGACGACACA GGATGAGGTA AATGACCAAT GTTCCACTAC AGTTGTCTC

Figure 15 (con't)

PDE10a and RACEs compiled

4081 AAGCTATCAC AACACCAAGGG CTGTGCACAC GTGCACACAC ATGTATGCAC AAGCACACAG
 4141 TTGATAGTG TTGTGGTCCC GACACGTGTG CACGTGTG TACATACGTG TTCTGTGTC
 ATGTATGTAC AGCACACACA CACACACACA CCCCCAAAAGG AGAGAAAAGG AAGAAAACAT
 TACATACATG TCCTGTGTGT GTGTGTGTGT GGGGTTTCC TCTCTTTCC TTCTTTGTA
 4201 TTATAAAAAG CGACAGCTAC CCCATATCAA AATAGTCTT CCTGTAGGAA ACAGGAGCTC
 AATATTTTC GCTGTCGATG GGGTATAGTT TTATCAGAAA GGACATCCTT TGTCCTCGAG
 4261 TCCATAAGGA ATTATCATGA GTGTGTTCTC CCATCAGTGC ACTCTCCCAG GGGTGTCA
 AGGTATTCTT TAATAGTACT CACACAAGAG GGTAGTCACG TGAGAGGGTC CCCACGAGTG
 4321 TGAAGCTGGT CCACRTCTAT AAACAGGTGA CACTGGCTGC AGCAGAAAAGC CATTGATCC
 ACTTCGACCA GGTGRAGATA TTGTCCTACT GTGACCGACG TCGTTTTGCG GTAGCTAGG
 4381 ACACAAATTG ATCTTCTATC ATCTTGGAAAT CTGAATTGCA GGGAGGAGCA GYATGTAAGA
 TGTGTTAAC TAGAAGATAG TAGAACCTTA GACTTAACGT CCCTCCTCGT CYTACATTCT
 4441 CGACCGTTA ATTCAAGGCAT TCCGAAGGCA TGAGCGCATG GATTCTRTCA CCAAGCGTAT
 GCTGGAAAT TAAGTCCGTA AGGCTTCCGT ACTCGCGTAC CTAAGARAGT GGTCGCA
 4501 AAAAGGACCC TGGCATTGGG AAACCTATGA CGGACTGTT TTGCTGTAAGA AGTAGGGATT
 TTTTCTGGG ACCGTAACCC TTGGATACT GCCTGACAAA AACGACATCT TCATCCCTAA
 4561 TTACAGAAGT CTCCCTGRAT TTGCCCTGCC TGGGGCAGTT TTGCAAGAGGA ACCTGCCAGA
 AATGTCCTCA GAGGAACRTA AACGGGACGG ACCCCGTCAA AACGTCCTCT TGGACGGTCT
 4621 GATTTATTGG CTGGTCAGTC TCTTGTGAAA TAGTATCATG TGAGAAACAG TTTGTAGAAA
 CTAATAAACC GACCAGTCAG AGAACACTTT ATCATAGTAC ACTCTTGTGAA AACATCTT
 4681 AAAACTATAC CTGGGAAGAC CTTTGCAACA TTGTTCTTC CATGGGCCAA GACTCAGTTA
 TTTTGATATG GACCCTCTG GAAACGTTGT AACAAAGGAAG GTACCCGGTT CTGAGTC
 4741 GGAGGCATAA ATCTGCCCGG AATAAAACTAG GCCAGGATAC AGCCATGTTT AGTTAATAAT
 CCTCCGTATT TAGACGGGCC TTATTTGATC CGGTCTATG TCGGTACAAA TCAATTATTA
 EcoR
 4801 TTGGTTTTAG AATTCAACACA GGCAGGATTG GTTTTTTGT GTCTGGCAA GTGGAGCATA
 AACCAAAATC TTAAGTGTGT CCGTCTAAC CAAAAAAACA CAGAACCGTT CACCTCGTAT
 4861 TTAACATAC AGGCATGGGA ATCCTGCCCT TTAGCTTTTC CCACCCCTTT GTCTCACCAA
 AAATTGTATG TCCGTACCC TAGGACGGAG AATCGAAAAG GGTGGGAGAA CAGAGTGGTT
 4921 GTTTTTCTC TCCAAAGGTT TCCAGGAATT TCTCATTAAT GGCTGATGCA AACTTAGTGA
 CAAAAAAAGAG AGGTTCTAA AGAGTAATTA CCGACTACGT TTGAATCACT
 4981 ATAATAATGA ATATAAACAA TGCTCACCTC ACCAAAATTA TATTATTTGAG AGTCATTTGT
 TATTATTACT TATATTGTT AGCAGTGGAG TGGTTTAAT ATAATAAACG TCAGTAAACA
 5041 GATAACACAA ATTTTATCGC AATGGTTATT ATTTAATTG TGGCCACACA CTGTGGTTAT
 CTATTGTGTT TAAAATAGCG TTACCAATAA TAAATTAAAC ACCGGTGTGT GACACCAATA
 5101 CTTTGTGTT GGTGTTCTC GAGAAAATGT TCTTGGATAT GAAAGTGCCTA ATACCAGTGT
 GAAAACAACA CCAACAAAGA CTCTTTACA AGAACCTATA CATTACGGT TATGGTCACA
 5161 GAAGTATTGA TCCCAGGCAG CAAAATACAG CCTAAGGTTT GAAACATCA ATTCTATCTC
 CTTCATAACT AGGGCCCGTC GTTTTATGTC GGATTCAAA CATTGTAGT TAAGATAGAG
 5221 AGTCATCAG AGGGCTGAG AAGCTGCGGG GCAGTGTAAA GAAAGTATG CTGGGCTGGT
 TCAAGTAGTC TCCCGGACTC TTGACGCC CGTCACATT CATTCTAC GACCCGACCA
 5281 GGTGGTCAGC CTCCCCCTGC CAAGAAGAGA GCAATTGAAT CCTGTCCCCA GCTCCCTCCA
 CCACCAAGTCG GAGGGGAACG GTTCTTCTCT CGTTAACTTA GGACAGGGGT CGAGGGAGGT
 5341 CGCCTGAAGA GTGACCAAGTG CTGGCCCGAC GGATCGCTGA GATATTCTCC CATAATGGCA
 GCGGACTTCT CACTGGTCAC GACCGGGCTG CCTAGCGACT CTATAAGAGG GTATTACCGT
 5401 AAAAAATAGG CAGTTGATG TGACCTGTTT AGTGTGGCTC TCTCTTTTG AGCATGTGTT
 TTTTTATCC GTCAAACATAC ACTGGACAAA TCACACCGAG AGGAGAAAAC TCGTACACAA

Figure 15 (con't)

PDE10a and RACES compiled

5461 AGCATTTTA TTTTATACTC ATCCAGTGAA CTCTGCTCTT CCAAGTGTGT TCATGTATGT
 TCGTAAAAAT AAAATATGAG TAGGTCACCTT GAGACGAGAA GGTTCACACA AGTACATACA

5521 GCTAGATATA TTAGCACAGC CTGCCCTCTG CTGCACAAACG CCTTAGAGAC CCGGCCTTTC
 CGATCTATAT AATCGTGTGCG GACCGAAGAC GACGTGTTGC GGAATCTCTG GGCCGGAAAG

5581 AATGAGCTTA GCTTGTGCTC TGTTCCTGCT CTCTTAGGTC TAAACTATGG TGTCAAGTTT
 TTACTCGAAT CGAACACAGG ACAAAAGACGA GAGAACATCCAG ATTGATACCC ACAGTCAAAA

5641 AATAGAACAA AAGTATGCAT CTTGCCTTGG CTTGAGCCTT TTCGTTTCA ATGCTGACTT
 TTATCTTGTGTT TTCATACGTA GAAACGGAAAC GAAACTCGGAA AAGCAAAAGT TACGACTGAA

5701 CTCCCCTTTC TCTCCTGTGC TCACCTTACCC TTTCCAGAGT GAAAGGGACA ACTTTTAAGG
 GAGGGGAAAG AGAGGACACG AGTGGAAATGG AAAGGCTCTCA CATTCCCTGT TGAAAATTCC

5761 AGGCGTGTCC CTGGTAGGGG CATCCCTGTT CACCAGGTGC CTGTCATCAC CCCACTTGAC
 TCCGCACAGG GACCATCCCC GTAGGGACAA GTGGTCCACG GACAGTAGTG GGGTGAAC

5821 TGACATCTAC CCTGGTGACT ATGGGTTCCCT CTTGTTGTA GGGAACGGTG GCTCCAGGTG
 ACTGTAGATG GGACCACTGAA TACCAAGGA GAAACAAACAT CCCTTGCCAC CGAGGTCCAC

5881 GAGGCATCAA TCTGTTGGGT TCTGGTTCCC GGCTGCCTT GTTTTGAAA GTCTCTCTC
 CTCCGTAGTT AGACAACCCA AGACCAAGGG CCGACGAAA CCACAAACTTT CAGAGAAGAG

5941 TGTATATTCC TACCCCTGCAT TTGCTTTGTG TGGTGTGAT GCTGTGGCAG TAGGATCTTG
 ACATATAAGG ATGGGACGTA AAGCAAAACAC ACCACGACTA CGACACOGTC ATCCTAGAAC

6001 GATGACTCTC CATCAGTCAC AGACTCCCCC TGTGCAAAG TGTCAAGGCTG ACTCGACAGT
 CTACTGAGAG GTAGTCAGTG TCTGAGGGGG ACAACGTTTC ACAGTCCGAC TGAGCTGTCA

6061 CACCGTAAAAA TCTGAGTCAG TCACACACAG GCTGTCAAGC ACCGGCTTCCA CTTGCATGGC
 GTGGCATTTT AGACTCAGTC AGTGTGTGTC CGACAGTCGG TGCCGAAGGT GAACGTACCG

6121 TATTCTATTTC TCACACGTGA GTTCTGTTG CTGGCTGGCT GACTGGCATT ATCTATGCTA
 ATAAGATAAA AGTGTGCACT CAAAGACAAAC GACCGACCGA CTGACCGTAA TAGATACGAT

6181 AGTTGAATTC AGGAGTGTGC CCAGCAGAGC CCATCATTCT CACTGTCTT GAAACAAAGC
 TCAACTTTAG TCCTCACACG GGTCGTCTCG GGTAGTAAGA GTGACAGAAA CTTTGTTCG

6241 TGTACGGTTT GATCGATGAA CGTATTTAAA GCATTTCATG CAATGACAAA GTGCTCAGTA
 ACATGCCAAA CTAGCTACTT GCATAAATTTC CGTAAAGTAC GTTACTGTGTT CACGAGTCAT

6301 GTGGAAGGCA GGCTGTGACC AGTCTGCCTG CTCCCTACTA TAATTGTGAG GATTGTTAC
 CACCTTCCGT CCGACACTGG TCAGACGGAC GAGGAATGAT ATTAACACTC CTAAACAAATG

6361 TGGAACAGTA CATGGAGGCC TGACCTTGTG GGGGCACAGG GTGGAACCTT AGCTGAAATAT
 ACCTGTGAT GTACCTCCGG ACTGGAACAC CCCCCTGTCC CACCTTGGAA TCGACTTATA

6421 AGTGTGTGTC TCAAGAGGAA GTCAAGGGTAC TAGCTCAGTG CTCAAATCTCC AGGTACTATA
 TCACACACAG AGTTCTCCTT CAGTCCCAGT ATCGAGTCAC GAGTTAGAGG TCCATGATAT

6481 TATACATTG CCCGTTTAT CTCTAATGTG AAATAAAATCC CCAAACACTT GTTATCGTG
 ATATGTAAAC GGGCAAAATA GAGATTACAC TTATTTAGG GTTTGTGAA CAAATAGCAC

6541 TAGCGTACCT AAAAGACTAT TCTATTATGG GTGTCCCCAC TTTCTGGTT TGGTCACCCCC
 ATCGCATGGA TTTCTGATA AGATAATACC CACAGGGGTG AAAAGAACAA ACCAGTGGGG

6601 GATCCCCCGG TCTTCTGCTG TATCTAGAAC AGTGAACATA AATGATGTAT GGGAAATAGTG
 CTAGGGGGCC AGAAGACGAC ATAGATCTTG TCACTGATAT TTACTACATA CCCTTATCAC

6661 TTTCCATATG ATCTGTTGTC TGGAGTATAT GCTACATGTT CATTACTGT AAAAAAACCC
 AAAGGTATAC TAGACAAACAG ACCTCATATA CGATGTACAA GTAAATGACA TGTTTTGGG

6721 AGTGCAGCTG ATGATGCAAAC GCAGTCTCTC TCTGTGACA GTGCCCCACC TATTTAAAAA
 TCACGTCGAC TACTACGTT CGTCAGAGAG AGACACATGT CACGGGGTGG ATAAATTTT


6781 TCACGTACAA NCCCAGAACAA CTGTGAAACA CTTAACATAA GAAACAAACG CAGCGTCTGG
 AGTGCATGTT NGGGTCTTGT GACACTTGT GAATTGTATT CTTGTTGTC GTCGCAGACC

Figure 15 (con't)

PDE10a and RACEs compiled

6841 ATTCTTCCA AGGAGAGCAG CTTTCTCAC AGGAACACAG TAACAAAAGA GGTCGCCGC
 TAAGAAAGGT TCCTCTCGTC GAAAGAGGTG TCCTTGTGTC ATTGTTTCT CCAGGCGGCG
 6901 CATCCACACC CAGCCAAGAC ACCTCAGAGG CCATAGGGAC AACCTCCTG CTGGCCAACA
 GTAGGTGTGG GTCGGTCTG TGGAGTCTCC GGTATCCCTG TTGGAGGAAC GACCGGTTGT
 6961 CCTGCTGGAG CAGGGCACAG GTCCCAGCAA CTGATCCCTA GTGGATGGGT CCGCAGTCAA
 GGACGACCTC GTCCCGTGTG CAGGGTCGTT GACTAGGAGT CACCTACCCA GGCGTCAGTT
HindIII EcoRV
 7021 AGCCTTAATG GGCTCTCTT TGAAGGGAA AGAAAANNTT CAAGCTTATG ATATCCAACA
 TCGGAATTAC CCGAGAGAAA ACTTCCCCTT TCTTNNAAA GTTCGAATAC TATAGGTTGT
 7081 TATTATAGT TGATGAGTTA GTAAATTCCG AAAAAAAAAG ATGATTTAT ATGTATGACA
 ATAATATCA ACTACTCAAT CATTAAAGGC TTTTTTTTC TACTAAAATA TACATACTGT
 7141 TAAAAAAAT CTTTGTAAAG TGCGCAAGTG CAATAATTAA AAGAGGTCTT ATCTTGCAT
 ATTTTTTTTA GAAACATTTA ACGCGTTCAC GTTATTAAAT TTCTCCAGAA TAGAAACGTA
 7201 TTATAAATTA TAAATATTGT ACATGTGTGT AATTTCAT GTATTCAATT GCAGTCTTG
 AATATTTAAT ATTTATAACA TGTACACACA TTAAAAAGTA CATAAGTAA CGTCAGAAC
 7261 TATTAAAAAA AACTTACTG TTATGTTTGT ATAATAGAAC ATTAATCATT TATTATAACT
 ATAAATTTTT TTGAAATGAC AATACAAACA TATTATCTTG TAATTAGTAA ATAATATTGA
 7321 CAGACAAGGT GTAAATAAAT TCATAATTCA AACAGCCAGT ATATATGCAT ATATGGGTGT
 GTCTGTTCCA CATTATTTA AGTATTAAGT TTGTCCGTCA TATATACGTA TATACCCACA
 7381 TACATTGCAA AAATCTCTAT CTTTGTCTA TTACACATGCT TAAAGAAGTA AGAAATCTTT
 ATGTAAACGTT TTTAGAGATA GAAACAAGAT AAGTGTACGA ATTCTTCAT TCTTGTAGAAA
 7441 TGTTGGATATG TAATTATACA TATAAAGTAT ATATATATGT ATGATACATG AAATATATTT
 ACACCTATAC ATTAATATGT ATATTCATA TATATATACA TACTATGTAC TTTATATAAA
 7501 AGAAATGTTCA ATAATTTAA TGATATTCT TTGGTGTGAA TAATTGAATA CAACATTTT
 TCTTGTAGAAG TATTAATTAACCTATAAGA AACCAACACTT ATTAACCTTAT GTTGTAAAAA
 7561 AAAATGAAAAA AAAAAAAA C
 TTTTACTTTT TTTTTTTT G

Figure 16



PDE10a and RACEs compiled
7581 bp

Figure 17

PDE10A compiled - coding sequence and features




Figure 18

PDE10A compiled - restriction sites




Figure 19

PDE10A compiled

1 CGCCCGGGCA GGTCTGTTGG AGGGCAGTTG GTCAACCTGA CCAGAGAGAG CTGAGCTGGA
 GCGGGCCCGT CCAGACAACC TCCCGTCAC CAGTTGGACT GGTCTCTCTC GACTCGACCT
 61 AGACCCCAC TGTGGGTGTC TGCCTTCAG TCCAGGAAGA AAGAAAGGAA GGATTCTGAG
 TCTGGGGTGA CTACACACG ACGGAAAGTC AGGTCTTCT TTCTTCCTT CCTAAGACTC
 121 GATTGGGCA AAGCCACATT CCTGGAGAAG TCTGTATACT GATGCCAAC CCAAGAGCTG
 CTAAACCGT TTGGGTGTA GGACCTCTC AGACATATGA CTACGGTTG GTTCTCGAC
 181 AGCTGCTGAT GAGGCCAGG GAGTAGCCCA CGGCCCTGA GCTGTTGGCT AGCAAGGCCT
 TCGACGACTA CTCCGGTCC CTCATCGGGT CGCGGGACT CGACAACCGA TCGTCCGGA
 241 TCCCTGCTCCA TGTGGCATGG AAAAATTATA TGGTTTGACG GATGAAAAGG TGAAGGCCCTA
 AGGACGAGGT ACACCGTAC TTTTAATAT ACCAAACTGC CTACTTTCC ACTTCCGGAT
 301 TCTTCTCTC CATCCCCAGG TATTAGATGA ATTGTTTCT GAAAGTGTAA GTGCAGAGAC
 AGAAAGAGAG GTAGGGTCC ATAATCTACT TAAACAAAGA CTTTACAAT CACGTCTCTG
 361 TGTGGAAAAG TGGCTGAAGA GGAAAACCA CAAAGCAAA GATGAACCAT CTCCAAGGA
 ACACCTTTTC ACCGACTTCT CCTTTTGTT GTTCGTTT CTACTTGGTA GAGGGTTCT
 421 AGTCAGCAGG TACCAAGGATA CGAATATGCA GGGAGTCGTG TACGAGCTGA ACAGCTACAT
 TCAGTCGTCC ATGGTCCAT GCTTATACTG CCCTCAGCAC ATGCTCGACT TGTCGATGTA
 481 AGAGCAGCGC CTGGACACGG GCGGGGACAA CCACCTGCTC CTCTATGAGC TCAGCAGCAT
 TCTCGTCGCG GACCTGTGCC CGCCCGTGT GGTGGACGAG GAGATACTCG AGTCGTCGTA
 541 CATCAGGATA GCCACAAAAG CCGACGGATT TGCACGTAC TTCTTGGAG AGTGAATAA
 GTAGTCCTAT CGGTGTTTC GGCTGCCTAA ACGTGACATG AAGGAACCTC TCACGTTATT
 601 TAGCCTGTT GTGTCATAC CACCCGGAT GAAGGAAGGC CAACCCCGC TCATCCCTGC
 ATCGGACACA CACAAGTATG GTGGGCCCTA CTTCTTCCG GTTGGGGCCG AGTAGGGACG
 661 AGGGCCCATC ACCCAGGGTA CCACCATCTC TGCTTACGTG GCCAAGTCTA GGAAGACGTT
 TCCCGGGTAG TGGTCCCCT GGTGGTAGAG ACGGATGCAC CGGTTAGAT CTTCTGCAA
 721 GTTGGTAGAG GATATCCTTG GGGATGAGCG ATTTCCTCGA GGTACTGGCC TGAATCAGG
 CAACCATCTC CTATAGGAAC CCCTACTCGC TAAAGGAGCT CCATGACCGG ACCTTAGTCC
 781 AACCGCCTAC CAGTCGTTT TTTGCTGCC CATTGTCACT GCCATTGGAG ACTTGATTGG
 TTGGCGTAG GTCAGACAAG AAACGAACGG GTAACAGTGA CGGTAACCTC TGAACTAACC
 841 CATCCTTGA CTGTACAGGC ACTGGGGAA AGAGGCCCTC TGCTCAGCC ATCAGGAGGT
 GTAGGAACCT GACATGTCCG TGACCCCGTT TCTCCGGAAG ACGGAGTCGG TAGTCCTCCA
 901 TGCAACAGCC AATCTGCTT GGGCTTCCGT AGCAATACAC CAGGTGCAGG TGTGTAGAGG
 ACGTTGTCCG TTAGAACGAA CCCGAAGGCA TCGTTATGTG GTCCACGTCC ACACATCTCC
 961 TCTCGCCAAA CAGACCGAAC TGAATGACTT CCTACTCGAC GTATCAAAGA CATACTTGA
 AGAGCGGTTT GTCTGGCTTG ACTTACTGAA GGATGAGCTG CATAGTTCT GTATGAAACT
 1021 TAACATAGTT GCCATAGACT CTCTACTTGA ACACATCATG ATATATGCAA AAAATCTAGT
 ATTGTATCAA CGGTATCTGA GAGATGAAC TGTGTAGTAC TATATACGTT TTTAGATCA
 1081 GAACGCCGAC CGCTCGCGC TCTTCCAGGT GGACCACAAAG AACAGGAGC TGTACTCGGA
 CTTCGGGCTG GCGACCGCGC AGAAGGTCCA CCTGGTGTTC TTGTTCTCG ACATGAGCCT
 1141 CCTGTTGAC ATTGGGGAGG AGAAGGAGGG GAAGCCCATC TTCAAGAAGA CCAAGGAGAT
 GGACAAACTG TAACCCCTCC TCTTCCCTCC CTTGGGTAG AAGTTCTCT GTTCCCTCTA
 1201 CAGATTTCC ATTGAGAAAG GGATTGCTGG TCAAGTGGCA AGAACAGGCG AAGTCTGAA
 GTCTAAAAGG TAACTCTTCC CCTAACGACC AGTCACCGT TCTTGTCCGC TTCAGAACTT
 1261 CATTCCCGAT GCCTACCGGG ACCCTCGCTT TAACAGGGAG GTGGACCTGT ACACAGGCTA
 GTAAGGGCTA CGGATGCGCC TGGGAGCGAA ATTGTCCCTC CACCTGGACA TGTGTCCGAT
 1321 CACCAAGGAGG AACATCTGT GTATGCCCAT AGTGAGCCGA GGCAGCGTGA TTGGCGTGGT
 GTGGTGTCTC TTGTAAGACA CATACGGGT AACTCGGCT CCGTCGCACT AACCGCACCA

Figure 19 (con't)

PDE10A compiled

1381 GCAGATGGTG AACAAAGATCA GCGGTAGCGC CTTCTCCAAG ACAGACGAGA ACAACTTCAA
 CGTCTACCAAC TTGTTCTAGT CGCCATCGCG GAAGAGGTTG TGTCTGCTCT TGTGAAAGTT
 1441 GATGTTTGCT GTCTTCGCG CACTGGCCCT GCACGTGCT AACATGTACC ACAGGATCCG
 CTACAAACGA CAGAAGACGC GTGACCGGAA CGTGACACGA TTGTACATGG TGTCTTAGGC
 1501 CCACTCAGAA TGCATCTACA GGGTTACCAT GGAGAAGCTT TCCTACCAAC GCATCTGCAC
 GGTGAGTCTT ACGTAGATGT CCCAATGGTA CCTCTTCGAA AGGATGGTGT CGTAGACGTG
 1561 CTCCGAGGAG TGGCAAGGCC TCATGCGCTT CAACCTACCA GCACGCATCT GCCGGGACAT
 GAGGCTCCTC ACCGTCCGG AGTACCGGAA GTTGGATGGT CGTGCAGTACA CGGGCCCTGTA
 1621 CGAGCTATTG CACTTGACA TTGGTCCTT CGAGAACATG TGGCCTGGGA TCTTTGTCTA
 GCTCGATAAG GTGAAACTGT AACCAGGAAA GCTCTTGTAC ACCGGACCT AGAAACAGAT
 1681 CATGATCCAT CGGTCTTGTG GGACATCCTG TTTGAACTT GAAAATTGT GCGGTTTAT
 GTACTAGGTA GCCAGAACAC CCTGTAGGAC AAAACTGAA CTTTTAAACA CGGCAAAATA
 1741 CATGTCTGTG AAGAAGAACT ATCGGCGGGT TCCTACCAAC AACTGGAAGC ATGCAGTCAC
 GTACAGACAC TTCTCTTGA TAGCCGCCA AGGAATGGT TTGACCTTCG TACGTCAGTG
 1801 GGTGGCACAC TGCATGTATG CCATACTTCA AAACAACAAT GGCCTCTTC CAGACCTCGA
 CCACCGTGTG ACGTACATAC GGTATGAAGT TTTGTTGTTA CCGGAGAAGT GTCTGGAGCT
 1861 GCGCAAAGGC CTGCTAATTG CGTGTCTGTG CCATGACCTG GACCACAGGG GCTTCAGTAA
 CGCGTTCCG GACGATTAAC GCACAGACAC GGTACTGGAC CTGGTGTCCC CGAAGTCATT
 1921 CAGCTACCTG CAGAAGTTCG ACCACCCCTC GGCAGCGCTG TACTCCACCT CCACCATGGA
 GTCGATGGAC GTCTCAAGC TGGTGGGGGA CCGCCGCGAC ATGAGGTGGA GGTGGTACCT
 1981 GCAACACCAAC TTCTCCCAGA CGGTGTCCAT CCTTCAGCTG GAAGGGACA ATATCTTCTC
 CGTTGTGGTG AAGAGGGTCT GCCACAGGTA GGAAGTCGAC CTTCCCGTGT TATAGAAGAG
 2041 CACCCCTGAGC TCCAGCGAGT ACGAGCAGGT GCTGGAGATC ATCCGCAAAG CCATCATCGC
 GTGGGACTCG AGGTGCTCA TGCTCGTCCA CGACCTCTAG TAGGCCTTTC GGTAGTAGGC
 2101 CACCGACCTC GCCCTATACT TTGGGAACAG GAAGCAGTTG GAGGAGATGT ACCAGACAGG
 GTGGCTGGAG CGGGATATGA AACCCCTTGTG CTTCGTCAAC CTCCCTCTACA TGGTCTGTCC
 2161 GTCGCTGAAC CTCCACAACC AGTCCCATCG AGACCGTGTG ATCGGCTTGA TGATGACTGC
 CAGCGACTTG GAGGTGTTGG TCAGGGTAGC TCTGGCACAG TAGCCGAACACT ACTACTGACCG
 2221 CTGTGATCTT TGCTCTGTGA CCAAACATG GCCAGTTACA AAATTGACAG CGAATGATAT
 GACACTAGAA ACGAGACACT GGTGATGATAC CGGTCAATGT TTTAACTGTC GCTTACTATA
 2281 ATATGCAGAA TTCTGGGCTG AGGGTGTGATGA GATGAAGAAG CTGGGCATAC AGCCCATTCC
 TATACGTCTT AAGACCCGAC TCCCACACT CTACTTCTTC GACCCGTATG TCGGGTAAGG
 2341 TATGATGGAC AGAGACAAGC GAGATGAAGT CCCTCAAGGG CAGCTCGGAT TCTACAATGC
 ATACTACCTG TCTCTGTGCT CCTACTTCA GGGAGTTCCC GTCGAGCCTA AGATGTTACG
 2401 TGTGGCCATT CCCTGCTATA CCACCTGAC GCAGATCCTC CCACCCACAG AGCCTCTGCT
 ACACCGTAA GGGACGATAT GGTGGAACGT CGTCTAGGAG GGTGGGTGTC TCGGAGACGA
 2461 GAAAGCCTGC AGGGATAACC TCAATCAGTG GGAGAAGGTA ATTCGCGGGG AAGAGACAGC
 CTTCCGGACG TCCCTATTGG AGTTAGTCAC CCTCTTCCAT TAAGCGCCCC TTCTCTGTGCG
 2521 AATGTGGATT TCAGGGCCAG GCCCGGGCCC TAGCAAGAGC ACACCTGAGA AGCTGAACGT
 TTACACCTAA AGTCCGGTC CGGGCCGGGG ATCGTCTCG TGTGGACTCT TCGACTTGCA
 2581 GAAGGTTGAA GACTGATCCT GAAGTGTACGT CCTGATGTCT GCCCAGCAAC CGACTCAACC
 CTTCCAACCTT CTGACTAGGA CTTCACTGCA GGACTACAGA CGGGTCGTTG GCTGAGTTGG
 2641 TGCTTCTGTG ACTTCGTTCT TTTGTTTC AAGGGGTGAA AACCCCTGT CAGAAGGTAC
 ACGAAGACAC TGAAGCAAGA AAAACAAAAG TTCCCCACTT TTGGGGGACA GTCTTCCATG
 2701 CGTCGCATAT CCATGTGAAG CAGACGACTC CCTGCTTGCC GCACACACCT CGGACAGTGA
 GCAGCGTATA GGTACACTTC GTCTGCTGAG GGACGAACGG CGTGTGTTGA GCCTGTCACT

Figure 19 (con't)

PDE10A compiled

2761	GCAACCCAGG	CTCTGCCGTG	TTCAGACGTC	GGCTACTCCG	TGGCTCCACC	TGACCTCCGA
	CGTTGGGTCC	GAGACGGCAC	AAGTCTGCAG	CCGATGAGGC	ACCGAGGTGG	ACTGGAGGCT
2821	ATGCTATTG	CTCCCAGGCC	AGCACTGCAC	TGTCTGGAGG	GGGCAGAGAC	CACAGGAGAG
	TACGATAAAC	GAGGGTCCGG	TCGTGACGTG	ACAGACCTCC	CCCCTCTCTG	GTGTCTCTC
2881	GTTCTGCCT	GCATCCTCCC	ATGAGGGTGT	GGCCAGTTCC	CTAGTTCTGT	GCCATGCTGC
	CAAGAACGGA	CGTAGGGAGGG	TACTCCCACA	CCGGTCAAGG	GATCAAGACA	CGGTACGACG
2941	TGCTTGGTGG	CATTGGTTAG	GAATGGGACA	CACGCCCTT	GTTGTGAAGT	TTACATGTGA
	ACGAACCACC	GTAACCAATC	CTTACCCCTGT	GTGGGGGAA	CAACACTTCA	AATGTACACT
3001	CCTTCTTATA	GGTTAACTGA	GTGGTGGCC	TGGGACACAT	GTAATGAAGG	TCACAGTCCA
	GGAAGAATAT	CCAATTGACT	CAAACACCGG	ACCCGTGTA	CATTACTTCC	AGTGTCAAGGT
3061	CAGGTGACAG	AGAAATCCAA	ACTGTTGATT	ACAGGTGCAC	TACAGGTATG	CTCTTCAGT
	GTCCACTGTG	TCTTAGGTT	TGACAACCAA	TGTCCACGTG	ATGTCCATAC	GAGAAAGTCA
3121	CTATCTGGGG	GCACATAGGT	GAGTCTGCTC	CACTCAGAAG	GAAGCATAAC	TCTSCCCTCA
	GATAGACCCC	CGTGTATCCA	CTCAGACGAG	GTGAGTCTTC	CTTCGTATGG	AGASGGGAGT
3181	TCCAGGGGAC	ACAGGGTACA	TCCCAGGCAT	CGGGGAACCTG	AAGCTCTCAC	TTCAAACCAT
	AGGTCCCCTG	TGTCCCATGT	AGGGTCCGTA	GCCCCTTGAC	TTCGAGAGTG	AAGTTGGTA
3241	GTCAAAGAAT	AAAAACACCT	CCCCTCCCCC	TCACTGTAGC	CTTCGGCAAC	TGGCCAATC
	CAGTTTCTTA	ATTTGTGGA	GGGGGAGGGGG	AGTACATCG	GAAGCCGTTG	ACGGGTTAG
3301	CCTTATACA	AAGAAAATAT	AGTAAGGCA	TATAAATTTC	CTCCAGCAAG	CAAATCTTGT
	GGAAATATGT	TTCTTTATA	TTCATTCCGT	ATATTTAAAG	GAGGTCGTTC	GTTAGAACA
3361	GGGTAAAAAA	AAAAAATGTG	AATTTAACCA	ACCTCTATAT	TTTCACTGTA	TGTATGGCA
	CCCATTTTTT	TTTTTACAC	TTAAAATTGT	TGGAGATATA	AAAGTGACAT	ACAATACCGT
3421	GAATTTAGT	CACGTCCAAA	ACAAAAGATT	ATTCCAGAAG	ATACCTCATC	CTATGCCTGA
	CTAAAATCA	GTGCAGGTTT	TGTTTCTAA	TAAGGTCTTC	TATGGAGTAG	GATACGGACT
3481	AAGCTCCACA	GCATGGCGTC	CGTCTCCAG	GGTTCTGATC	CGTCTCCCTCA	CGGTGCAATC
	TTCGAGGTGT	CGTACCGCAG	GCAGAGGGTC	CCAAGACTAG	GCAGAGGAGT	GCCACGTTAG
3541	AGGCAGGACA	GGAGGGAGGTG	CAGGGCTACC	ACATTGACCC	AGATGGTATC	TCCCTCTCACC
	TCCGTCTGT	CCTCCTCCAC	GTCCCGATGG	TGTAACTGGG	TCTACCATAG	AGGAGAGTGG
3601	ATTCAAGACAT	CCATAAGGAA	TGCCAAATGC	TGTATTGAAT	AGTTCTCTG	TGTGACTTT
	TAAGTCTGTA	GGTATTCTT	ACGGTTTACG	ACATAACTTA	TCAAGAGGAC	ACACTGAAAG
3661	TAGAGAAGCC	AGGACACCCC	TGAGCCTTC	CTGGGAACTC	CTAAGGAAGT	CACAGGTTCA
	ATCTCTCGG	TCCTGTGGGG	ACTCGGAAAG	GACCCCTTGAG	GATTCCCTCA	GTGTCCAAGT
3721	CACCGTGGGG	ATTTTCAGGA	TAGCATGGAG	ACCAGAGAAT	CCCGGTTCCG	TTGTTCTCAC
	GTGGCACCCC	TAAAAGTCCT	ATCGTACCTC	TGGTCTCTTA	GGGCCAAGCC	AACAAGAGTG
3781	TCGGTGAGCC	TTGAGAAGGA	AGAGACTGAC	CAGAAACACT	CACTCAGCAC	TCTGGCAGGA
	AGCCACTCGG	AACTCTCCT	TCTCTGACTG	GTCTTGTGA	GTGAGTCGTG	AGACCGTCCT
3841	GCAGGAGAAG	ATACTTTAAG	ATGAATCTT	GGGATAGATT	TTGATACACC	CAATACCATA
	CGTCTCTTC	TATGAAATTC	TACTTAGAAA	CCCTATCTAA	AACTATGTGG	GTTATGGTAT
3901	CACACAGGAG	CTTGGCATT	GCAAAGTCTA	TTCAGTTCC	TTCCACACTC	TGACCCACGG
	GTGTGTCTC	GAACCGTAAA	CGTTTCAGAT	AAGTCAAAGG	AAGGTGTGAG	ACTGGGTGCC
3961	TTGTAGCGGA	GTGGGCTGAA	CACTGTAACA	CTGTACATGC	GATTTCCCCA	TGGGCTCTA
	AACATCGCCT	CACCCGACTT	GTCACATTGT	GACATGTACG	CTAAAGGGGT	ACCCGAAGAT
4021	AAATGTCACC	ATCTCCTCCC	CTGCTGTGTC	CTACTCCATT	TACTGGTAC	AAGGTGATGT
	TTTACAGTGG	TAGAGGAGGG	GACGACACAG	GATGAGGTAA	ATGACCAATG	TTCCACTACA
4081	CAACAAGAGA	AGCTATCACA	ACACCAGGGC	TGTGCACACG	TGCACACACA	TGTATGCACA
	GTTGTTCTCT	TCGATAGTGT	TGTGGTCCCG	ACACGTGTG	ACGTGTGTGT	ACATACGTGT

Figure 19 (con't)

PDE10A compiled

4141 AGCACACAGA TGTATGTACA GCACACACAC ACACACACAC CCCAAAAGGA GAGAAAAGGA
 TCGTGTGTCT ACATACATGT CGTGTGTGTG TGTGTGTGTG GGGTTTCCT CTCTTTCT
 4201 AGAAAACATT TATAAAAAGC GACAGCTACC CCCATATTCA AAAATAGTTC TTTTCCCTGT
 TCTTTGTAA ATATTTTCG CTGTCGATGG GGGTATAAGT TTTTATCAAG AAAAGGGACA
 4261 AGGGAAACAG GTAGCTCTCC ATAAGGAAAT TATCATGAGT GTGTTCTCCC ATCAGTGAC
 TCCCTTGTC CATCGAGAGG TATTCCTTA ATAGTACTCA CACAAGAGGG TAGTCACGTG
 4321 TTCTCCCAGG GGTGTCACT GAAGCTGGTC CACGTCTATA AACAGGTGAC ACTGGCTGCA
 AAGAGGGTCC CCACGAGTGA CTTCGACCAAG GTGCAGATAT TTGTCCACTG TGACCGACGT
 4381 GCAAAAAGCC ATTGATCCA CACAAATTGA TCTTCTATCA TCTTCCAATC TGAATTGCAAG
 CGTTTTCCGG TAAGCTAGGT GTGTTAACT AGAAGATAGT AGAACCTTAG ACTTAACGTC
 4441 GGAGGAGCAG CATGTAAGAC GACCGTTAA TTCAGGCATT CCGAAGGCAT GAGCGCATGG
 CCTCCTCGTC GTACATTCTG CTGGCAAATT AAGTCCGTAA GGCTTCCGTA CTCGCGTACC
 4501 ATTCTGTAC CAAGCGTATA AAAGGACCCCT GGCATTGGGA AACCTATGAC GGACTGTTT
 TAAGACAGTG TTTCGATAT TTTCTGGGA CCGTAAACCTT TTGGATACTG CCTGACAAAA
 4561 TGCTGTAGAA GTAGGGATTT TACAGAAGTC TCCTTGGATT TGCCCTGCCT GGGGCAGTTT
 ACAGACATCTT CATCCCTAAA ATGTCTTCAG AGGAACCTAA ACAGGGACGGA CCCCCGTCAA
 4621 TGCAAGAGGA CCTGCCAGAG ATTTATTGGC TGGTCAGTCT CTTGTAAAT AGTATCATGT
 ACGTCTCCCTT GGACGGTCTC TAAATAACCG ACCAGTCAGA GAACACTTTA TCATAGTACA
 4681 GAGAAACAGT TTGTAGAAAA AACTATACCA TGGGAAGACC TTTGCAACAT TGTTCCCTCC
 CTCTTGTC AACATCTTT TTTGATATGG ACCCTTCTGG AAACGTTGTA ACAAGGAAGG
 4741 ATGGGCCAAG ACTCAAGTTAG GAGGCATAAA TCTGCCCCGA ATAAACTAGG CCAGGATAACA
 TACCCGGTTC TGAGTCAATC CTCCGTATTT AGACGGGCCT TATTGATCC GGTCCCTATGT
 4801 GCCATGTTA GTTAATAATT TGGTTTTAGA ATTCAACACAG GCAGGATTGG TTTTTTGTG
 CGGTACAAAT CAATTATTAA ACCAAAAATCT TAAGTGTGTC CGTCCTAACCC AAAAAAACAC
 4861 TCTTGGCAAG TGGAGCATAT TTAACATACA GGCATGGGA TCCCTGCCTCT TAGCTTTTCC
 AGAACCGTTC ACCTCGTATA AATTGTATGT CCGTACCCCTT AGGACGGAGA ATCGAAAAGG
 4921 CACCCCTCTG TCTCACCAAG TTTTTCTCT CCAAAGGTTT CCAGGAATT TCTATTAAAG
 GTGGGAGAAC AGAGTGGTTC AAAAAAGAGA GGTTTCCAAA GGTCTTAAAG GAGTAATTAC
 4981 GCTGATGCAA ACTTAGTGA TAATAATGAA TATAAACAAAT GTCACCTCA CCAAAATTAT
 CGACTACGTT TGAATCACTT ATTATTACTT ATATTTGTTA CGAGTGGAGT GTTTTAATA
 5041 ATTATTGCA GTCATTTGTG ATAACACAAA TTTATCGCA ATGGTTATTA TTAATTGTT
 TAATAACGT CAGTAACAC TATTGTGTT AAAATAGCGT TACCAATAAT AAATTAAACA
 5101 GGCCACACAC TGTGGTTATC TTTTGTGTG GTTGTTCCTG AGAAAATGTT CTTGGATATG
 CCGGTGTGTG ACACCAATAG AAAACAAACAC CAACAAAGAC TCTTTACAA GAACCTATAC
 5161 TAAGTGCCAA TACCAAGTGTG AAGTATTGAT CCCGGGCAGC AAAATACAGC CTAAGGTTTG
 ATTCACGGTT ATGGTCACAC TTCTACAAGA GGGCCCGTCC TTTTATGTG GATTCCAAAC
 5221 TAAACATCAA TTCTATCTCA GTTCATCAGA GGGCCTGAGA AGCTGCGGGG CAGTGTAAAG
 ATTGTAGTT AAGATAGAGT CAAAGTAGTCT CCCGGACTCT TCGACGCCCG GTCACATTTC
 5281 TAAAGTATGC TGGGCTGGTG GTGGTCAGCC TCCCCCTGCC AAGAAGAGAG CAATTGAATC
 ATTTCATACG ACCCGACCAAC CACCAGTCGG AGGGGAACGG TTCTTCTCTC GTTAACTTAG
 5341 CTGTCCCCAG CTCCCTCCAC GCCTGAAGAG TGACCAAGTGC TGGCCCGACG GATCGCTGAG
 GACAGGGGTC GAGGGAGGTG CGGACTTCTC ACTGGTCACG ACCGGGCTGC CTAGCGACTC
 5401 ATATTCTCCC ATAATGGCAA AAAATAGGC AGTTGATGT GACCTGTTA GTGTGGCTCT
 TATAAGAGGG TATTACCGTT TTTTATCCG TCAAACATACA CTGGACAAAT CACACCGAGA
 5461 CCTCTTTGA GCATGTGTTA GCATTTTAT TTTTACTCA TCCAGTGAAC TCTGCTCTTC
 GGAGAAAACCT CGTACACAAAT CGTAAAAATA AAATATGAGT AGGTCACTTG AGACGAGAAG

Figure 19 (con't)

PDE10A compiled

5521	CAAGTGTGTT	CATGTATGTG	CTAGATATAT	TAGCACAGCC	TGCCTCTGC	TGCACAACGC
	GTTCACACAA	GTACATACAC	GATCTATATA	ATCGTGTGCG	ACGGAAGACG	ACGTGTTGCG
5581	CTTAGAGACC	CGGCGTTCA	ATGAGCTTAG	CTTGTGCTCT	GTTTCTGCTC	TCTTAGGTCT
	GAATCTCTGG	GCCGGAAAGT	TACTCGAATC	GAACACGAGA	CAAAGACGAG	AGAATCCAGA
5641	AAACTATGGT	GTCAGTTTA	ATAGAACAAA	AGTATGCATC	TTGCCTGGC	TTGAGCCTT
	TTTGATACCA	CAGTCAAAAT	TATCTTGT	TCATACGTAG	AACGGAACCG	AACTCGGAA
5701	TCGTTTCAA	TGCTGACTTC	TCCCCTTTCT	CTCCGTGCT	CACCTTACCT	TTCCAGAGTG
	AGCAAAAGTT	ACGACTGAAG	AGGGGAAAGA	GAGGACACGA	GTGGAATGGA	AAGGTCTCAC
5761	TAAGGGACAA	CTTTAAGGA	GGCGTGTCCC	TGGTAGGGGC	ATCCCTGTT	ACCAGGTGCC
	ATTCCTGTT	GAAAATTCT	CCGCACAGGG	ACCATCCCCG	TAGGGACAAG	TGGTCCACGG
5821	TGTCATCACC	CCACTTGACT	GACATCTACC	CTGGGTGACTA	TGGGTTCTC	TTGTTTGTAG
	ACAGTAGTGG	GGTGAACTGA	CTGTAGATGG	GACCAACTGAT	ACCCAAGGAG	ACAAACATC
5881	GGAACGGTGG	CTCCAGGTGG	AGGCATCAAT	CTGTTGGGTT	CTGGTTCCCG	GTCGCCTT
	CCTTGCCACC	GAGGTCCACC	TCCGTAGTTA	GACAACCCAA	GACCAAGGGC	CGACGGAAAC
5941	GTGTTGAAAG	TCTCTTCTCT	GTATATTCT	ACCCCTGCATT	TGTTTGTGT	GGTGTGATG
	CAAACCTTC	AGAGAAGAGA	CATATAAGGA	TGGGACGTAA	ACGAAACACA	CCACGACTAC
6001	CTGTGGCAGT	AGGATCTTGG	ATGACTCTCC	ATCAGTCACA	GACTCCCCCT	GTTGCAAAGT
	GACACCGTCA	TCCTAGAAC	TACTGAGAGG	TAGTCAGTGT	CTGAGGGGGA	CAACGTTCA
6061	GTCAGGCTGA	CTCGACAGTC	ACCGTAAAAT	CTGAGTCAGT	CACACACAGG	CTGTCAGGCC
	CAGTCCGACT	GAGCTGTCA	TGGCATT	GACTCAGTCA	GTGTGTGTC	GACAGTCGGT
6121	CGGCTTCCAC	TTGCATGGCT	ATTCTATTTT	CACACGTGAG	TTTCTGTTGC	TGGCTGGCTG
	GCCGAAGGTG	AACGTACCGA	TAAGATAAAA	GTGTGCACTC	AAAGACAACG	ACCGACCGAC
6181	ACTGGCATT	TCTATGCTAA	GTTGAATCA	GGAGTGTGCC	CAGCAGAGCC	CATCATTCTC
	TGACCGTAAT	AGATACGATT	CAACTTTAGT	CCTCACACGG	GTGCTCTCG	GTAGTAAGAG
6241	ACTGTCTTG	AAACAAAGCT	GTACGGTTG	ATCGATGAAC	GTATTTAAAG	CATTCATGC
	TGACAGAAC	TTTGTTCGA	CATGCCAAC	TAGCTACTTG	CATAAATTTC	GTAAAGTACG
6301	AATGACAAG	TGCTCAGTAG	TGGAAGGGCAG	GCTGTGACCA	GTCTGCCTGC	TCCTTACTAT
	TTACTGTTTC	ACGAGTCATC	ACCTCCGTC	CGACACTGGT	CAGACGGACG	AGGAATGATA
6361	AATTGTGAGG	ATTTGTTACT	GGAACAGTAC	ATGGAGGCCT	GACCTTGTGG	GGGCACAGGG
	TTAACACTCC	AAACAAATGA	CCTTGTCATG	TACCTCCGGA	CTGGAACACC	CCCGTGTCCC
6421	TGGAACCTTA	GCTGAATATA	GTGTGTGCT	CAAGAGGAAG	TCAGGGTACT	AGCTCAGTGC
	ACCTTGGAA	CGACCTTATAT	CACACACAGA	GTTCTCCTTC	AGTCCCAGTGA	TCGAGTCACG
6481	TCAATCTCCA	GGTACTATAT	ATACATTG	CCGTTTATC	TCTAATGTGA	AATAAATCCC
	AGTTAGAGGT	CCATGATATA	TATGAAACG	GGCAAAATAG	AGATTACACT	TTATTTAGGG
6541	CAAACACTTG	TTTATCGTGT	AGCGTACCTA	AAAGACTATT	CTATTATGGG	TGTCCCCACT
	GTTCGTGAA	AAATAGCACA	TCGCATGGAT	TTCTGTATAA	GATAATACCC	ACAGGGGTGA
6601	TTCTTGGTT	GGTCACCCCG	ATCCCCGGGT	CTTCTGCTGT	ATCTAGAAC	GTGACTATAA
	AAGAACCAAA	CCAGTGGGGC	TAGGGGGCCA	GAAGACGACA	TAGATCTGT	CACTGTGATATT
6661	ATGATGTATG	GGAATAGTGT	TTCCATATGA	TCTGTGTCT	GGAGTATATG	CTACATGTT
	TACTACATAC	CCTTATCACA	AAGGTATACT	AGACAAACAGA	CCTCATATAC	GATGTACAAG
6721	ATTTACTGTA	AAAAACCCA	GTGCAGCTGA	TGATGCAAAG	CAGTCTCTCT	CTGTGTACAG
	AAAATGACAT	TTTTTGGGT	CACGTGCACT	ACTACGTTTC	GTCAGAGAGA	GACACATGTC
6781	TGCCCCACCT	ATTTAAAAT	CACGTACAAN	CCCAGAACAC	TGTAAACAC	TTAACATAAG
	ACGGGGTGG	AAAATT	GTGCATGTT	GGGTCTTGTG	ACACTTTGTG	AATTGTATT
6841	AAACAAACGC	AGCGTCTGGA	TTCTTCCAA	GGAGAGCAGC	TTTCTCCACA	GGAACACAGT
	TTTGTGCG	TCGCAGACCT	AAGAAAGGTT	CCTCTCGTCG	AAAGAGGTGT	CCTGTGTC

Figure 19 (con't)

PDE10A compiled

6901 AACAAAAGAG GTCCGCCGCC ATCCACACCC AGCCAAGACA CCTCAGAGGC CATAGGGACA
 TTGTTTCTC CAGGCGCGG TAGGTGTGGG TCGGTTCTGT GGAGTCTCCG GTATCCCTGT
 6961 ACCTCCTTGC TGGCCAACAC CTGCTGGAGC AGGGCACAGG TCCCAGCAAC TGATCCTCAG
 TGGAGGAACG ACCGGTTGTG GACCGACCTCG TCCCCTGTCC AGGGTCGTTG ACTAGGAGTC
 7021 TGGATGGGTC CGCAGTCAAA GCCTTAATGG GCTCTCTTT GAAGGGGAAA GAAANNNTTC
 ACCTACCCAG GCGTCAGTTT CGGAATTACC CGAGAGAAAA CTTCCCCTTT CTTTNNAAAG
 7081 AAGCTTATGA TATCCAACAT TATTATAGTT GATGAGTTAG TAAATTCCGA AAAAAAAAGA
 TTCGAATACT ATAGGTTGTA ATAATATCAA CTACTCAATC ATTAAGGCT TTTTTTTCT
 7141 TGATTTATA TGTATGACAT AAAAAAAATC TTTGTAAAGT GCGCAAGTGC AATAATTAA
 ACTAAAATAT ACATACTGTA TTTTTTTAG AAACATTTCA CGCGTTCCAG TTATTAAATT
 7201 AGAGGTCTTA TCTTGCATT TATAAATTAT AAATATTGTA CATGTGTGTA ATTTTCATG
 TCTCCAGAAT AGAAACGTAATATTTAATA TTTATAACAT GTACACACAT TAAAAGTAC
 7261 TATTCAATTG CAGTCTTGT ATTTAAAAAA ACTTTACTGT TATGTTGTA TAATAGAAC
 ATAAGTAAAC GTCAGAAACA TAAATTTTT TGAAATGACA ATACAAACAT ATTATCTGT
 7321 TTAATCATT ATTATAACTC AGACAAGGTG TAAATAAATT CATAATTCAA ACAGCCAGTA
 AATTAGTAAA TAATATTGAG TCTGTTCCAC ATTTATTAA GTATTAAGT TGCGGTCA
 7381 TATATGCATA TATGGGTGTT ACATGCAAA AATCTCTATC TTTGTTCTAT TCACATGCTT
 ATATAACGTAT ATACCCACAA TGTAACGTT TTAGAGATAG AAACAAGATA AGTGTACGAA
 7441 AAAGAAGTAA GAAATCTTT GTGGATATGT AATTATAACAT ATAAAGTATA TATATATGTA
 TTTCTTCATT CTTTAGAAA CACCTATACA TTAATATGTA TATTTCATAT ATATATACAT
 7501 TGATACATGA AATATATTGA GAAATGTTCA TAATTTTAAT GGATATTCTT TGGTGTGAAT
 ACTATGTACT TTATATAAAT CTTTACAAGT ATTAATAATT CCTATAAGAA ACCACACTTA
 7561 AATTGAATAC AACATTTTA AAATGAAAAA AAAAAAAA AAAAAAAA AAAAAAAA
 TTAACTTATG TTGTAATAAT TTTACTTTT TTTTTTTTT TTTTTTTTT

SEQUENCE LISTING

<110> ROBERTSON, Harold
DENOVAN-WRIGHT, Eileen
NOVANEURON, INC.

<120> GENE NECESSARY FOR STRIATAL FUNCTION, USES THEREOF, AND
COMPOUNDS FOR MODULATING SAME

<130> 36541-0005

<140>
<141>

<150> US60/158,043

<151> 1999-10-07

<150> US60/217,765

<151> 2000-07-12

<160> 12

<170> PatentIn Ver. 2.0

<210> 1
<211> 3236
<212> DNA
<213> mouse

<400> 1
cactgaagct ggtccacgtc tataaacagg tgacactggc tgcagcaaaa agccattcga 60
tccacacaaa ttgatcttct atcatcttgg aatctgaatt gcagggagga gcagtatgt 120
agacgaccgt ttaattcagg cattccgaag gcatgagcgc atggattctg tcaccaagcg 180
tataaaagga ccctggcatt gggaaaccta tgacggactg tttttgtgtt agaagtaggg 240
attttacaga agtctcccttgc aatttgcctt gcctggggca gttttgcaga ggaacctgcc 300
agagatttat tggctggtca gtctcttgc aatatgtatc atgtgagaaa cagttgttag 360
aaaaaaaaacta tacctggaa gacctttgca acattgttcc ttccatgggc caagactcag 420
tttaggaggca taaatctgcc cggaataaac taggccagga tacagccatg ttttagttaat 480

atattttttt tagaattcac acaggcagga ttgggttttt tgggtcttgg caagtggagc 540
atatttaaca tacaggcatg ggaatcctgc ctcttagctt ttcccaccct cttgtctcac 600
caagttttt ctctccaaag gttccagga atttctcatt aatggctgat gcaaacttag 660
tgaataataa tgaatataaa caatgctcac ctcaccaaaa ttatattatt tgcagtcatt 720
tgtgataaca caaattttat cgcaatggtt attatttaat ttgtggccac acactgtggt 780
tatctttgt tgggtttgtt tctgagaaaa tgggttttggta tatgttaagtg ccaataccag 840
tgtgaagtat tgatcccggg cagcaaaata cagcctaagg tttgtaaaca tcaattctat 900
ctcagttcat cagagggcct gagaagctgc ggggcagtgt aaagtaaagt atgctggcgt 960
ggtggtggtc agcctccgc ctgaagagtg accagtgctg gcccacgga tcgctgagat 1020
attctcccat aatggcaaaa aaataggcag tttgtatgtga cctgttttagt gtggctctcc 1080
tcttttggc atgtgttagc atttttattt tatactcatc cagtgaactc tgctttcca 1140
agtgtgtca tggatgtgtc agatataatta gcacagcctg ccttctgctg cacaacgcct 1200
tagagacccg gcctttcaat gagcttagct tggctctgt ttctgctctc ttaggtctaa 1260
actatgggt cagtttaat agaacaaaaag tatgcatttgcctt ggccttgcgtt gaggctttc 1320
gtttcaatg ctgacttctc cccttctct cctgtgtca ccttacctt ccagagtgtta 1380
agggacaact ttaaggagg cgtgtccctg gtaggggcat ccctgttac caggtgcctg 1440
tcatcacccc acttgactga catctaccct ggtgactatg ggttccctt gttttaggg 1500
aacgggtggct ccaggtggag gcatcaatct gttgggttct ggttcccggtc tgcctttgg 1560
tttgaagtc tcttctctgt atattcctac cctgcatttgc tttgtgtgg tgctgatgt 1620
gtgcgcagta ggattcttgg atgactctcc atcagtcaca gactccccct gttgcaaagt 1680
gtcaggctga ctcgacagtc accgtaaaat ctgagtcagt cacacacagg ctgtcagcca 1740
cggtttccac ttgcattggct attctatattt cacacgtgag tttctgttgc tggctggctg 1800
actggcatta tctatgtcaa gttgaaatca ggagtgccta gcagagccca tcattctcac 1860
tgtcttgaa acaaagctgt acggttttagt cgatgaacgt atttaaagca tttcatgcaa 1920
tgacaaagtg ctcagtagtg gaaggcagggc tggaccagt ctgcctgctc cttactataa 1980
ttgtgaggat ttgttactgg aacagtacat ggaggcctga ccttgtgggg gcacagggtg 2040
gaaccttagc tgaatatagt gtgtgtctca agaggaagtc agggtaactag ctcaagtgc 2100
aatctccagg tactatataat acatttgcctt gtttatctc taatgtgaaa taaatcccc 2160
aacactgtt ttcgtgttag cgtacctaata agactattct attatgggtg tccccacttt 2220
cttggtttgg tcaccccgat ccccccgtct tctgctgtat cttagaacagt gactataat 2280
gatgtatggg aatagtgttt ccatatgatc tggatgttgg agtataatgtc acatgttcaa 2340
ttactgtaca aaaacccagt gcagctgtatc atgcaagca gtcctctctc gtgtacagt 2400
ccccacctat ttaaaaatca cgtacaascc cagaacactg tggaaacactt aacataagaa 2460
caaacgcagc gtctggattc tttccaagga gagcagcttt cttccacagga acacagtaac 2520
aaaagaggcgc cggccatc cacacccagc caagacacact cagaggccat agggacaacc 2580
tccttgcgtgg ccaacacactg ctggagcagg ggcacaggc ccagcaactg atcctcagtg 2640
gatgggtccg cagtcaaagc cttaatgggc tcttttga agggaaaaga aagaatttca 2700
agcttatgtat atccaaacattt attatagttg atgagtttagt aaattccaaa aaaaaaaagat 2760
gatttatataat gtatgacata aaaaaaaatct ttgtaaagtg cgcaagtgcataaatttaaa 2820

gaggctttat ctttgcattt ataaattata aatattgtac atgtgtgtaa tttttcatgt 2880
attcatttgc agtctttgtt tttaaaaaaa ctttactgtt atgtttgtat aatagaacat 2940
taatcattta ttataactca gacaagggtt aaataaaattc ataattcaaa cagccagtt 3000
atatgcataat atgggtgtta cattgcaaaa atctctatct ttgttctatt cacatgctta 3060
aagaagtaag aaatcttttgc tggtatgtt attatacata taaaagtatata atatatgtat 3120
gatacatgaa atatatttttag aaatgttcat aattttaatg gatattcttt ggtgtgaata 3180
attgaataca acatttttaa aatgaaaaaaaaaaaaaaaaaaaaaaa 3236

<210> 2
<211> 5752
<212> DNA
<213> mouse

<400> 2
aagtgtaaat aaaataaaaca tctaataaaa aaaattacat accatagagg aacaagataa 60
tttctgccc aacctcatacc ctccagcgta tagtggtag gttggctg ttgctgtgt 120
ttgtaatgt aatgttaaatt ctctacctga aggtctaggc ctacaagtga attctcatgt 180
ttatagagtt ttgttgtgca aaccttggc cttaaattaa aactatggtt aaaaaacaaa 240
acaaaactgg ctacagccaa taactgaagg gggttaccc gttgaagggg tggaaaagag 300
agaggagggaa gaagggaggt caagagaagg agaagaacaa gaggagagga ggaagctgcc 360
acgaggggag atgggcccattt agaacttggc caggagaaat agccagtatc tggagtagac 420
caactgaggag gtagccaggc tagcagttag aagagtagat taggggttat tttccccca 480
ctccacatag ttatcaaagc caaataaaat aaccatagtc tgagtctcat ctatttgtaa 540
gtctgtggg tataagatta atttggctgt actacagttt agatttctaa cataggaact 600
atcaaaaact tgctcaaaca agaacatgct gacaatattt taaaatgatt atttatattg 660
tttgcacttt ctaaagttc ttctaaatgt tccatggtca aataaaaaaaaa tatacatatt 720
ggctattaaa ttcgtctaag tggggctgga gagatagctc agaggtaag agcactgact 780
gtcttcag aggtcctgag ttcaattccc agcgaccaca tggggctca cagccatctg 840
taatagatag gatctgacgc cctcttctgg agtgtctgaa gacagctaca atgtactcat 900
atataattaaa taaaataat tagaaaaattc ttctaaatgt atcatttata gaatatttaa 960
atataaaagt aaatgcctca gggaaatataa acttggaaattt aaatcaaaga acttcatgag 1020
tagtggggca caaaaaatgt gtaccagggg aagaccggag ggaggggaga aggaagggat 1080
ggagatagaa ttttgcctct gcattccttg ggctggcaca ggtataatgc tggggaaattt 1140
ggaaaactac aaggaagctg caaagctggg cggaaactcgt ttccgcaagc tgggctcatc 1200
aagtgtcca tgcattggctg ccacactgca gtgaacttta aaacatttgc gttccagaga 1260
gttagagatg ctcacaatag tacaaaggcg ggagggaggt atttccagac taagaggaag 1320
aaaaccatt gctgattaaa catctgcata tgagcgcacc cacccatcata cacacacacaca 1380
acacacacaca cacacacacaca caaccaaaca gaacaaatac acatgcatttgc ctacagcctg 1440
aggaacaaa atggtatgtc tgtgaggaac caggagatgc acaggtccta acctctgtct 1500

cctacaagcc ctgaagtctg gtcagggtca aatgtacaaa agcaggctaa ggaagctgtt 1560
tagtgaaaaga ttttttctt caactctagg aacaacctat ttccttaggtt ttggagagtg 1620
ctcaggagga aacattcaga caactgatgc tctctgtgtt ccccagattc aggtattggg 1680
gtagtttagtt gtgctcatgt atgtgctaga tatattagca cagcctgcct tctgctgcac 1740
aacgccttag agacccggcc tttcaatgag cttagcttgt gctctgttc tgctctctta 1800
ggtctaaact atgggtgtcag ttttaataga acaaaaagtat gcatcttgcc ttggcttgag 1860
ccttttcgtt ttcaatgctg acttctcccc tttctctctt gtgctcacct tacctttcca 1920
gagtgttaagg gacaactttt aaggaggcgt gtcctggta ggggcattccc tgttcaccag 1980
gtgcctgtca tcacccact tgactgacat ctaccctggt gactatgggt tccctttgtt 2040
tgttaggaaac ggtggctcca ggtggaggca tcaatctgtt gggttctggt tcccggtgc 2100
ctttggtttt gaaagtctct tctctgtata ttccttaccct gcatttgtt tgtgtgggtc 2160
tgcgtgtg cgcagcagga ttcttggatg actctccatc agtcacagac tccccctgtt 2220
gcaaaagtgtc aggctgactc gacagtcacc gtaaaatctg agtcagtac acacaggctg 2280
tcagccacgg ctccacttg catggctatt ctatttcac acgtgagtt ctgttgctgg 2340
ctggctgact ggcattatct atgctaagtt gaaatcaggg gtgcccagca gagcccatca 2400
ttctcactgt ctgttcaaaca aagctgtacg gtttgcgtt tgaacgtatt taaagcattt 2460
catgaatga caaaagtgtc agtagtgaa ggcaggctgt gaccagtctg cctgctcctt 2520
actataattt tgaggatttg ttactggaaac agtacatgga ggcctgaccc tggggggca 2580
cagggtgaa ccttagctga atatagtgtg tgtctcaaga ggaagtcagg gtactagctc 2640
agtgcataat ctccaggta tatataaca tttgcccgtt ttatctctaa tgtgaaataa 2700
atccccaaac acttggttat cgtgttagcgt acctaaaaga ctattctatt atgggtgtcc 2760
ccactttctt gggttggta ccccgatccc ccggcttctt gctgtatcta gaacagtgac 2820
tataaatgat gtagggaaat agtggtaatc tatgatctgt tgtctggagt atatgcata 2880
tgttcattta ctgtacaaaa acccagtgcgca gctgatgtt gaaagcagtc tctctgtt 2940
tacagtgcac cacctattt aaaaatcacgt acttgcacccag aacactgtga aacacttaac 3000
ataagaacaa acgcagcgtc tggattctt ccaaggagag cagcttctc cacaggaaca 3060
cagtaacaaa agaggtccgc cgccatccac acccagccaa gacaccttag aggcctagg 3120
gacaacctcc ttgctggca acacctgctg gaggcgggc acagggtccca gcaactgatc 3180
ctcagtggat gggctctgcag ccaaagcctt aatgggtctt ctggtaagg gggaaagaaaag 3240
aatttcacgc ttatgtatc caatattatt atagttgtatg agttgtaaa ttccaaaaaaa 3300
aaaagatgat ttatgtatgta tgacataaaa aaaatctttt gaaatgtgcgc aagtgcataa 3360
atttaaagag gtcttatctt tgcattttata aattataaaat attgtacatg tgtgtatatt 3420
ttcatgtatt catttgcagt ctttgtatatt aaaaaaaactt tactgttatg tttgtataat 3480
agaacattaa tcattttata taactcagac aaggtgtaaa taaattcata attcaaacag 3540
ccagttatata tgcataatag ggtgttacat tgcaaaaatc tctatcttgc ttctattcac 3600
atgcttaaag aagtaagaaaa tcttttgcgg atatgtatatt atacatataa agtataatata 3660
tatgtatgtt acatgaaata tatttagaaa tggtcataat ttatgtatgtt attctttgg 3720
gtgataattt gaataacaaca ttttttttt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3780
aaaattttttt ttatccaga gattaaagac actagatctt taaccttgaa 3840

gggcaggcaa gaggtcggca atgctgtcaa catagaagtc agggaccatt ttcttcttga 3900
acatgcagtc actttcctga ttgctcttca catcctcaag gctccggaat tccgggggtg 3960
tggtgggctt tgcgttcagg actctggagg cagaacgagg cagatctctg tgaatatgag 4020
gccagcctgc actacacaga gctccagacc agtcatggct acatcatgaa accctgtctc 4080
aaaaagaaaa taaaaactgt tgcgtttcta ccatagtgtt aaactcagag tctgagtaat 4140
gtcgggctga catgctcggg tggttaacat accttcagct ttgacgaggc gctgaacagt 4200
caaagtctgg ccttggggag cggtggctgt gtttgctc aagtccaccg tgaaatcctg 4260
attgtgaatt tggacaaccg tgccttctt cttggccttc catgcaacct ccaacttcat 4320
gttggtcatt ttgtcaaaac actgtgtgat gttttatca atatactgcc attccacata 4380
tgtagagatg tagtctgcct ggcttcctt ttcttagcc aatcgaatgc tcttgatcat 4440
gccctcaatc tcacatcttag cttttatcac gtctctgcta attcctgaaa cttgaatcga 4500
agtttcttc tggttcatct caatggtgat gttcagttcc ttctgaatct cattcagttt 4560
ctcgtaactcc tccatgtcaa agtcaactgac acactcatcg tcattggtgt agggaaagctg 4620
ctctttggta atcagttcct ttagccagga gattgttttgc ttcacactgt ctaccctga 4680
accacataacc tggaaaactg tgcgtctat tttctttcc aaaaccaggg tggcttttt 4740
gggggaagct tgcttggaa agccaagaaa ggctaaagag aaaatggaaa ttaatgttcc 4800
tttactccc ttcaacatca aggttaggaa tatgtatttc ataaaagcta acaactcaca 4860
ggcaatctta gacatcaactg actgcttggc aggcgactgc ttggggggag ctggagagcc 4920
ttctctttct ttcatgttgc cgaaaaaaaa ttgcagaata tggggctgga agataacaac 4980
tttaactctc ttacagcct gcaactgattt tttctggaca aattcttcaa tggcatctat 5040
tatcgctttt gctactacgt ttgggcctg ttgagcattt cttcaaaaaa caaaaaaaagc 5100
acattttaa aaagtcaagg ttaagatcca cctgaaaaaa aaagctgcaa tataagcgag 5160
gaattctagt tgtcacagga aataaaaaatg tctgttccca ctataatcaa tgcgtactga 5220
taatattatg ccagcaaata gtttgaagt cctaggcaca gtgggaggag gtttgttcc 5280
acgctgttca taagccaata ccccagcaaa agaccttaaa ggacaactg taatttggga 5340
cattcacatc tgctcttcc atctgatctg gctccagtg tcactctcta acacggctt 5400
tagagggaca atttacccct gcctctgctt gatcttatgc atgtatctgt attcttccag 5460
ccatccctgg cgacctgatt ttcttaaggc accaaaaact gtaagctact tcttataatc 5520
tataattctg agcatattag ttagcctgag cctccaggat atcttcttc cctataactca 5580
gtccagtttt agctgcccag aaggattcaa agctgatcta cgagtagatc actcctgtct 5640
acagcttgc ttcttaatca tgggtgtggc ccaaagtcaa tggccgaaat tc 5752

<210> 3

<211> 475

<212> DNA

<213> mouse

<400> 3

tgtatggaa tagtgttcc atatgatctg ttgtctggag tatatgctac atgttcattt 60
actgtacaaa aacccagtgc agctgatgat gcaaaggagt ctctctctgt gtacagtgcc 120
ccacccatattt aaaaatcacg tacttgccca gaacactgtg aaacacttaa cataagaaca 180
aacgcagcgt ctggattttt tccaaggaga gcagcttct ccacaggaac acagtaacaa 240
aagaggtccg cgcgcatcca caccgcacca agacacctca gaggccatag ggacaacctc 300
cttgctggcc aacacctgct ggagcagggg cacaggtccc agcaactgat cctcagtgga 360
tgggtctgca gccaaaggct taatgggctc tctttgaag gggaaagaaa gaatttcaag 420
cttatgatat ccaatattat tatagttgat gagttagtaa attccaaaaa aaaaaa 475

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 4

agggctgtca atcatgctgg

20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 5

aaactcacgg tcgggtgcagc

20

<210> 6

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:probe

<400> 6

attnaaccctc actaaatgct gtat

24

<210> 7

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:probe

<400> 7

cattatgctg agtgatatct ttttttttcg

30

<210> 8

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:probe

<400> 8

gaacatgtag catatactcc agacaacaga tcataatgg

38

<210> 9

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:probe

<400> 9

cagttctcc acaggaacac agtaacaaag ag

32

<210> 10

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 10

ctatttcaca agagactgac cagccaataa atctc

35

<210> 11

<211> 7581

<212> DNA

<213> Unknown

<400> 11

cgccggggca ggtctgttgg agggcagttg gtcaacctga ccagagagag ctgagctgga 60
agaccccaact gatggtgtgc tgccttcag tccaggaaga aagaaaggaa ggattctgag 120
gatttgggca aagccacatt cctggagaag tctgtatact gatgccaaac ccaagagctg 180
agctgctgat gaggcccagg gagtagccca cgccctga gctgttggtc agcaaggcct 240
tcctgctcca tgtggcatgg aaaaattata tggtttgacg gatgaaaagg tgaaggccta 300
tctttctctc catccccagg tattagatga atttgttct gaaagtgtt a tgcagagac 360
tgtggaaaag tggctgaaga gaaaaaccaa caaagcaaaa gatgaaccat ctcccaagga 420
agtcagcagg taccaggata cgaatatgca gggagtcgtg tacgagctga acagctacat 480
agagcagcgc ctggacacgg gcggggacaa ccacctgctc ctctatgagc tcagcagcat 540
catcaggata gccacaaaag ccgacggatt tgcactgtac ttccctggag agtgcataa 600
tagcctgtgt gtgttcatac caccgggat gaaggaaggc caaccccgcc tcatccctgc 660
agggcccatc acccagggta ccaccatctc tgcctacgtg gccaagtcta ggaagacgtt 720
gttggtagag gatatccttgc gggatgagcg atttcctcga ggtactggcc tggaatcagg 780
aaccggcattc cagtctgttc tttgcttgcc cattgtcact gccattggag acttgattgg 840
catccttgcatttgccttgc gggatgagcg atttcctcga ggtactggcc tggaatcagg 900
tgcaacagcc aatcttgctt gggcttccgt agcaatacac caggtgcagg tggatcagg 960
tctcgccaaa cagaccgaac tgaatgactt cctactcgac gtatcaaaga catactttga 1020
taacatagtt gccatagact ctctacttga acacatcatg atatatgcaa aaaatctagt 1080
gaacggcgcac cgctgcgcgc tcttccagggt ggaccacaag aacaaggagc tggatcgg 1140
cctgtttgac attggggagg agaaggaggg gaagccatc ttcaagaaga ccaaggagat 1200
cagattttcc attgagaaag ggattgctgg tcaagtggca agaacaggcg aagtcttgc 1260
cattcccgat gcctacgcgg accctcgctt taacaggaggt gtggacctgt acacaggcta 1320
caccacgagg aacattctgt gtatgcccatttgc ggcagcgtga ttggcgtgg 1380
gcagatggtg aacaagatca gcggtagcgc cttctccaag acagacgaga acaacttcaa 1440
gatgttgct gtcttctgctt gactggcctt gactgtgct aacatgtacc acaggatccg 1500

ccactcagaa tgcacatcaca gggttaccat ggagaagctt tcctaccaca gcacatgcac 1560
ctccgaggag tggcaaggcc tcatgcgctt caacccatcca gcacgcacat gcccggacat 1620
cgagctattc cactttgaca ttggtccttt cgagaacatg tggcctggga tctttgtcta 1680
catgatccat cggtcttgcg ggacatcctg ttttgaactt gaaaaattgt gcccgtttat 1740
catgtctgtg aagaagaact atcggcggtt tccttaccac aactggaagc atgcagtcac 1800
ggtggcacac tgcacatgtatg ccatacttca aaacaacaat ggcctttca cagacctcga 1860
gcccggaaaggc ctgcttaattt cgtgtctgtg ccatgacactg gaccacaggg gcttcagtaa 1920
cagctacactg cagaagttcg accacccctt ggcggcgctg tactccacat ccaccatgga 1980
gcaacaccac ttctcccaga cggtgtccat cttcagctg gaagggcaca atatcttctc 2040
caccctgagc tccagcgagt acgagcaggt gctggagatc atccgcaaag ccacatcgac 2100
caccgacactc gcccataact ttgggaacag gaagcagttt gaggagatgt accagacagg 2160
gtcgctgaac ctccacaaacc agtcccatcg agaccgtgtc atcggcttga tgatgactgc 2220
ctgtgatctt tgctctgtga ccaaactatg gccagttaca aaattgacag cgaatgatata 2280
atatgcagaa ttctggctg agggtgatga gatgaagaag ctgggcatac agccattcc 2340
tatgatggac agagacaagc gagatgaagt ccctcaaggg cagctcgat tctacaatgc 2400
tgtggccatt ccctgctata ccaccttgac gcagatcctc ccacccacag agcctctgct 2460
gaaggcctgc agggataacc tcaatcagtg ggagaaggta attcgcccc aagagacagc 2520
aatgtggatt tcaggcccag gcccggcgcc tagcaagagc acacctgaga agctgaacgt 2580
gaaggttcaa gactgatctt gaagtgcgt cctgatgtct gcccagcaac cgactcaacc 2640
tgcttctgtg acttcgttct ttttgtttt aaggggttcaa aacccctgt cagaaggtac 2700
cgtcgcatat ccatgtgaag cagacgactc cctgcttgcg gcacacacat cggacagtga 2760
gcaacccagg ctctggcggt ttcagacgtc ggctactccg tggctccacc tgacccatcc 2820
atgctatccat ctcacccaggcc agcaactgcac tgtctggagg gggcagagac cacaggagag 2880
gttcttgctt gcacccatccc atgaggggttcc ggcagttcc ctagttctgt gccatgctgc 2940
tgcttgggttgg cattgggttag gaatgggaca cacgccccctt gttgtgaagt ttacatgtga 3000
ccttcttata ggttaactga gtttgtggcc tggacacatg taatgaaggt cacagtccac 3060
agggtacaga gaaatccaaa ctgttgcattt caggtgcact acaggtatgc tcttcagtc 3120
tatctggggg cacatagggtg agtctgctcc actcagaann aacgcataccctt ctgcctccat 3180
ccagggggaca cagggtacat cccaggcactt ggggaaactga agctctcact tcaaaccatg 3240
tcaaagaatt aaaacacccctt ccctcccccacttgcactt ttcgacaaactt ggcacatcc 3300
ctttatacaa agaaaataaa agtaaggcat ataaatttcc tccagcaagc aaatcttgc 3360
ggtaaaaaaaa aagcatgtga atnntaacaa cttctanant ntncnngnat gttatggcag 3420
aatttttagtc acgtccaaaa caaaaagattt attccagaag atacctcattt ctatgcctga 3480
aaggctccac agcatggcggtt ccgtctccca gggttctgtat ccgtctcctc acgggtgcac 3540
caggcaggac agagaggagg gctgcaggcc taccacattt acccagaagg tatctccctt 3600
caccatttcac acatccataaa ggaatgccaatg atgctgtattt gaatagttctt ctgtgtgact 3660
ttcttagagaa gccaggacac cctgagccctt tccngggaa ctctaaaggag tccacagggttc 3720
acaccgtggg gattttcagg atagcatgga gacagagatc cggtcgttgc tctcactcgt 3780
gagccttgcg aaggagagac tgaccagaaa cactcactca gcaactctgca ggagcaggag 3840

aagatactt aagatgaatc ttggatagat tttgatacac ccaataccat acacacagga 3900
gcttggcatt tgcaaagtct attcagttc cttccgcgtc ctgacccacg gtttagcgg 3960
agtgggctga acactgtAAC actgtacatg cgattcccc atgggcttct aaaatgtcac 4020
catctcctcc cctgctgtgt cctactccat ttactggtta caaggtgatg tcaacaagag 4080
aagctatcac aacaccaggg ctgtcacac gtgcacacac atgtatgcac aagcacacag 4140
atgtatgtac agcacacaca cacacacaca ccccaaaagg agagaaaagg aagaaaacat 4200
ttataaaaag cgacagctac cccatatacaa aatagtctt cctgttaggaa acaggagctc 4260
tccataagga attatcatga gtgtgttctc ccatcagtgc actctccag gggtgctcac 4320
tgaagctggt ccacrtctat aaacaggta cactggctgc agcaaaaagc cattcgatcc 4380
acacaaattg atcttctatc atcttggaat ctgaattgca gggaggagca gyatgttaaga 4440
cgaccgttta attcaggcat tccgaaggca tgagcgcgtg gattctrtca ccaagcgtat 4500
aaaaggaccc tggcattggg aaacctatga cggactgttt ttgctgtaga agtagggatt 4560
ttacagaagt ctccttgrat ttgccctgcc tggggcagtt ttgcagagga acctgccaga 4620
gatttattgg ctggtcagtc tcttgtaaa tagtacatg tgagaaacag ttttagaaaa 4680
aaaactatac ctggaaagac ctttgcacaca ttgttcccttc catgggccaa gactcagtt 4740
ggaggcataa atctgcccgg aataaaactag gccaggatac agccatgtt agttaataat 4800
ttgggttttag aattcacaca ggcaggattt gttttttgt gtcttggcaa gtggagcata 4860
tttaacatac aggcattggg atcctgcctc ttagctttc ccaccctttt gtctcaccaa 4920
gtttttctc tccaaaggatt tccaggaatt tctcattaat ggctgatgca aacttagtga 4980
ataataatga atataaacaa tgctcacctc accaaaatta tattatttgc agtcatttgc 5040
gataacacaa attttatgc aatggttatt attaatttgc tggccacaca ctgtggttat 5100
cttttgcgtt ggttgcgtt gagaatgtat tcttggatat gtaagtgcac ataccagtgt 5160
gaagtattga tcccggcag caaaaatacag cctaaggattt gtaaacatca attctatctc 5220
agttcatcag agggcctgag aagctgcggg gcagtgtaaa gtaagtatg ctggcgttgt 5280
gggtggcagc ctcccccttc caagaagaga gcaattgaat cctgtccca gctccctcca 5340
cgccctgaaga gtgaccagtg ctggcccgac ggatcgctga gatattctcc cataatggca 5400
aaaaaaatagg cagttgtatg tgacctgttt agtgtggctc tcctctttt agcatgtgtt 5460
agcattttta ttttataactc atccagtgaa ctctgcctt ccaagtgtgt tcatgtatgt 5520
gctagatata ttagcacagc ctgccttctg ctgcacaacg ccttagagac ccggccttc 5580
aatagactta gcttgcgtc tggctgtgtct ctcttaggtc taaactatgg tgtcagtttt 5640
aatagaacaa aagtatgcac ctgccttgg cttgagccctt ttcgtttca atgctgactt 5700
ctcccccttc tctcctgtgc tcaccttacc tttccagagt gtaagggaca acttttaagg 5760
aggcgtgtcc ctggtagggg catccctgtt caccagggtgc ctgtcatcac cccacttgac 5820
tgacatctac cctgggtact atgggttctt cttgtttgtt gggaaacgggtg gctccaggtg 5880
gaggcatcaa tctgttggtt tctgggtccc ggctgcctt gggtttgaaa gtctttctc 5940
tgtatattcc taccctgcac ttgtttgtt tgggtgtat gctgtggcag taggatctt 6000
gatgactctc catcagtac agactcccc tggcacaag tggcaggctg actcgacagt 6060
caccgtaaaa tctgagtcac tcacacacag gctgtcagcc acggcttcca cttgcacggc 6120
tattctatcc tcacacgtga gtttctgtt cttggctggct gactggcatt atctatgcta 6180

agttgaaatc aggagtggtgc ccagcagagc ccatcattct cactgtctt gaaaacaaagc 6240
 tgtacggttt gatcgatgaa cgtatTTaaa gcatttcatg caatgacaaa gtgctcagta 6300
 gtggaaaggca ggctgtgacc agtctgcctg ctccttacta taattgttag gatttggtag 6360
 tggAACAGTA catggaggcc tgaccttggtag ggggcacagg gtggAACCTT agctgaatAT 6420
 agtgtgtgtc tcaagaggaa gtcagggtac tagctcagtg ctcaatctcc aggtactata 6480
 tatacatttg cccgttttat ctctaattgtg aaataaatcc ccaaACACtt gtttattcgtg 6540
 tagcgtaccc aaaagactat tctattatgg gtgtccccac tttcttgggt tggtcacccc 6600
 gatccccccgg tcttctgctg tatctagaac agtgaCTATA aatgtatgtat gggAAATAGTG 6660
 tttccatATG atctgtgtc tggagtataat gctacatgtt cattttactgt acaaaaACCC 6720
 agtgcagctg atgatgcaaa gcagtctctc tctgtgtaca gtgccccacc tattttaaaaaa 6780
 tcacgtacaa ncccagaaca ctgtgaaaca cttaacataa gaaACAAACG cagcgtctgg 6840
 attcttcca aggagagcag ctttctccac aggaACACAG taacAAAAGA ggtccgcccgc 6900
 catccacacc cagccaaAGAC acctcagagg ccatAGGGAC aacctccttg ctggccaaca 6960
 cctgctggag cagggcacAG gtcccAGCAA ctgatcctca gtggatgggt ccgcAGTCAA 7020
 agccttaatg ggctctctt tgaAGGGAA agaaanNTT caagcttATG atatccaaca 7080
 ttatttatagt tgatgagttt gtaaattccg aaaaaaaaaaAG atgatTTT atgtatgaca 7140
 taaaaaaaaat ctgtaaAG tgCGCAAGTG caataatttA aagaggTCTT atctttgcAT 7200
 ttataaaATTA taaatattgt acatgtgtgt aatttttcat gtattcatTT gcagtcttg 7260
 tattttaaaaa aactttactg ttatgtttgt ataataAGAAC attaatcatt tattataact 7320
 cagacaAGGT gtaaataat tcataattca aacAGCCAGT atatATGcat atatGGGTGT 7380
 tacattgcaa aaatctctat ctttGTTcta ttcatGCTt taaAGAAGTA agaaatCTT 7440
 tggatATG taattataca tataAAAGTAT atatATATGT atgatacATG aaatATATT 7500
 agaaatgttc ataattttAA tggatattct ttgggtgtgaa taattgaata caacatttt 7560
 aaaatgaaaa aaaaaaaaaaC 7581

<210> 12

<211> 7618

<212> DNA

<213> mouse

<400> 12

cggccggggca ggtctgttgg agggcagttg gtcaACCTGA ccAGAGAGAG ctgagctgga 60
 agaccccaCT gatgggtgtc tgcTTTCAg tccAGGAAGA aAGAAAGGAA ggattctgag 120
 gatttgggca aAGCCACATT cctggagaAG tctgtataCT gatGCCAAAC ccaAGAGCTG 180
 agctgtgtat gaggcccAGG gAGTAGCCCA cgcGCCCTGA gctgttggct agcaAGGCCT 240
 tcctgttcca tggatTTGATGG AAAAATTATA tggTTTGTACG gatgAAAAGG tgaAGGCCTA 300
 tctttctctc catccccAGG tattAGATGA atttGTTCT gaaAGTGTta gtgcAGAGAC 360
 tggatTTGAAAG tggctGAAGA gggAAACCAA caaAGCAAAA gatgaACCCAT ctcccAAGGA 420
 agtcAGCAGG taccaggata cgaatATGCA gggagTCGTG tacGAGCTGA acagctacat 480

agagcagcgc ctggacacgg gcggggacaa ccacctgctc ctctatgagc tcagcagcat 540
catcaggata gccacaaaaag ccgacggatt tgcactgtac ttccctggag agtgcataa 600
tagcctgtgt gtgttcatac caccggat gaaggaaggc caaccccgac tcatccctgc 660
agggcccatc acccaggta ccaccatctc tgcctacgtg gccaagtcta ggaagacgtt 720
gttggtagag gatatcctt gggatgagcg atttcctcga ggtactggcc tggaatcagg 780
aacccgcac cagtctgttc tttgcttgcc cattgtcaact gccattggag acttgattgg 840
catccttcaa ctgtacaggc actggggcaa agaggccttc tgcctcagcc atcaggaggt 900
tgcaacagcc aatcttgctt gggctccgt agcaatacac caggtgcagg tgttagagg 960
tctcgccaaa cagaccgaac tgaatgactt cctactcgac gtatcaaaga catactttga 1020
taacatagtt gccatagact ctctacttga acacatcatg atatatgcaa aaaatctagt 1080
gaacggcgac cgctgcgcgc tcttccaggt ggaccacaag aacaaggagc tgtactcgga 1140
cctgtttgac attggggagg agaaggaggg gaagccatc ttcaagaaga ccaaggagat 1200
cagatttcc attgagaaag ggattgctgg tcaagtggca agaacaggcg aagtcttgaa 1260
cattcccgat gcctacgcgg accctcgctt taacagggag gtggacctgt acacaggcta 1320
caccacgagg aacattctgt gtatgcccatt agtgagccga ggcagcgtga ttggcgtggt 1380
gcagatggtg aacaagatca gcggtagcgc cttctccaag acagacgaga acaacttcaa 1440
gatgtttgct gtcttctgcg cactggcctt gcactgtgct aacatgtacc acaggatccg 1500
ccactcagaa tgcatactaca gggttaccat ggagaagctt tccattaccaca gcatctgcac 1560
ctccgaggag tggcaaggcc tcatgcgcctt caacctacca gcacgcattt gcccggacat 1620
cgagctattt cactttgaca ttggcctttt cgagaacatg tggcctggga tctttgtcta 1680
catgatccat cggctttgtg ggacatcctg ttttgaactt gaaaaattgt gcccgtttat 1740
catgtctgtg aagaagaact atcggcggtt tccttaccac aactggaaagc atgcagtcac 1800
ggtggcacac tgcatactatg ccatacttca aaacaacaat ggctcttca cagacctcg 1860
gcfgaaaggc ctgctaattt cgtgtctgtg ccatgacctg gaccacaggg gttcagtaa 1920
cagctacctg cagaagttcg accacccctt ggcggcgtg tactccaccc ccaccaatgg 1980
gcaacaccac ttctcccaga cgggtccat cttcagctg gaagggcaca atatcttc 2040
caccctgagc tccagcgaatg acgagcaggat gctggagatc atccgcaaaag ccatacatcg 2100
caccgacccgc gcccataact ttggaaacag gaagcagttt gaggagatgt accagacagg 2160
gtcgctgaac ctccacaacc agtcccattt cgtgtctgtg agaccgtgtc atcggcttga tgatgactgc 2220
ctgtgatctt tgctctgtga ccaaactatg gccagttaca aaattgacag cgaatgat 2280
atatgcagaa ttctggctg aggggtatga gatgaagaag ctgggcatac agccattcc 2340
tatgatggac agagacaagc gagatgaatg ccctcaaggg cagctcggat tctacaatgc 2400
tgtggccatt ccctgctata ccaccttgcac gcagatccctc ccacccacag agcctctgt 2460
gaaggcctgc agggataacc tcaatcgtt gggaaaggta attcgcgggg aagagacagc 2520
aatgtggatt tcaggcccag gcccggcgcc tagcaagagc acacacgtt gactgaacgt 2580
gaaggttcaa gactgatcctt gaagtgacgt cctgtatgtt gcccagcaac cgtactcaacc 2640
tgcttctgtg acttcgtttt aaggggttcaa aacccctgt cagaaggtac 2700
cgtcgcataat ccatgtgaag cagacgactc cctgcttgcc gcacacaccc cggacagtga 2760
gcaacccagg ctctgcccgtt ttcagacgtc ggctactccg tggctccacc tgacccatcc 2820

atgcatttg ctcccaggcc agcaactgcac tgtctggagg gggcagagac cacaggagag 2880
gttcttgcct gctccccc atgagggtgt ggccagttcc ctagttctgt gccatgctgc 2940
tgcttggtagtgg caatggtag gaatgggaca cacgccccctt gttgtgaagt ttacatgtga 3000
ccttcttata ggttaactga gtttggcc tgggacacat gtaatgaagg tcacagtcca 3060
caggtgacag agaaatccaa actgttgatt acaggtgcac tacaggtatg ctcttcagt 3120
ctatctgggg gcacataggt gagtctgctc cactcagaag gaagcataacc tctscctca 3180
tccaggggac acagggtaca tcccaggcat cggggactg aagctctcac ttcaaaccat 3240
gtcaaagaat taaaacacact cccctcccc tcactgttagc cttcggcaac tgcgccaatc 3300
cctttataca aagaaaat aagtaaggca tataaatttc ctccagcaag caaatcttgt 3360
gggtaaaaaaa aaaaaatgtg aattttaca acctctat tttcaactgta tgttatggca 3420
gaattttagt cacgtccaaa acaaaagatt attccagaag atacctcatc ctatgcctga 3480
aagctccaca gcacatggcgtc cgtctccag gggtctgatc cgtctccatc cggtgcaatc 3540
aggcaggaca ggaggaggtg cagggctacc acattgaccc agatggtac tcctctcacc 3600
attcagacat ccataaggaa tgccaaatgc tgtattgaat agttctctg tgtgactttc 3660
tagagaagcc aggacaccccc tgagccttc ctgggactc ctaaggaagt cacaggtca 3720
caccgtgggg attttcagga tagcatggag accagagaat cccggttcgg ttgttctcac 3780
tcggtgagcc ttgagaagga agagactgac cagaaacact cactcagcac tctggcagga 3840
gcaggagaag atacttaag atgaatctt gggatagatt ttgatacacc caataccata 3900
cacacaggag cttggcattt gcaaagtcta ttcagttcc ttccacactc tgacccacgg 3960
ttgtagcga gtgggctgaa cactgtaaca ctgtacatgc gatttccca tggccttcta 4020
aaatgtcacc atctccccc ctgctgtgtc ctactccatt tactggttac aaggtgatgt 4080
caacaagaga agctatcaca acaccaggc tgtgcacacg tgcacacaca tgtatgcaca 4140
agcacacaga tgtatgtaca gcacacacac acacacacac cccaaaagga gagaaaagga 4200
agaaaaacatt tataaaaagc gacagctacc cccatattca aaaatagttc tttccctgt 4260
agggaaacag gtagctctcc ataaggaaat tatcatgagt gtgttctccc atcagtgcac 4320
ttctccagg ggtgctcaact gaagctggtc cacgtctata aacaggtgac actggctgca 4380
gcaaaaagcc attcgatcca cacaattga tcttctatca tcttggaaatc tgaattgcag 4440
ggaggagcag catgtaagac gaccgtttaa ttcaggcatt ccgaaggcat gagcgcattgg 4500
attctgtcac caagcgtata aaaggaccct ggcattggaa aacctatgac ggactgtttt 4560
tgctgttagaa gttaggattt tacagaagtc tcttggatt tgccctgcct gggcagttt 4620
tgcagaggaa cctgccagag atttattggc tggtcagtct cttgtgaaat agtacatgt 4680
gagaaaacagt ttgtagaaaa aaactatacc tggaaagacc tttgcaacat tttcccttcc 4740
atgggccaag actcagttag gaggcataaa tctgccccga ataaaactagg ccaggataca 4800
gccatgttta gttataatt tggttttaga attcacacag gcaggattgg ttttttgg 4860
tcttggcaag tggagcatat ttaacatatac ggcattggaa tctgcctct tagctttcc 4920
caccctcttgc ttcaccaag tttttctct ccaaaggattt ccaggatattt ctcattaaatg 4980
gctgatgcaa acttagtgaa taataatgaa tataaacaat gtcacactca ccaaaattat 5040
attatttgca gtcatttgta ataacacaaa ttttacgca atggttatata tttatgtt 5100
ggccacacacac ttttttttttgc gttgttctg agaaaatgtt cttggatatg 5160

taagtgccaa taccagtgtg aagtattgtat cccgggcagc aaaatacagc ctaagggttg 5220
taaacatcaa ttctatctca gttcatcaga gggcctgaga agctgcgggg cagtgtaaag 5280
taaagtatgc tgggctggg gtggtcagcc tcccctgcc aagaagagag caattgaatc 5340
ctgtccccag ctccctccac gcctgaagag tgaccagtgc tggcccgacg gatcgctgag 5400
atattctccc ataatggcaa aaaaataggc agtttgcgt gacctgttta gtgtggctct 5460
cctctttga gcatgtgttgc catttttat ttatactca tccagtgaac tctgctctc 5520
caagtgtgtt catgtatgtg ctagatata tagcacagcc tgccttctgc tgcacaacgc 5580
cttagagacc cggcctttca atgagcttag cttgtgtctt gtttctgctc tcttaggtct 5640
aaactatggt gtcagttta atagaacaaa agtatgcattt ttgccttggc ttgagcctt 5700
tcgccccaa tgctgacttc tcccctttct ctcctgtgtt cacccttaccc ttccagagtg 5760
taagggacaa ctttaaggga ggcgtgtccc tggtaggggc atccctgttc accagggtgc 5820
tgtcatcacc ccacttgact gacatctacc ctggtgacta tgggttcctc ttgtttgttag 5880
ggaacggtgg ctccaggtgg aggcattcaat ctgttgggtt ctgggtcccg gtcgccttg 5940
gttttgcggaaag tctcttctct gtatattccct accctgcatt tgctttgtgt ggtgctgatg 6000
ctgtggcagt aggcatttgg atgactctcc atcagtcaca gactccccct gttgcaaaagt 6060
gtcaggctga ctcgacagtc accgtaaaat ctgagtcagt cacacacagg ctgtcagcc 6120
cggctccac ttgcattggctt attctatccc cacacgtgag tttctgttgc tggctggctg 6180
actggcatta tctatgctaa gttgaaatca ggagtgtgcc cagcagagcc catcattctc 6240
actgtcttg aaacaaagct gtacggtttgc atcgatgaaac gtatTTaaag catttcattgc 6300
aatgacaaag tgctcagtag tggaaaggcag gctgtgacca gtctgcctgc tccttactat 6360
aattgtgagg atttgcgttact ggaacagttac atggaggcct gacccgttgg gggcacaggg 6420
tggAACCTTA gctgaatata gtgtgtgtct caagaggaag tcagggtact agtcagtg 6480
tcaatctcca ggtactatata atacatttgc cggccccatc tctaattgtga aataaatccc 6540
caaacacttg ttatcgtgt agcgtaccta aaagactatt ctattatggg tgtccccact 6600
ttcttgggtt ggtcaccccg atccccccgtt cttctgtgt atctagaaca gtgactataa 6660
atgatgtatg ggaatagtgt ttccatatga tctgtgttgc ggagtatatg ctacatgttc 6720
atttactgtt caaaaaccca gtgcagctga tgatgcaaaag cagtcattctt ctgtgtacag 6780
tgccccacccctt attaaaaat cacgtacaan cccagaacac tgtgaaacac ttaacataag 6840
aaacaaacgc agcgtctggaa ttcttccaa ggagagcagc tttctccaca ggaacacagtt 6900
aacaaaaagag gtccggccgccc atccacaccc agccaagaca cctcagaggc catagggaca 6960
accccttgc tggccaaacac ctgctggagc agggcacagg tcccagcaac tgatcctcag 7020
tggatgggtc cgcagtcataa gccttaatgg gctctttttt gaaaggggaaa gaaannnttc 7080
aagctttaga tatccaacat tattatgtt gatgagttttag taaattccga aaaaaaaaaaaga 7140
tgatTTTata tttatgtacat aaaaaaaatc tttgtaaagt gcgcaagtgc aataatttaa 7200
agaggtcttac tctttgcatt tataaattat aaatattgtt catgtgtgtt atttttcatg 7260
tattcatttgc cagtcatttgc atttaaaaaa actttactgt tatgtttgtt taatagaaca 7320
ttaatcattt attataactc agacaagggtt taaataaatt cataattcaa acagccagta 7380
tatatgcata tatgggtgtt acattgcataa aatctctatc tttgttctat tcacatgtt 7440
aaagaqaatgaaatctttt gtggatgtt aattatacat ataaagtata tatatgtt 7500

tgatacatga aatatattta gaaatgttca taattttaat ggatattctt tggtgtgaat 7560
aattgaatac aacatttta aaatgaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 7618

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number
WO 01/24781 A3(51) International Patent Classification⁷: **A61K 31/505.**
31/4174, 31/65, 31/4985, 31/522, 31/4745, 31/519,
31/7048, 31/395, A61P 25/14, G01N 33/68

(21) International Application Number: PCT/CA00/01188

(22) International Filing Date: 6 October 2000 (06.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2,285,690 7 October 1999 (07.10.1999) CA
60/158,043 7 October 1999 (07.10.1999) US
60/217,765 12 July 2000 (12.07.2000) US(71) Applicant (for all designated States except US): **NOVA-NEURON INC.** [CA/CA]; 5859 University Avenue, Sir Charles Tupper Medical Bldg., Room 15D7, Halifax, Nova Scotia B3H 4H7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROBERTSON, Harold, A.** [CA/CA]; 2384 Clifton Street, Halifax, Nova Scotia B3K 4V1 (CA). **DENOYAN-WRIGHT, Eileen, M.** [CA/CA]; 22 Fleming Drive, Halifax, Nova Scotia B3P 1A9 (CA).(74) Agent: **HELLER, David, J.**; Ridout & Maybee, One Queen Street East, Suite 2400, Toronto, Ontario M5C 3B1 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
7 February 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/24781 A3

(54) Title: GENE NECESSARY FOR STRIATAL FUNCTION, USES THEREOF, AND COMPOUNDS FOR MODULATING SAME

(57) Abstract: PDE10A, a gene that is normally highly expressed in mammalian striatum and elsewhere, has been found to decrease in expression during the development of CAG repeat disorders such as Huntington's disease. The invention teaches a method for detecting the presence of or the predisposition for a CAG repeat disorder. Compounds which modulate CAG repeat disorders and their uses are taught. Methods for screening for further compounds to modulate CAG repeat disorders are also taught.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01188

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/505 A61K31/4174 A61K31/65 A61K31/4985 A61K31/522
 A61K31/4745 A61K31/519 A61K31/7048 A61K31/395 A61P25/14
 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 789 395 A (ABRAMSON STEVEN B ET AL) 4 August 1998 (1998-08-04) abstract column 4, line 20 - line 62 column 6, line 59 - line 67 column 7, line 13 - line 30 column 8, line 39 - line 45 ---	1,2,5-7
X	WO 99 48522 A (INOUE JUN ; SAKAMOTO YUJI (JP); YOSHIDA YUKUO (JP); SENJU PHARMA CO) 30 September 1999 (1999-09-30) page 1, paragraph 2 -page 2, paragraph 1 ---	1,4-7
X	US 5 849 290 A (BROWN ROBERT ET AL) 15 December 1998 (1998-12-15) abstract column 6, line 17 - line 51 ---	1,2,5-7
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

^a Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

27 April 2001

Date of mailing of the international search report

16/10/01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Cielen, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01188

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 06545 A (MAX PLANCK GESELLSCHAFT ;LEHRACH HANS (DE); WANKER ERICH (DE); SCH) 11 February 1999 (1999-02-11) page 1, paragraph 1 - paragraph 4 page 17, paragraph 3 - paragraph 6 claims 20-22 ---	1,2,5-7
X	US 5 750 376 A (REYNOLDS BRENT ET AL) 12 May 1998 (1998-05-12) column 1, line 40 - line 57 column 11, line 26 - line 29 column 18, line 6 - line 9 column 20, line 41 - line 56 column 26, line 63 -column 27, line 32 column 27, line 62 -column 28, line 6 ---	1,4-7
X	EP 0 930 069 A (JOHNSON & JOHNSON MEDICAL LTD) 21 July 1999 (1999-07-21) abstract page 2, line 54 - line 57 example 1 claims 1,6 ---	1,4
X	US 4 367 217 A (GRUBER PETER ET AL) 4 January 1983 (1983-01-04) abstract column 1, line 6 - line 11 example I claim 1 ---	1,4
X	US 5 461 068 A (THALER IRWIN ET AL) 24 October 1995 (1995-10-24) abstract column 5, line 4 - line 14 claims 1,6 ---	1,2
X	US 4 292 312 A (GRIFFON HENRI) 29 September 1981 (1981-09-29) abstract examples claims 9,10 ---	1,2
X	WO 97 03985 A (GLAXO WELLCOME LAB SA ;DAUGAN ALAIN CLAUDE MARIE (FR); GELIBERT F) 6 February 1997 (1997-02-06) abstract page 1, line 3 - line 14 page 2, line 13 -page 3, line 2 page 5, line 15 - line 17 page 12, line 6 - line 12 claims 5,11 ---	1,3
		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01188

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>VEMULAPALLI SUBBARAO ET AL: "Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor." JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 28, no. 6, 1996, pages 862-869, XP000998260 ISSN: 0160-2446 abstract figures 2-5 page 867, column 2, paragraph 4 ---</p>	1,4
X	<p>ICHIMURA MICHIO ET AL: "KS-505a, an isoform-selective inhibitor of calmodulin-dependent cyclic nucleotide phosphodiesterase." BIOCHEMICAL JOURNAL, vol. 316, no. 1, 1996, pages 311-316, XP000998314 ISSN: 0264-6021 abstract page 312, column 1, paragraph 1 page 315, column 2, paragraph 2 - paragraph 3 ---</p>	1,4
A	<p>US 5 932 423 A (SEILHAMER JEFFREY J ET AL) 3 August 1999 (1999-08-03) abstract column 3, line 8 - line 18 column 4, line 27 - line 45 column 11, line 1 - line 7 column 12, line 24 - line 30 column 12, line 53 - line 63 column 19, line 55 - line 62 column 21, line 53 - line 65 column 22, line 10 - line 14 column 25, line 5 - line 17 ---</p>	1,4-7
A	<p>CEPEDA CARLOS ET AL: "Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons." EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 10, no. 11, November 1998 (1998-11), pages 3491-3497, XP000998317 ISSN: 0953-816X abstract page 3491, column 1, paragraph 1 figure 3C page 3494, column 2, paragraph 2 page 3495, column 1, paragraph 2 page 3496, column 1, paragraph 3 ---</p> <p style="text-align: center;">-/-</p>	1,2,5-7

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01188

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 99 42596 A (ICOS CORP) 26 August 1999 (1999-08-26) cited in the application abstract page 2, line 31 -page 3, line 8 page 4, line 27 -page 5, line 19 page 14, line 22 -page 15, line 23 page 18, line 25 - line 30 page 19, line 14 - line 16 ---</p>	
A	<p>FUJISHIGE K ET AL: "CLONING AND CHARACTERIZATION OF A NOVEL HUMAN PHOSPHODIESTERASE THAT HYDROLYZES BOTH CAMP AND CGMP (PDE10A)" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 26, 25 June 1999 (1999-06-25), pages 18438-18445, XP000983162 ISSN: 0021-9258 abstract table II page 18443, column 2, paragraph 3 -page 18444, column 1, paragraph 1 page 18444, column 2, paragraph 2 ---</p>	1,4
A	<p>LOUGHNEY K., SNYDER P.B. ET AL.: "Isolation and characterisation of PDE10A, a novel human 3',5'-cyclic nucleotide phosphodiesterase." GENE, vol. 234, 1999, pages 109-117, XP002166002 abstract page 114, column 2, paragraph 3 table 1 ---</p>	1,4
P,X	<p>WO 00 27422 A (BIOGEN INC ;GALDES ALPHONSE (US); ONTOGENY INC (US); MAHANTHAPPA N) 18 May 2000 (2000-05-18) page 3, line 25 - line 30 page 4, line 19 -page 7, line 7 page 10, line 6 - line 16 page 11, line 14 - line 18 page 13, line 1 - line 6 page 15, line 15 - line 25 ---</p> <p style="text-align: right;">-/-</p>	1-4,6

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01188

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>CHEN MINGHUA ET AL: "Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease."</p> <p>NATURE MEDICINE, vol. 6, no. 7, July 2000 (2000-07), pages 797-801, XP000998293 ISSN: 1078-8956</p> <p>abstract page 797, column 2, paragraph 2 -page 798, column 1, paragraph 1 figure 1 page 800, column 2, paragraph 2 - paragraph 3 -----</p>	1,2,5-7

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 00/01188

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

SEE ~~uncertified~~ copy claims

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-7

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-7

A composition and its use for treating a CAG repeat disorder comprising a compound which modulates PDE10A expression and a pharmaceutically acceptable carrier.

2. Claims: 8-14

A method for identifying a compound which inhibits or promotes a CAG repeat disorder.

3. Claims: 15-19

A method for detecting the presence of or the predisposition for a CAG repeat disorder.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/01188

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 5789395	A 04-08-1998	AU 718234	B	13-04-2000	
		AU 4080897	A	19-03-1998	
		EP 0966525	A	29-12-1999	
		US 5919775	A	06-07-1999	
		WO 9808480	A	05-03-1998	
-----	-----	-----	-----	-----	-----
WO 9948522	A 30-09-1999	AU 2852699	A	18-10-1999	
		BR 9908948	A	21-11-2000	
		CN 1301173	T	27-06-2001	
		EP 1064021	A	03-01-2001	
		HU 0101428	A	28-09-2001	
		NO 20004679	A	26-10-2000	
		PL 342970	A	16-07-2001	
-----	-----	-----	-----	-----	-----
US 5849290	A 15-12-1998	US 5843641	A	01-12-1998	
		CA 2157041	A	01-09-1994	
		EP 0686203	A	13-12-1995	
		JP 8510377	T	05-11-1996	
		WO 9419493	A	01-09-1994	
-----	-----	-----	-----	-----	-----
WO 9906545	A 11-02-1999	EP 1001987	A	24-05-2000	
-----	-----	-----	-----	-----	-----
US 5750376	A 12-05-1998	US 6071889	A	06-06-2000	
		US 5981165	A	09-11-1999	
		US 6294346	B	25-09-2001	
		US 5980885	A	09-11-1999	
		US 5851832	A	22-12-1998	
		AU 697894	B	22-10-1998	
		AU 8056194	A	29-05-1995	
		CA 2175992	A	18-05-1995	
		WO 9513364	A	18-05-1995	
		CN 1141058	A	22-01-1997	
		EP 0728194	A	28-08-1996	
		FI 961855	A	04-06-1996	
		JP 9507747	T	12-08-1997	
		NO 961859	A	03-07-1996	
		AU 714837	B	13-01-2000	
		AU 3515295	A	09-04-1996	
		CA 2200709	A	28-03-1996	
		WO 9609543	A	28-03-1996	
		EP 1130394	A	05-09-2001	
		EP 0783693	A	16-07-1997	
		FI 971168	A	20-03-1997	
		JP 10505754	T	09-06-1998	
		NO 971245	A	18-03-1997	
		AU 716811	B	09-03-2000	
		AU 3836795	A	06-06-1996	
		WO 9615226	A	23-05-1996	
		CN 1170435	A	14-01-1998	
		EP 0792350	A	03-09-1997	
		FI 971956	A	04-07-1997	
		JP 10509592	T	22-09-1998	
		NO 972171	A	07-07-1997	
		AU 665012	B	14-12-1995	
		AU 2242592	A	11-02-1993	
		CA 2113118	A	21-01-1993	
		WO 9301275	A	21-01-1993	
		EP 0594669	A	04-05-1994	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/01188

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5750376	A	FI 935929 A JP 6509225 T NO 940056 A WO 9416718 A AU 683023 B AU 5147493 A CA 2147162 A WO 9409119 A EP 0664832 A FI 951677 A JP 8502172 T NO 951378 A AU 703729 B	02-02-1994 20-10-1994 03-03-1994 04-08-1994 30-10-1997 09-05-1994 28-04-1994 28-04-1994 02-08-1995 07-04-1995 12-03-1996 07-04-1995 01-04-1999
EP 0930069	A 21-07-1999	GB 2333041 A AU 1129699 A BR 9900046 A JP 11279080 A SG 77214 A	14-07-1999 05-08-1999 02-05-2000 12-10-1999 19-12-2000
US 4367217	A 04-01-1983	DE 3000979 A AR 221983 A AT 6585 T AU 539618 B AU 6615681 A CA 1148084 A CS 8100232 A DD 156943 A DE 3067058 D DK 9481 A, B, EP 0032562 A ES 498393 D ES 8207428 A FI 810058 A, B, GB 2067073 A, B GR 73102 A HK 62184 A HU 184366 B IE 50807 B IL 61887 A IN 155158 A JP 1350517 C JP 56103111 A JP 61016368 B KE 3402 A MY 55985 A NO 810061 A, B, NZ 195994 A OA 6720 A PH 17063 A PL 229157 A PT 72330 A, B SG 28184 G YU 3981 A ZA 8100161 A	23-07-1981 31-03-1981 15-03-1984 11-10-1984 16-07-1981 14-06-1983 18-06-1984 06-10-1982 19-04-1984 13-07-1981 29-07-1981 16-09-1982 16-12-1982 13-07-1981 22-07-1981 02-02-1984 17-08-1984 28-08-1984 23-07-1986 30-09-1984 05-01-1985 28-11-1986 18-08-1981 30-04-1986 08-06-1984 31-12-1985 13-07-1981 27-04-1984 30-06-1982 24-05-1984 18-09-1981 01-02-1981 15-02-1985 30-09-1983 29-09-1982
US 5461068	A 24-10-1995	NONE	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/01188

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
US 4292312	A 29-09-1981	FR 2459046	A	09-01-1981	
		DE 3071091	D	24-10-1985	
		DK 303679	A	16-12-1980	
		EP 0021953	A	07-01-1981	
		FR 2489148	A	05-03-1982	
-----	-----	-----	-----	-----	-----
WO 9703985	A 06-02-1997	AU 702324	B	18-02-1999	
		AU 6419296	A	18-02-1997	
		BR 9609780	A	09-03-1999	
		CA 2226761	A	06-02-1997	
		CN 1195349	A, B	07-10-1998	
		CZ 9800032	A	17-06-1998	
		EP 0846118	A	10-06-1998	
		HR 960321	A	31-08-1998	
		HU 9900006	A	28-04-1999	
		JP 11509535	T	24-08-1999	
		NO 980154	A	10-03-1998	
		PL 324527	A	08-06-1998	
		SK 3898	A	04-11-1998	
		US 5981527	A	09-11-1999	
		US 6143746	A	07-11-2000	
-----	-----	-----	-----	-----	-----
US 5932423	A 03-08-1999	US 5798246	A	25-08-1998	
		US 6080548	A	27-06-2000	
		AU 724247	B	14-09-2000	
		AU 2542797	A	17-10-1997	
		CA 2248675	A	02-10-1997	
		EP 0907742	A	14-04-1999	
		WO 9735989	A	02-10-1997	
-----	-----	-----	-----	-----	-----
WO 9942596	A 26-08-1999	AU 3307999	A	06-09-1999	
		EP 1060251	A	20-12-2000	
-----	-----	-----	-----	-----	-----
WO 0027422	A 18-05-2000	AU 1611600	A	29-05-2000	
		EP 1126865	A	29-08-2001	
-----	-----	-----	-----	-----	-----

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)